



FIG. 1

The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.

(72) **Inventeurs(suite)/Inventors(continued)**: GALLICHOTTE, EMILY, US; ROYAL, SCOTT, US; DESILVA, ARAVINDA, US;  
SWANSTROM, JESICA, US

(74) **Agent**: AIRD & MCBURNEY LP

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau(10) International Publication Number  
**WO 2016/070178 A1**(43) International Publication Date  
6 May 2016 (06.05.2016)

## (51) International Patent Classification:

*C07K 19/00* (2006.01) *A61K 39/295* (2006.01)  
*C07K 14/18* (2006.01) *G01N 33/68* (2006.01)  
*C12N 7/00* (2006.01) *G01N 33/569* (2006.01)  
*C12N 15/62* (2006.01) *G01N 33/53* (2006.01)  
*C12N 15/40* (2006.01) *A61P 31/14* (2006.01)

## (21) International Application Number:

PCT/US2015/058610

## (22) International Filing Date:

2 November 2015 (02.11.2015)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/074,053 2 November 2014 (02.11.2014) US

(71) Applicant: **THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL** [US/US]; 100 Europa Drive, Suite 430, Chapel Hill, North Carolina 27517 (US).

(72) Inventors: **BARIC, Ralph**; 2600 North Stream Court, Haw River, North Carolina 27258-9529 (US). **WIDMAN, Douglas**; 111 Tanglewood Lane, Carrboro, North Carolina 27510 (US). **YOUNT, Boyd**; 1002 Scotsburg Trail, Hillsborough, North Carolina 27278 (US). **GALLICHOTTE, Emily**; 200 Barnes St., Apt. B7, Carrboro, North Carolina 27510 (US). **ROYAL, Scott**; 605 Jones Ferry Road, Apt. SS02, Carrboro, North Carolina 27510 (US). **DESILVA, Aravinda**; 102 Whistling Tree Court, Chapel Hill, North Carolina 27514 (US). **SWANSTROM, Jesica**; 1301 Hemby Ridge Lane, Morrisville, North Carolina 27560 (US).

(74) Agents: **MILLER, Mary L.** et al.; Myers Bigel Sibley & Sajovec, P. A., P.O. Box 37428, Raleigh, NC 27627 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS AND COMPOSITIONS FOR RECOMBINANT DENGUE VIRUSES FOR VACCINE AND DIAGNOSTIC DEVELOPMENT




FIG. 1

(57) Abstract: The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.

WO 2016/070178 A1

## **METHODS AND COMPOSITIONS FOR RECOMBINANT DENGUE VIRUSES FOR VACCINE AND DIAGNOSTIC DEVELOPMENT**

### **STATEMENT OF PRIORITY**

5           This application claims the benefit, under 35 U.S.C. § 119(e), of U.S. Provisional Application Serial No. 62/074,053, filed November 2, 2014, the entire contents of which are incorporated by reference herein.

### **STATEMENT OF GOVERNMENT SUPPORT**

10           This invention was made with government support under Grant Nos. AI 057157, AI 097560, AI 107731 and AI 109761, awarded by the National Institutes of Health. The United States government has certain rights in the invention.

### **FIELD OF THE INVENTION**

15           The present invention is directed to dengue virus vaccines that induce neutralizing antibodies against more than one dengue virus serotype from a single source.

### **BACKGROUND OF THE INVENTION**

20           Dengue virus (DENV) is a mosquito-borne flavivirus that is spreading at an unprecedented rate and has developed into a major health and economic burden in over 50 countries. Current DENV vaccines protecting against all four DENV serotypes must be delivered as a "tetravalent" formulation of four viruses or four recombinant proteins, each intended to confer protection against that serotype. The correct mix of serotypes in the tetravalent cocktail to achieve a balanced antibody response is not known, underscored by the  
25           recent failure of the most advanced tetravalent live attenuated chimeric virus to provide clinically meaningful protection in a large phase 2B trial in Thailand (Sabchareon et al., 2012). Viral interference is thought to contribute to failure as one or more virus serotypes out-compete the others.

30           The present invention overcomes previous shortcomings in the art by providing chimeric dengue viruses that induce neutralizing antibodies against more than one dengue virus serotype from a single source.

## SUMMARY OF THE INVENTION

In one aspect, the present invention provides a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone that comprises amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone, wherein the dengue virus E glycoprotein backbone is from dengue virus serotype 4 and the antibody is reactive with dengue virus serotype 3.

In a further aspect, the present invention provides a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone that comprises amino acid substitutions that introduce a protein domain from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone, wherein the dengue virus E glycoprotein backbone is from dengue virus serotype 4 and the protein domain is from dengue virus serotype 2.

In another aspect, the present invention provides a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone that comprises amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone, wherein the dengue virus E glycoprotein backbone is from dengue virus serotype 2 and the antibody is reactive with dengue virus serotype 1.

Also provided herein is a method of producing an immune response to a dengue virus in a subject (e.g., a subject in need thereof), comprising administering to the subject an effective amount of the E glycoprotein of this invention, the flavivirus particle of this invention, the VLP of this invention, the nucleic acid molecule of this invention, the population of this invention, and/or the composition of this invention and any combination thereof.

Additionally provided herein is a method of treating a dengue virus infection in a subject (e.g., a subject in need thereof), comprising administering to the subject an effective amount of the E glycoprotein of this invention, the flavivirus particle of this invention, the VLP of this invention, the nucleic acid molecule of this invention, the population of this invention, and/or the composition of this invention and any combination thereof.

Further provided herein is a method of preventing a disorder associated with dengue virus infection in a subject (e.g., a subject in need thereof), comprising administering to the subject an effective amount of the E glycoprotein of this invention, the flavivirus particle of this invention, the VLP of this invention, the nucleic acid molecule of this invention, the

population of this invention, and/or the composition of this invention and any combination thereof.

As an additional aspect, the present invention provides a method of protecting a subject from the effects of dengue virus infection, comprising administering to the subject an effective amount of the E glycoprotein of this invention, the flavivirus particle of this invention, the VLP of this invention, the nucleic acid molecule of this invention, the population of this invention, and/or the composition of this invention and any combination thereof.

In further aspects, the present invention provides methods of identifying the presence of a neutralizing antibody to specific dengue virus serotypes or combinations thereof (e.g., 4/3, 4/2, 2/1) in a biological sample from a subject, comprising: a) administering a composition comprising a particular E glycoprotein this invention to the subject in an amount effective to induce an antibody response to the E glycoprotein; b) contacting a biological sample from the subject with flavivirus particles comprising the particular E glycoprotein above under conditions whereby neutralization of the flavivirus particles can be detected; and c) detecting neutralization in step (b), thereby identifying the presence of a neutralizing antibody to the specific dengue virus serotypes or combinations thereof in the biological sample from the subject.

The present invention additionally provides a method of identifying the presence of a neutralizing antibody to specific dengue virus serotypes or combinations thereof (e.g., 4/3, 4/2, 2/1) in a biological sample from a subject, comprising: a) contacting a biological sample from a subject that has been administered a particular E glycoprotein of this invention with flavivirus particles comprising the E glycoprotein under conditions whereby neutralization of the flavivirus particles can be detected; and b) detecting neutralization in step (a), thereby identifying the presence of a neutralizing antibody to the specific dengue virus serotypes or combinations thereof in the biological sample from the subject.

In other embodiments, the present invention provides a method of identifying an immunogenic composition that induces a neutralizing antibody to specific dengue virus serotypes or combinations thereof (e.g., 4/3, 4/2, 2/1) in a subject, comprising: a) administering an immunogenic composition comprising a particular E glycoprotein of this invention to a subject in an amount effective to induce an antibody response to the E glycoprotein; b) contacting a biological sample from the subject with flavivirus particles comprising the E glycoprotein of step (a) under conditions whereby neutralization of the flavivirus particles can be detected; c) determining if the biological sample comprises an

antibody that neutralizes flavivirus particles comprising the E glycoprotein of step (a); and d) identifying the immunogenic composition as inducing a neutralizing antibody to the specific dengue virus serotypes or combinations thereof in the subject if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of (a).

Further provided herein is a method of identifying an immunogenic composition that induces a neutralizing antibody to specific dengue virus serotypes or combinations thereof (e.g., 4/3, 4/2, 2/1) in a subject, the method comprising: a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising a particular E glycoprotein of this invention with flavivirus particles comprising the E glycoprotein under conditions whereby neutralization of the flavivirus particles can be detected; b) determining if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of step (a); and c) identifying the immunogenic composition as inducing a neutralizing antibody to the specific dengue virus serotypes or combinations thereof in the subject if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of (a).

The present invention also provides a method of detecting an antibody to a specific dengue virus serotype or combination thereof in a sample, comprising; a) contacting the sample with a particular E glycoprotein of this invention under conditions whereby an antigen/antibody complex can form; and b) detecting formation of an antigen/antibody complex, thereby detecting an antibody to the specific dengue virus serotype or combination thereof in the sample.

Additionally provided herein is a method of identifying an antibody to a specific dengue virus serotype or combination thereof in a biological sample from a subject, comprising: a) administering a composition comprising a particular E glycoprotein of this invention to the subject in an amount effective to induce an antibody response to the E glycoprotein; b) contacting a biological sample from the subject with the E glycoprotein of (a) under conditions whereby an antigen/antibody complex can form; and c) detecting formation of an antigen/antibody complex, thereby identifying an antibody to dengue virus serotype 3 and/or 4 in the biological sample from the subject.

A further aspect of the invention provides a method of identifying an antibody to a specific dengue virus serotype or combinations thereof in a biological sample from a subject, comprising: a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising a particular E glycoprotein of this invention with the E

glycoprotein under conditions whereby an antigen/antibody complex can form; and c) detecting formation of an antigen/antibody complex, thereby identifying an antibody dengue virus serotype 3 and/or 4 in the biological sample from the subject.

The present invention additionally provides a method of identifying an immunogenic composition that induces an antibody to a specific dengue virus serotype or combination thereof in a subject, the method comprising: a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising a particular E glycoprotein of this invention with the E glycoprotein under conditions whereby an antigen/antibody complex can form; and b) detecting formation of an antigen/antibody complex, thereby identifying an immunogenic composition that induces an antibody to the specific dengue virus serotype or combination thereof in the subject.

A further embodiment of the invention is a method of identifying an immunogenic composition that induces a neutralizing antibody to a specific dengue virus serotype or combination thereof in a subject, comprising: a) administering an immunogenic composition comprising a particular E glycoprotein to a subject in an amount effective to induce an antibody response to the E glycoprotein; b) contacting a biological sample from the subject with the E glycoprotein of (a) under conditions whereby an antigen/antibody complex can form; and c) detecting formation of an antigen/antibody complex, thereby identifying an immunogenic composition that induces a neutralizing antibody to the specific dengue virus serotype or combination thereof in the subject.

Additionally provided herein is a dengue virus particle, a flavivirus particle and/or a virus like particle (VLP) comprising the E glycoprotein of this invention.

An isolated nucleic acid molecule encoding the E glycoprotein of this invention is also provided herein, as well as an isolated nucleic acid molecule encoding the dengue virus particle, flavivirus particle or VLP of this invention.

The present invention also provides a composition comprising the E glycoprotein of this invention in a pharmaceutically acceptable carrier and also provides a composition comprising the nucleic acid molecule of this invention, the vector of this invention, the particle of this invention and/or the population of this invention, in a pharmaceutically acceptable carrier.

The present invention further provides the E glycoprotein of this invention, the dengue virus particle of this invention, the flavivirus particle of this invention, the VLP of this invention, the nucleic acid molecule of this invention, the vector of this invention, the

population of this invention and/or the composition of this invention, singly or in any combination, for use in the manufacture of a medicament for producing an immune response to a dengue virus in a subject, for treating a dengue virus infection in a subject in need thereof, for preventing a dengue virus infection in a subject and/or for protecting a subject from the effects of dengue virus infection.

Also provided herein is the use of the E glycoprotein of this invention, the dengue virus particle of this invention, the flavivirus particle of this invention, the VLP of this invention, the nucleic acid molecule of this invention, the vector of this invention, the population of this invention and/or the composition of this invention, singly or in any combination, for use in producing an immune response to a dengue virus in a subject, in treating a dengue virus infection in a subject in need thereof, in preventing a dengue virus infection in a subject and/or in protecting a subject from the effects of dengue virus infection.

### BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1. Design of infectious cDNA clones of DENV 3 and 4 and generation of recombinant DENV4/3 viruses.** (A) Genome schematic of DENV3 and DENV4 infectious clone design including restriction endonucleases used to generate subgenomic fragments. Size of subgenomic fragments indicates positions in DENV genome where breaks were made to circumvent bacterial instability and toxicity. (B) Amino acids changed in DENV4 E protein by transplantation of DENV3 sequences to generate DENV4 M12, M14, and M16 respectively. Amino acid number represents residue from start of E protein of DENV4. Ribbon structure of DENV3 E protein dimer with AA transferred into DENV4 M12 (C; green residues), DENV4 M14 (D; green+cyan residues), and DENV4 M16 (E; green+cyan+orange residues) indicated. Colors correspond to highlighted AA residues in (B).

**Figure 2. Growth characteristics of rDENV4/3 on mammalian cells.** (A) DENV3, DENV4, DENV4 M12, DENV4 M14, and DENV4 M16 were propagated on C6/36 cells until maximal cytopathology was observed (typically 4 days post-inoculation) and harvested for titration on Vero-81 cells. Infectious titers are presented as ffu/ml cell culture supernatant. (B) Infectious foci size and morphology of WT and rDENV viruses on Vero-81 cells.

**Figure 3. Growth characteristics of rDENV4/3 on arthropod cells.** (A) Multi-step growth curve analysis of DENV3, DENV4, DENV4 M12, DENV4 M14, and DENV4 M16 inoculated on C6/36 cells at an MOI=0.01. Cell culture supernatants were titrated on C6/36 cells as described. (B) Infectious focus size and morphology of WT and rDENV on C6/36 cells.

**Figure 4. Binding and neutralization of hmAb 5J7 on rDENV4/3.** (A) ELISA OD values for DENV3-specific hmAb 5J7 on DENV3, DENV4, DENV4 M14, and DENV4 M16. 5J7 did not bind DENV4 M12 and displayed an identical curve to WT DENV4 (data not shown). Neutralization assays on Vero-81 (B) and U937-DC-SIGN (C) for DENV3, DENV4, DENV4 M12, M14, and M16. Data presented as  $\mu\text{g/ml}$  required to neutralize 50% of viral infectivity.

**Figure 5. Polyclonal DENV3 serum neutralization.** (A-D) Sera collected from human donors recovered from primary DENV3 infection were assayed against DENV3, DENV4, DENV4 M12, and DENV4 M14 on Vero-81 cells to assess sensitivity to DENV3 humoral immune responses. (E-G) Sera collected from human donors recovered from primary DENV3 infection were assayed against DENV3, DENV4, DENV4 M14, and DENV4 M16 on U937-DC-SIGN cells to assess sensitivity to DENV3 humoral immune responses.

**Figure 6. Polyclonal DENV4 serum neutralization.** (A) Sera collected from human donors recovered from primary DENV4 infection were assayed against DENV3, DENV4, DENV4 M12, and DENV4 M14 on Vero-81 cells to assess sensitivity to DENV4 humoral immune responses. (B-D) Sera collected from human donors recovered from primary DENV4 infection were assayed against DENV3, DENV4, DENV4 M14, and DENV4 M16 on U937-DC-SIGN cells to assess sensitivity to DENV4 humoral immune responses.

**Figure 7. Heterotypic serum neutralization.** (A, B) Sera collected from human donors recovered from primary DENV1 infection were assayed against DENV1, DENV3, DENV4 M12, and DENV4 M14 on Vero-81 cells to assess sensitivity to non-specific humoral immune responses. (C, D) Sera collected from human donors recovered from primary DENV2 infection were assayed against DENV2, DENV3, DENV4 M12, and DENV4 M14 on Vero-81 cells to assess sensitivity to DENV4 humoral immune responses.

**Figure 8. Design of infectious cDNA clones of DENV 1 and 2 and generation of recombinant DENV2/1 viruses.** (A) Genome schematic of DENV1 and DENV2 infectious clone design including restriction endonucleases used to generate subgenomic fragments. Size of subgenomic fragments indicates positions in DENV genome where breaks were made to circumvent bacterial instability and toxicity. (B) Amino acids changed in DENV2 E protein by transplantation of DENV1 sequences to generate DENV2-1F4E. Amino acid number represents residue from start of E protein of DENV2. (C) Ribbon structure of DENV2 E protein dimer with AA transferred into DENV2-1F4E.

**Figure 9. Growth characteristics of rDENV2/1.** DENV1, DENV2, and DENV2-1F4E were propagated on C6/36 cells until maximal cytopathology was observed (typically 4 days post-inoculation) and harvested for titration on Vero-81 (A) or C6/36 (B) cells. Infectious titers are presented as ffu/ml cell culture supernatant. (C) Multi-step growth curve analysis of DENV1, DENV2, and DENV2-1F4E inoculated on C6/36 cells at an MOI=0.01. Cell culture supernatants were titrated on C6/36 cells as described. (D) Infectious foci size and morphology of WT and DENV2-1F4E viruses on C6/36 cells.

**Figure 10. Binding and neutralization of hmAb 1F4 on rDENV2/1** (A) ELISA OD values for DENV1-specific hmAb 1F4 on DENV1, DENV2, and DENV2-1F4E. Neutralization assays on C6/36 (B) and U937-DC-SIGN (C) for DENV1, DENV2, and DENV2-1F4E. Data presented as  $\mu\text{g/ml}$  required to neutralize 50% of viral infectivity.

**Figure 11. Polyclonal DENV1 and DENV2 serum neutralization.** (A and B) Sera collected from human donors recovered from primary DENV1 infection were assayed against DENV1, DENV2, and DENV2-1F4E on U937-DC-SIGN cells to assess sensitivity to DENV1 humoral immune responses. (C-E) Sera collected from human donors recovered from primary DENV2 infection were assayed against DENV1, DENV2, and DENV2-1F4E on U937-DC-SIGN cells to assess sensitivity to DENV2 humoral immune responses.

**Figure 12. Murine survival.** Interferon  $\alpha/\beta/\gamma$  deficient mice on a C57BL/6 background were inoculated intraperitoneally with  $3.3 \times 10^6$  ffu DENV1, DENV2, or DENV2-1F4E. Mice were monitored for weight loss and clinical illness for 56 days.

**Figure 13. Design and construction of DV4-EDIII-DV2 virus.** (A) Amino acid alignment of DENV2 and DENV4 linear envelope domain III (EDIII) sequence, residues 296-395 of entire E sequence (99 aa total). Residues differing between DENV2 and DENV4 are highlighted grey. Recombinant DENV4 virus containing EDIII from DENV3, rDENV4/2, replaces differing residues from DENV4 with those from DENV2, highlighted in light grey. (B) Cartoon (left) and space filling (right) crystal structure model of DENV2 E protein dimer, with swapped residues colored. (C) Reverse genetics system for manipulating DENV genome, top = DENV2, bottom = DENV4. DENV genome is divided into four plasmid cassettes which can be individually mutated, ligated together, and electroporated into cells to generate recombinant virus. DENV4-A cassette contains the envelope gene, EDIII is highlighted in grey. Replacing EDIII residues with those from DENV2, in DENV4 backbone creates DV4-EDIII-DV2 virus.

**Figure 14. DENV4 and DV4-EDIII-DV2 virions have similar maturation profiles.** Viruses were grown in C6/C36 cells, culture supernatant was collected and

centrifuged to remove any cellular debris. Samples were run on 12% SDS-PAGE gel and blots were probed with anti-E (4G2) and anti-PrM (2H12 and 5L20) antibodies. DENV2 has substantial levels of PrM present, indicating either incomplete Furin processing or PrM dissociation. PrM bands are not detectable in either DENV4 or DV4-EDIII-DV2 samples.

5 **Figure 15. DV4-EDIII-DV2 has 2 log growth attenuation in Vero cells relative to parental viruses.** (A) Vero-81 cells were infected at an MOI = 0.01. Viral supernatants were collected every 24 hours and subsequently titrated on Vero-81 cells. (B) DENV forms infectious foci in Vero-81 cells (DENV2, DENV4 and DV4-EDIII-DV2 fixed 5, 4 and 6 days post-infection, respectively). DV4-EDIII-DV2 foci are smaller than both parental viruses.

10 **Figure 16. DV4-EDIII-DV2 has no growth attenuation in C6/C36 cells.** (A) C6/C36 cells were infected at an MOI = 0.01. Viral supernatants were collected every 24 hours and subsequently titrated on C6/C36 cells. (B) DENV forms infectious foci in C6/C36 cells (DENV2, DENV4 and DV4-EDIII-DV2 fixed 4, 3 and 5 days post-infection, respectively). With additional day(s) of growth, DV4-EDIII-DV2 foci reach sizes comparable  
15 to parental viruses.

**Figure 17. Transfer of binding and neutralization of DV4-EDIII-DV2 by type-specific DENV2 human MAb.** (A) Summary table of human MAb 2D22, a strongly neutralizing DV2 MAb that binds to a quaternary epitope. (B) Previously generated 2D22 escape mutant resulted in one escape mutation, R323G, mapping to EDIII. (C) ELISA assay  
20 shows transferred partial binding of 2D22 to DV4-EDIII-DV2, above levels of parental DV4 but not to DV2 levels. (D) ELISA binding of cross-reactive control antibody, 2J20, shows comparable levels of virus present and maintained virus structural integrity. (E) Vero-81 based Focus Reduction Neutralization Test (FRNT) was performed using 2D22 and FRNT<sub>50</sub> (concentration of antibody required to neutralize 50% of infection) values were calculated.  
25 (F) U937+DC-SIGN based neutralization assay (Neut) was performed using 2D22 and Neut<sub>50</sub> values were calculated. In both assays (E, F), DV4-EDIII-DV2 gained neutralization to 2D22 to levels higher than DV2. DV4 was not neutralized with the maximum concentration of 2D22 in either assay.

**Figure 18. DV4-EDIII-DV2 gained neutralization to many additional DV2 type-specific MAbs.** (A, B, E) DENV E protein dimer crystal structure with escape mutant or scanning alanine mutation residues (from Table 2) are indicated residue 382 for DVC3.7, residue 311 for DVC10.16, and residues 101 and 108 for DVC13.6 respectively. (C, D, F-I) Vero-81 FRNT assay for each MAb. With the exception of 3F9, DV4-EDIII-DV2

neutralization to the given MAbs was transferred to levels equal to or higher than that of the parental DV2 virus. 3F9 does not bind DV4-EDIII-DV2 (*ELISA binding data not shown*).

**Figure 19. DV4-EDIII-DV2 is not neutralized by a DV4 type-specific EDIII MAb.** (A) DENV E protein dimer crystal structure with scanning alanine mutation residues (from Table 2) indicated at residues 331 and 361. (B) Vero-81 FRNT assay shows DV-E88 is not capable of neutralizing DV4-EDIII-DV2 or DV2, but can neutralize the parental DV4.

**Figure 20. DV4-EDIII-DV2 gained neutralization to polyclonal DENV2 immune sera.** (A–L) Vero-81 FRNT assay shows gain of polyclonal immune sera neutralization to DV4-EDIII-DV2, comparable to levels of DV2 neutralization, indicating transfer of EDIII from DV2 into DV4 is sufficient to transfer majority of DENV2 neutralization. \* = FNRT<sub>50</sub> < 20

**Figure 21. DV4-EDIII-DV2 maintained neutralization to polyclonal DENV4 immune sera.** (A–F) Vero-81 FRNT assay shows DV4-EDIII-DV2 maintains majority neutralization, indicating transfer of EDIII from DV2 does not disrupt the DV4 neutralizing epitope. \* = FNRT<sub>50</sub> < 20

**Figure 22. DV4-EDIII-DV2 gains DV2 sera neutralization and preserves DV4 sera neutralization.** (A) Summary of DV2 polyclonal neutralization data presented in Figure 19. (B) Summary of DV4 polyclonal neutralization data presented in Figure 20. Samples with FNRT<sub>50</sub> < 20 graphed at sera dilution factor of 19.

**Figure 23. DV4-EDIII-DV2 does not gain neutralization to heterotypic polyclonal immune sera.** Vero-81 FRNT assay shows no gain of neutralization to heterotypic (A) DENV1 or (B) DENV3 polyclonal immune sera above either parental DV2 or DV4 neutralization titers. Samples with FNRT<sub>50</sub> < 20 graphed at sera dilution factor of 19.

**Figure 24. Design and construction of rDENV4/2 virus.** (A) Residues from DENV2 (right) can be moved into DENV4 backbone, generating a recombinant DENV 4/2 virus (rDENV4/2). (B) Reverse genetics system for manipulating the DENV genome. Top = DENV2, bottom = DENV4. The DENV genome is divided into four plasmid cassettes which can be individually mutated, ligated together, and electroporated into cells to generate recombinant virus. The DENV4-A cassette contains the envelope gene where mutations are made. Replacing the DENV4 residues with those from DENV 2 creates an rDENV4/2 virus, built entirely on the DENV4 genetic backbone.

**Figure 25. A new method for serotype identification by RT-PCR and confirmation of DENV4 backbone recombinant virus.** (A) Design of RT-PCR primers for serotype-specific RT-PCR. Primers utilize a common sense oligonucleotide targeting the

highly conserved 3' end NS1 gene. Serotype-specific antisense primers target the highly divergent NS2A gene. (B) Viruses were grown in C6/36 cells, culture supernatant was collected and centrifuged to remove any cellular debris. Viral RNA was isolated using QIAGEN QIAmp Viral RNA Miniprep Kit. PCR was run for 35 cycles, and PCR product  
 5 was analyzed on a 1.5% Ultrapure agarose gel. Control RNA (DV1/DV2/DV3/DV4) and water are run as positive and negative controls. Expected product sizes: DV1 = 205 bp, DV2 = 539 bp, DV3 = 455 bp, DV4 = 401 bp.

**Figure 26. Restriction fragment length polymorphism distinguishes rDENV4/2 from parental DENV4.** (A) Restriction fragment length polymorphism (RFLP) designed to  
 10 distinguish rDENV4/2 (bottom) from parental DENV4 (top). Mutations (represented as asterisks) introduced into the DENV4 E genome to generate rDENV4/2 disrupt an XmnI restriction enzyme site present in DENV4. (B) PCR products are gel purified and digested with XmnI. Digest products were analyzed on a 1.5% Ultrapure agarose gel. Expected product sizes: full length undigested = 1031 bp, digested products = 931 bp and 113 bp.

**Figure 27. DENV4 and rDENV4/2 virions have similar maturation profiles.** Viruses grown in C6/36 cells, culture supernatant was collected and centrifuged to remove any cellular debris. Samples were run on a 12% SDS-PAGE gel and blots were probed with anti-E (4G2) and anti-PrM (2H12 and 5L20) antibodies. DENV2 has substantial levels of PrM present, indicating either incomplete Furin processing or PrM dissociation. PrM bands  
 15 are not detected in either DENV4 or rDENV4/2 samples.

**Figure 28. rDENV4/2 has a 2 log growth attenuation in Vero cells relative to parental viruses.** (A) Vero-81 cells were infected at an MOI = 0.01. Viral supernatants were collected every 24 hrs. and subsequently titered on Vero-81 cells. (B) DENV forms infectious foci in Vero-81 cells (DENV2, DENV4, and rDENV4/2) fixed 5, 4, and 6 days post-  
 25 infection, respectively). rDENV4/2 foci are smaller than both parental viruses.

**Figure 29. rDENV4/2 has no growth attenuation in C6/36 cells and forms similar infectious foci relative to parental viruses.** (A) C6/36 cells were infected at an MOI = 0.01. Viral supernatants were collected every 24 hrs. and subsequently titered on C6/36 cells. (B) DENV forms infectious foci on C6/36 cells (DENV2, DEVN4, and rDENV4/2 fixed 4, 3, and  
 30 5 days post-infection, respectively). With additional day(s) of growth, rDENV4/2 foci reach sizes comparable with parental viruses.

**Figure 30. Transfer of binding and neutralization of rDENV4/2 by type-specific DENV2 human MAb.** (A) Summary table of human MAb 2D22, a strongly neutralizing DV2 MAb that binds to a quaternary epitope. (B) ELISA assay shows transferred partial

binding of 2D22 to rDENV4/2, above levels of parental DV4 but not to DV2 levels. (C) ELISA binding of cross-reactive control antibody, 2J20, shows comparable levels of virus present and maintained virus integrity. (D) Vero-81 based Focus Reduction Neutralization Test (FRNT) was performed using 2D22 and FRNT<sub>50</sub> (concentration of antibody required to neutralize 50% of infection) values were calculated. (E) U937+DC-SIGN based neutralization assay (Neut) was performed using 2D22 and Neut<sub>50</sub> values were calculated. In both assays (E, F) rDENV4/2 gained neutralization to 2D22 to levels higher than DV2. DV4 was not neutralized with the maximum concentration of 2D22 in either assay.

**Figure 31. rDENV4/2 gains neutralization to DENV2 polyclonal immune sera while preserving neutralization to DENV4 polyclonal sera.** Vero-81 FRNT assay shows rDENV4/2 (A) gains neutralization to DENV2 polyclonal immune sera to levels comparable to parental DENV2. (B) rDENV4/2 shows no loss to neutralization by DENV4 polyclonal immune sera. rDENV4/2 shows no gain of neutralization to heterotypic (C) DENV1 and (D) DENV3 polyclonal immune sera above either parental DENV 2 or DENV4 neutralization titers. Sera from individuals with either nature infection, or experimental vaccination are coded as indicated. Samples with FRNT<sub>50</sub> < 20 graphed at sera dilution factor of 19.

**Figure 32A. Alignment of recombinant DENV4/2 sequences.** The amino acid sequences of wild-type DENV2, recombinant DV4-EDIII-DV2 and wild-type DENV4 are shown, along with a consensus sequence and amino acid conservation percentage.

**Figure 32B. Alignment of recombinant DENV2/1 sequences.** The amino acid sequences of wild-type DENV1, recombinant DENV2-1F4E and wild-type DENV2 are shown, along with a consensus sequence and amino acid conservation percentage.

**Figure 32C. Alignment of recombinant DENV4/3 sequences.** The amino acid sequences of wild-type DENV3, recombinant DENV4 M12, DENV4 M14, DENV4 M16 and wild-type DENV4 are shown, along with a consensus sequence and amino acid conservation percentage.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on the unexpected discovery that one or more epitope regions that define one or more DENV serotypes can be transferred into a protein backbone of a different DENV serotype to create a chimeric molecule that contains antibody targets for multiple serotypes, thereby functioning as a multivalent (e.g., bivalent, trivalent or tetravalent) vaccine that can induce neutralizing antibodies against two, three or four different DENV serotypes from a single source or fewer than four sources. Thus, the present invention

provides a platform for construction of a chimeric dengue virus E glycoprotein backbone that comprises amino acid substitutions that introduce one or more epitomes that are recognized by respective antibodies that are reactive with one or more than one dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.

5 In some embodiments, that dengue virus E glycoprotein backbone is from dengue virus serotype 1. In some embodiments, the dengue virus E glycoprotein backbone can be from dengue virus serotype 2, dengue virus serotype 3 or dengue virus serotype 4.

In some embodiments, the antibody that is reactive with a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone is an  
10 antibody that is reactive with dengue virus serotype 1, dengue virus serotype 2, dengue virus type 3 or dengue virus serotype 4.

In some embodiments, one or more dengue virus protein domains from one or more respective dengue virus serotypes can be introduced into a dengue virus E glycoprotein backbone of a different dengue virus serotype.

15 It would be understood that any combination of a first dengue virus serotype for the dengue virus E glycoprotein backbone and a dengue virus epitope or dengue virus protein domain as identified in a second, third and/or fourth dengue virus serotype, respectively, can be used, provided that the first dengue virus serotype and the second, third and/or fourth dengue virus serotype are different (i.e., the second, third and/or fourth serotypes are not the  
20 same serotype as the first dengue virus serotype and/or the second, third and/or fourth dengue virus serotypes are different from one another).

Thus, in some embodiments, the present invention provides a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone that comprises amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone, wherein the dengue virus E glycoprotein backbone is from dengue virus serotype 4 and the antibody is reactive with dengue virus serotype 3. In some  
embodiments, the antibody is monoclonal antibody 5J7 and in some embodiments, the E glycoprotein can comprise, consist essentially of, or consist of the amino acid sequence:

25 MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAKEVA  
LLRTYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWGNGCGLFGKG  
GVVTCAKFSCSGKITGNLVQIENLEYTVVVTVHNGDTHAVGNDTSNHGVTATITPRS  
PSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHKQWFLDLPLPWTAGA  
DTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHM  
FAGHLKCKVRMEKLRIGMSYTMCSGKFSIDKEMAETQHGTTVVKVKYEGAGAPC  
KVPIEIRDVNKEKVVGRVISSTPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWF

RKGSSIGKMFESTYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMF  
GGVSWMIRILIGFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA (WT\_DENV4,  
SEQ ID NO:1),

wherein said amino acid sequence comprises all or less than all in any combination, of the  
5 following amino acid substitutions:

T49E, K51T, E52Q, V53L, L55T, T58K, Y59L, S122L, G123E, K124P, T126E, N128K,  
L129V, I132Y, M199L, K200T, T205A, L207M, K210R, L214F, A222S, V270I, D271Q,  
S272N, G273S, D274G, N276T, H277S and M278I, and wherein said amino acid sequence  
can further comprise one or more of the following amino acid substitutions in any

10 combination: A71D, T148Q, D225T, V229P, D307K, K321Q and V362P.

In some embodiments, the chimeric dengue virus E glycoprotein described above as a  
4/3 dengue virus glycoprotein can comprise, consist essentially of or consist of the amino  
acid sequence:

15 MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTATQLAT  
LRKLCIEASISNITTATRCPTQGEPLYKEEQDQQYICRRDVVDRGWGNGCGLFGKGG  
VVTCAKFSCSGPIEGKVQIENLEYTVVVTVHNGDTHAVGNDTSNHGVTATITPRSP  
SVEVKLPDYGELTLDCEPRSGIDFNEMILLTMKKKAWMVHRQWFFDLPLPWTSGAD  
TSEVHWNKYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEIQNSGGTSIFAG  
HLKCKVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTVVKVKYEGAGAPCKVPI  
20 EIRDVNKEKVVGRRVISSTPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGS  
SIGKMFESTYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVS  
WMIRILIGFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA (DENV4\_M12, SEQ ID  
NO:2),

or the amino acid sequence:

25 MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTEATQLAT  
LRKLCIEASISNITTATRCPTQGEPLYKEEQDQQYICRRDVVDRGWGNGCGLFGKGG  
VVTCAKFSCLEPIEGKVQYENLEYTVVVTVHNGDTHAVGNDTSNHGVTATITPRSP  
SVEVKLPDYGELTLDCEPRSGIDFNEMILLTMKKKAWMVHRQWFFDLPLPWTSGAD  
TSEVHWNKYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEIQNSGGTSIFAG  
30 HLKCKVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTVVKVKYEGAGAPCKVPI  
EIRDVNKEKVVGRRVISSTPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGS  
SIGKMFESTYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVS  
WMIRILIGFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA (DENV4\_M14, SEQ ID  
NO:3),

35 or the amino acid sequence:

40 MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTEATQLAT  
LRKLCIEASISNITTDTRCPTQGEPLYKEEQDQQYICRRDVVDRGWGNGCGLFGKGG  
VVTCAKFSCLEPIEGKVQYENLEYTVVVTVHNGDQHAVGNDTSNHGVTATITPRSP  
SVEVKLPDYGELTLDCEPRSGIDFNEMILLTMKKKAWMVHRQWFFDLPLPWTSGAT  
TSEPHWNKYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEIQNSGGTSIFAG  
HLKCKVRMEKLRIKGMSYTMCSGKFSIKKEMAETQHGTTVVKVKYEGAGAPCKVPI  
EIRDVNKEKVVGRRVISSTPLAENTNSPTNIELEPPFGDSYIVIGVGNSALTLHWFRKGS  
SIGKMFESTYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVS

WMIRILIGFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA (DENV4\_M16, SEQ ID NO:4).

In some embodiments, the present invention provides a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone that comprises amino acid substitutions that introduce a protein domain from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone, wherein the dengue virus E glycoprotein backbone is from dengue virus serotype 4 and the protein domain is from dengue virus serotype 2.

In some embodiments, the dengue virus E glycoprotein backbone of dengue virus serotype 4 comprises amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2. In some embodiments, the antibody is monoclonal antibody 2D22.

In some embodiments, the protein domain is E glycoprotein domain III and in some embodiments, the chimeric dengue virus E glycoprotein described above as 4/2 can comprise, consist essentially of or consist of the amino acid sequence:

MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAKEVALLR  
TYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWGNGCGLFGKGGV  
VTCAKFSCSGKITGNLVQIENLEYTVVVTVHNGDTHAVGNDTSNHGVTATITPRSP  
SVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHKQWFLDLPLPWTAGAD  
TSEVHWNKYKERMVTFKVPFAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMF  
AGHLKCKVRMEKLRLKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKI  
PFEITDLEKRHVLGRLITVNPIVTEKDSPVNIEAEPFPGDSYIIIGVEPGQLKLNWFKKG  
SSIGKMFESTYRGAKRMAILGETAWDFGSVGGGLFTSLGKAVHQVFGSVYTTMFGGV  
SWMIRILIGFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA (DV4-EDIII-DV2,  
SEQ ID NO:5).

In some embodiments, the chimeric dengue virus E glycoprotein can comprise the amino acid sequence:

MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAKEVALLR  
TYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWGNGCGLFGKGGV  
VTCAKFSCSGKITGNLVQIENLEYTVVVTVHNGDTHAVGNDTSNHGVTATITPRSP  
SVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHKQWFLDLPLPWTAGAD  
TSEVHWNKYKERMVTFKVPFAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMF  
AGHLKCKVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTVVKVKYEGAGAPCK  
VPPIERDVNKEKVVGRVISSTPLAENTNSVTNIELEPPFPGDSYIVIGVGNSALTLHWF  
RKGSSIGKMFESTYRGAKRMAILGETAWDFGSVGGGLFTSLGKAVHQVFGSVYTTMF  
GGVSWMIRILIGFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA (WT\_DENV4,  
SEQ ID NO:1),

wherein said amino acid sequence comprises all, or less than all in any combination, of the following amino acid substitutions:

T300S, S303T, S307K, D309V, M312I, T320I, V322I, K323R, K325Q, A329D, A331S, V335I, I337F, R340T, V342L, N343E, E345R, K346H, V348L, V351L, S353T, S354V, T355N, L357I, A358V, E359T, N360E, T361K, N362D, V364P, T365V, L369A, V379I, G383E, N384P, S385G, A386Q, T388K, H390N and R393K.

5

Further embodiments of this invention include the reciprocal exchange virus, i.e., a dengue virus E glycoprotein of dengue virus serotype 2 with amino acid substitutions that introduce a dengue virus protein domain (e.g., domain III) from dengue virus serotype 4. Any other combination of dengue virus serotype backbone and substituted dengue virus protein domain from a different dengue virus serotype is included as an embodiment of this invention, including, for example the combinations 1/2, 1/3, 1/4, 1/2/3, 1/2/4, 1/3/4, 1/2/3/4, 2/1, 2/3, 2/4, 2/1/3, 2/1/4, 2/3/4, 2/1/3/4, 3/1, 3/2, 3/4, 3/1/2, 3/1/4, 3/2/4, 3/1/2/4, 4/1, 4/2, 4/3, 4/1/3, 4/1/2, 4/3/2, or 4/3/2/1 (wherein the first number of each combination defines the serotype of the backbone and the second, third or fourth number of each combination defines the serotype of the epitope(s) or domain(s) that have been introduced into the backbone).

Some embodiments of the present invention provide a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone that comprises amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone, wherein the dengue virus E glycoprotein backbone is from dengue virus serotype 2 and the antibody is reactive with dengue virus serotype 1. In some embodiments, the antibody is monoclonal antibody 1F4 and in some embodiments, the chimeric dengue virus E glycoprotein comprises, consists essentially of or consists of the amino acid sequence:

25 MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELFKTEVTNPAVLR  
KYCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFICKHSMVDRGWGNGCGLFGKGGIV  
TCAMFTCKKNMEGKVVQPENLKYSVIVTVHSGEEHAVGNDTTEHGTTATITPQAPT  
SEIQLTDYGALTLECSPTGLDFNEMVLLQMEDKAWLVHRQWFLDLPLPWLPGADT  
QESNWIQKETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQTSGTTTLFTGH  
30 LKCRLRMDKLQLKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIT  
DLEKRHVLGRLITVNPIVTEKDSPVNIEAEPFGDSYIIIGVEPGQLKLNWFKKGSSIGQ  
MFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFGVSWTM  
KILIGVIITWIGMNSRSTSLSVSLVLVGVVTLVYLGAVVQA (DENV2-1F4E, SEQ ID  
NO:6).

35 In some embodiments of this invention, the chimeric E glycoprotein can comprise a dengue virus E glycoprotein backbone of dengue virus serotype 1, dengue virus serotype 2, or dengue virus serotype 3, that comprises one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,

14 or all 15) of the following amino acid substitutions, in any combination to introduce an epitope from dengue virus serotype 4 that is reactive with monoclonal antibody 5H2: A at residue 155, V at residue 160, T at residue 161, A at residue 162, M at residue 163, S at residue 168, S at residue 170, V at residue 171, V at residue 173, K at residue 174, P at residue 176, D at residue 177, E at residue 180, K at residue 291 and R at residue 293. Amino acid numbering is based on the amino acid sequence of WT\_DENV4 provided herein.

The present invention provides additional no limiting examples of chimeric dengue virus E glycoprotein's of this invention that can be used in the compositions and methods described herein in the SEQUENCES section provided herein.

10 The present invention also provides various therapeutic methods, including, for example, method of producing an immune response to a dengue virus in a subject, comprising administering to the subject an effective amount of the E glycoprotein of this invention, the flavivirus particle of this invention, the VLP of this invention, the nucleic acid molecule of this invention, the population of this invention, and/or the composition of this invention and any combination thereof.

15 Additionally provided herein is a method of treating a dengue virus infection in a subject, comprising administering to the subject an effective amount of the E glycoprotein of this invention, the flavivirus particle of this invention, the VLP of this invention, the nucleic acid molecule of this invention, the population of this invention, and/or the composition of this invention and any combination thereof.

20 In further embodiments, the present invention provides a method of preventing a disorder associated with dengue virus infection in a subject, comprising administering to the subject an effective amount of the E glycoprotein of this invention, the flavivirus particle of this invention, the VLP of this invention, the nucleic acid molecule of this invention, the population of this invention, and/or the composition of this invention and any combination thereof.

25 Also provided herein is a method of protecting a subject from the effects of dengue virus infection, comprising administering to the subject an effective amount of the E glycoprotein of this invention, the flavivirus particle of this invention, the VLP of this invention, the nucleic acid molecule of this invention, the population of this invention, and/or the composition of this invention and any combination thereof.

30 The present invention also provides various diagnostic methods, including, for example, a method of identifying the presence of a neutralizing antibody to dengue virus serotype 3 and/or 4 in a biological sample from a subject, comprising: a) administering a

composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 4 to the subject in an amount effective to induce an antibody response to the E glycoprotein; b) contacting a biological sample from the subject with flavivirus particles comprising the E glycoprotein of step (a) above under conditions whereby neutralization of the flavivirus particles can be detected; and c) detecting neutralization in step (b), thereby identifying the presence of a neutralizing antibody to dengue virus serotype 3 and/or 4 in the biological sample from the subject.

Further provided herein is a method of identifying the presence of a neutralizing antibody to dengue virus serotype 2 and/or 4 in a biological sample from a subject, comprising: a) administering a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 4 to the subject in an amount effective to induce an antibody response to the E glycoprotein; b) contacting a biological sample from the subject with flavivirus particles comprising the E glycoprotein of step (a) above under conditions whereby neutralization of the flavivirus particles can be detected; and c) detecting neutralization in step (b), thereby identifying the presence of a neutralizing antibody to dengue virus serotype 2 and/or 4 in the biological sample from the subject.

The present invention also provides a method of identifying the presence of a neutralizing antibody to dengue virus serotype 1 and/or 2 in a biological sample from a subject, comprising: a) administering a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 2 to the subject in an amount effective to induce an antibody response to the E glycoprotein; b) contacting a biological sample from the subject with flavivirus particles comprising the E glycoprotein of step (a) above under conditions whereby neutralization of the flavivirus particles can be detected; and c) detecting neutralization in step (b), thereby identifying the presence of a neutralizing antibody to dengue virus serotype 1 and/or 2 in the biological sample from the subject.

A method is also provided herein of identifying the presence of a neutralizing antibody to dengue virus serotype 3 and/or 4 in a biological sample from a subject, comprising: a) administering a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 4 to the subject in an amount effective to induce an antibody response to the E glycoprotein; and b) detecting neutralization in step (a), thereby identifying the presence of a neutralizing antibody to dengue virus serotype 3 and/or 4 in the biological sample from the subject.

Furthermore, the present invention provides a method of identifying the presence of a neutralizing antibody to dengue virus serotype 2 and/or 4 in a biological sample from a subject, comprising: a) administering a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 4 to the subject in an amount effective to induce an antibody response to the E glycoprotein; and b) detecting neutralization in step (a), thereby identifying the presence of a neutralizing antibody to dengue virus serotype 2 and/or 4 in the biological sample from the subject.

In additional embodiments, the present invention provides a method of identifying the presence of a neutralizing antibody to dengue virus serotype 1 and/or 2 in a biological sample from a subject, comprising: a) administering a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 2 to the subject in an amount effective to induce an antibody response to the E glycoprotein; and b) detecting neutralization in step (a), thereby identifying the presence of a neutralizing antibody to dengue virus serotype 1 and/or 2 in the biological sample from the subject.

The present invention further provides a method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 3 and/or 4 in a

subject, the method comprising: a) administering a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 4 to the subject in an amount effective to induce an antibody response to the E glycoprotein; b) contacting a biological sample from the subject with flavivirus particles comprising the E glycoprotein of step (a) under conditions whereby neutralization of the flavivirus particles can be detected; c) determining if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of step (a); and d) identifying the immunogenic composition as inducing a neutralizing antibody to dengue virus serotype 3 and/or 4 in the subject if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of (a).

Furthermore, the present invention provides a method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 2 and/or 4 in a subject, the method comprising: a) administering a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 4 to the subject in an amount effective to induce an antibody response to the E glycoprotein; b) contacting a biological sample from the subject with flavivirus particles comprising the E glycoprotein of step (a) under

conditions whereby neutralization of the flavivirus particles can be detected; c) determining if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of step (a); and d identifying the immunogenic composition as inducing a neutralizing antibody to dengue virus serotype 2 and/or 4 in the subject if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of (a).

The present invention further provides a method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 1 and/or 2 in a subject, the method comprising: a) administering a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 2 to the subject in an amount effective to induce an antibody response to the E glycoprotein; b) contacting a biological sample from the subject with flavivirus particles comprising the E glycoprotein of step (a) under conditions whereby neutralization of the flavivirus particles can be detected; c) determining if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of step (a); and d identifying the immunogenic composition as inducing a neutralizing antibody to dengue virus serotype 1 and/or 2 in the subject if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of (a).

In additional embodiments, the present invention provides a method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 3 and/or 4 in a subject, the method comprising: a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein

backbone of serotype 3 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 4, with flavivirus particles comprising the E glycoprotein under conditions whereby neutralization of the flavivirus particles can be detected; b) determining if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of step (a); and c) identifying the immunogenic composition as inducing a neutralizing antibody to dengue virus serotype 3 and/or 4 in the subject if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of (a).

Additionally, the present invention provides a method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 2 and/or 4 in a subject, the method comprising: a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 4 with flavivirus particles comprising the E glycoprotein under conditions whereby neutralization of the flavivirus particles can be detected; b) determining if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of step (a); and c) identifying the immunogenic composition as inducing a neutralizing antibody to dengue virus serotype 2 and/or 4 in the subject if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of (a).

Additionally provided herein is a method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 1 and/or 2 in a subject, the method comprising: a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 2 with flavivirus particles comprising the E glycoprotein under conditions whereby neutralization of the flavivirus particles can be detected; b) determining if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of step (a); and c) identifying the immunogenic composition as inducing a neutralizing antibody to dengue virus serotype 1 and/or 2 in the subject if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of (a).

The present invention further provides a method of detecting an antibody to dengue virus serotype 3 and/or 4 in a sample, comprising: a) contacting the sample with a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 4 under conditions whereby an antigen/antibody complex can form; and b) detecting formation of an

antigen/antibody complex, thereby detecting an antibody to dengue virus serotype 3 and/or 4 in the sample.

The present invention also provides a method of detecting an antibody to dengue virus serotype 2 and/or 4 in a sample, comprising: a) contacting the sample with a composition  
5 comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid  
10 substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid  
15 substitutions that introduce a dengue virus protein domain of dengue virus serotype 4 under conditions whereby an antigen/antibody complex can form; and b) detecting formation of an antigen/antibody complex, thereby detecting an antibody to dengue virus serotype 3 and /or 4 in the sample.

Also provided herein is a method of detecting an antibody to dengue virus serotype 1 and/or 2 in a sample, comprising; a) contacting the sample with a composition comprising an  
20 E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2 and/or  
25 a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 2 under conditions whereby an  
30 antigen/antibody complex can form; and b) detecting formation of an antigen/antibody complex, thereby detecting an antibody to dengue virus serotype 1 and /or 2 in the sample.

Further provided herein is a method of identifying an antibody to dengue virus serotype 3 and/or 4 in a biological sample from a subject, comprising: a) administering a composition comprising an E glycoprotein comprising an E glycoprotein backbone of

serotype 4 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 4 to the subject in an amount effective to induce an antibody response to the E glycoprotein; b) contacting a biological sample from the subject with the E glycoprotein of (a) under conditions whereby an antigen/antibody complex can form; and c) detecting formation of an antigen/antibody complex, thereby identifying an antibody to dengue virus serotype 3 and/or 4 in the biological sample from the subject.

Additionally provided herein is a method of identifying an antibody to dengue virus serotype 2 and/or 4 in a biological sample from a subject, comprising: a) administering a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 4 to the subject in an amount effective to induce an antibody response to the E glycoprotein; b) contacting a biological sample from the subject with the E glycoprotein of (a) under conditions whereby an antigen/antibody complex can form; and c) detecting formation of an antigen/antibody complex, thereby identifying an antibody to dengue virus serotype 2 and/or 4 in the biological sample from the subject.

In yet further embodiments, the present invention provides a method of identifying an antibody to dengue virus serotype 1 and/or 2 in a biological sample from a subject, comprising: a) administering a composition comprising an E glycoprotein comprising an E

glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 2 to the subject in an amount effective to induce an antibody response to the E glycoprotein; b) contacting a biological sample from the subject with the E glycoprotein of (a) under conditions whereby an antigen/antibody complex can form; and c) detecting formation of an antigen/antibody complex, thereby identifying an antibody to dengue virus serotype 1 and/or 2 in the biological sample from the subject.

A method is additionally provided herein of identifying an antibody to dengue virus serotype 3 and/or 4 in a biological sample from a subject, comprising: a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 4 with the E glycoprotein under conditions whereby an antigen/antibody complex can form; and c) detecting formation of an antigen/antibody complex, thereby identifying an antibody to dengue virus serotype 3 and/or 4 in the biological sample from the subject.

The present invention further provides a method of identifying an antibody to dengue virus serotype 2 and/or 4 in a biological sample from a subject, comprising: a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4

comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with  
5 dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 4 with the  
10 E glycoprotein under conditions whereby an antigen/antibody complex can form; and b) detecting formation of an antigen/antibody complex, thereby identifying an antibody dengue virus serotype 2 and/or 4 in the biological sample from the subject.

The present invention further provides a method of identifying an antibody to dengue virus serotype 1 and/or 2 in a biological sample from a subject, comprising: a) contacting a  
15 biological sample from a subject that has been administered an immunogenic composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid  
20 substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid  
25 substitutions that introduce a dengue virus protein domain of dengue virus serotype 2 with the E glycoprotein under conditions whereby an antigen/antibody complex can form; and b) detecting formation of an antigen/antibody complex, thereby identifying an antibody dengue virus serotype 1 and/or 2 in the biological sample from the subject.

The present invention further provides a method of identifying an immunogenic  
30 composition that induces an antibody to dengue virus serotype 3 and/or 4 in a subject, the method comprising: a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 3 and/or

a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 4 with the E glycoprotein under conditions whereby an antigen/antibody complex can form; and b) detecting formation of an antigen/antibody complex, thereby identifying an immunogenic composition that induces an antibody to dengue virus serotype 3 and/or 4 in the subject.

Further provided herein is a method of identifying an immunogenic composition that induces an antibody to dengue virus serotype 2 and/or 4 in a subject, the method comprising: a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising an E glycoprotein of any of claims 6-8 with the E glycoprotein under conditions whereby an antigen/antibody complex can form; and b) detecting formation of an antigen/antibody complex, thereby identifying an immunogenic composition that induces an antibody to dengue virus serotype 2 and/or 4 in the subject.

Also provided herein is a method of identifying an immunogenic composition that induces an antibody to dengue virus serotype 1 and/or 2 in a subject, the method comprising: a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 2 with the E glycoprotein under conditions whereby an antigen/antibody complex can form; and b) detecting formation of an antigen/antibody complex, thereby identifying an immunogenic composition that induces an antibody to dengue virus serotype 1 and/or 2 in the subject.

In some embodiments of the present invention, a method is provided of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 3 and/or 4 in a subject, comprising: a) administering a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 3 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 3 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 4 to the subject in an amount effective to induce an antibody response to the E glycoprotein; b) contacting a biological sample from the subject with the E glycoprotein of (a) under conditions whereby an antigen/antibody complex can form; and c) detecting formation an antigen/antibody complex, thereby identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 3 and/or 4 in the subject.

The present invention additionally provides a method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 2 and/or 4 in a subject, comprising: a) administering a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 4 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 4 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 4 to the subject in an amount effective to induce an antibody response to the E glycoprotein; b) contacting a biological sample from the subject with the E glycoprotein of (a) under conditions whereby an antigen/antibody complex can form; and c) detecting formation an antigen/antibody complex, thereby

identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 2 and/or 4 in the subject.

Also provided herein is a method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 1 and/or 2 in a subject, comprising:

- 5 a) administering a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid substitutions that introduce an epitope that is recognized by an
- 10 antibody that is reactive with dengue virus serotype 2 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 2 comprising amino acid substitutions that introduce a dengue virus protein domain of dengue virus serotype 1 and/or a composition comprising an E glycoprotein comprising an E glycoprotein backbone of serotype 1 comprising amino acid substitutions that introduce a dengue virus protein domain
- 15 of dengue virus serotype 2 to the subject in an amount effective to induce an antibody response to the E glycoprotein; b) contacting a biological sample from the subject with the E glycoprotein of (a) under conditions whereby an antigen/antibody complex can form; and c) detecting formation an antigen/antibody complex, thereby identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 1 and/or 2 in the
- 20 subject.

In some embodiments, the present invention provides a method of determining an amount of the antibodies produced to the transplanted epitope or domain. For example, DENV3 antibodies that target the 5J7 region could be measured by comparing neutralization of DENV4 M14 with the parent DENV4, with the expectation that DENV3 antibodies could

25 neutralize some portion of DENV4 M14 but not parental DENV4.

The present invention also provides a dengue virus particle, a flavivirus particle and a virus like particle (VLP) comprising the chimeric E glycoprotein of this invention. The dengue virus E glycoprotein of the invention can be present in an intact virus particle (*e.g.*, a killed or live attenuated virus particle or a recombinant dengue virus vector) or a virus-like

30 particle (VLP), which may optionally be an intact dengue virus particle or dengue virus VLP.

Also provided is an isolated nucleic acid molecule encoding the E glycoprotein of this invention, an isolated nucleic acid molecule encoding the dengue virus particle, the flavivirus particle or the VLP of this invention, a vector comprising the nucleic acid molecule of this

invention and a population of dengue virus particles and/or flavivirus particles comprising the dengue virus particle and/or flavivirus particle this invention.

Further provided herein is a composition comprising the E glycoprotein of this invention in a pharmaceutically acceptable carrier, a composition comprising the nucleic acid molecule of this invention in a pharmaceutically acceptable carrier, a composition comprising the virus particle of this invention, a composition comprising the population of this invention in a pharmaceutically acceptable carrier and a composition comprising the VLP of this invention in a pharmaceutically acceptable carrier.

In some embodiments, production of the chimeras of this invention can be carried out by introducing some (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, etc.) or all of the amino acid substitutions identified as part of a dengue virus epitope and/or dengue virus protein domain into a dengue virus E glycoprotein backbone or flavivirus E glycoprotein backbone. Not every amino acid identified as part of a dengue virus epitope or dengue virus protein domain is required to be substituted to produce a chimeric protein of this invention.

For example, in some embodiments further substitutions and/or omission of substitutions of about 1, 2, 3, 4 or 5 amino acids at either end of the contiguous amino acid sequences identified as part of a dengue virus epitope or dengue virus domain can be included in the production of a chimera of this invention. The number of substitutions necessary to produce the desired conformational epitope or domain can be readily determined by one of ordinary skill in the art according to the teachings herein and according to protocols well known in the art. The amino acid residue numbering provided in the amino acid sequences set forth here is based on the respective unmodified (e.g., wild type) E glycoprotein amino acid sequence of the respective DENV serotype, as provided herein. However it would be readily understood by one of ordinary skill in the art that the equivalent amino acid positions in other dengue virus E glycoprotein amino acid sequences or other flavivirus E glycoprotein amino acid sequences can be readily identified and employed in the production of the chimeric proteins of this invention.

In some embodiments, the present invention provides a chimeric flavivirus E glycoprotein in which amino acid substitutions are made to introduce one or more dengue virus epitomes into a flavivirus E glycoprotein from a flavivirus that is not a dengue virus. Thus, in some embodiments, the present invention provides a flavivirus E glycoprotein comprising a chimeric E glycoprotein comprising a flavivirus E glycoprotein backbone that is not a dengue virus E glycoprotein backbone, wherein the flavivirus E glycoprotein backbone

comprises amino acid substitutes that introduce one or more epitomes that are recognized by a respective antibody that is reactive with a dengue virus.

No limiting examples of flaviviruses that can be used include yellow fever virus (YFV) (e.g., GenBank<sup>®</sup> Database Accession No. JX503529) Japanese encephalitis virus (JEV) (e.g., GenBank<sup>®</sup> Database Accession No. U14163), West Nile virus (WNV) (e.g., GenBank<sup>®</sup> Database Accession No. DQ211652) and any other flavivirus now known or later identified.

It is known in the art that many attempts to produce dengue virus vaccines result in the production of non-neutralizing antibodies, which may increase the likelihood of pathology upon subsequent exposure to natural infection or vaccine. Another approach to provide an engineered epitope is to deliver all or a portion of the dengue virus E protein incorporated into another flavivirus particle or VLP. In representative embodiments, the heterologous flavivirus is West Nile virus or Yellow Fever virus. Portions of the E protein can be grafted into the E protein of the heterologous flavivirus backbone, e.g., to reduce the generation of non-neutralizing dengue virus antibodies to non-neutralizing epitopes present in the dengue virus E protein and/or other dengue virus structural proteins.

Thus, a chimeric flavivirus or chimeric flavivirus VLP can present the quaternary dengue virus epitope in proper conformation while reducing the generation of non-neutralizing antibodies to other portions of the dengue virus E protein and/or other structural proteins that are not presented in the chimeric flavivirus or flavivirus VLP.

In some embodiments of the invention the individual and conformational epitopes of the flavivirus E glycoprotein or dengue virus E glycoprotein can be presented on a synthetic backbone or support structure so that the epitopes within the synthetic backbone or support structure mimic the conformation and arrangement of the epitopes within the structure of the E glycoprotein, virus particle or VLP.

In still further embodiments of the invention, the present invention provides peptide mimitopes (see, Meloen et al. (2000) *J. Mol. Recognit.* 13, 352–359) that mimic the individual and conformational epitopes of the E glycoproteins of the invention. Mimitopes may be identified using any technique known in the art, including but not limited to surface stimulation, random peptide libraries or phage display libraries, as well as an antibody or antibodies to the individual and conformational epitopes of the E glycoproteins of the invention.

The invention further provides a nucleic acid molecule (*e.g.*, isolated nucleic acid molecule) encoding a dengue virus peptide, a dengue virus protein domain, a dengue virus polypeptide or a flavivirus polypeptide of the invention.

The invention further provides a nucleic acid molecule (*e.g.*, an isolated nucleic acid molecule) encoding a chimeric flavivirus particle or a chimeric flavivirus virus-like particle (VLP) (*e.g.*, a viral coat of the flavivirus particle) of the invention.

Also provided is a nucleic acid vector comprising a nucleic acid molecule of the invention.

Also provided is a cell (*e.g.*, an isolated cell) comprising a vector, a nucleic acid molecule, a dengue virus protein, a dengue virus peptide, a dengue virus protein domain, a flavivirus protein, a flavivirus peptide, flavivirus protein domain, a chimeric dengue virus particle, a chimeric dengue virus VLP, a chimeric flavivirus VLP and/or a chimeric flavivirus particle of this invention, singly or in any combination.

The invention also provides immunogenic compositions comprising the cells, vectors, nucleic acids molecules, dengue virus proteins, chimeric dengue virus VLPs, chimeric dengue virus particles, chimeric flavivirus VLPs and/or chimeric flavivirus particles of the invention, singly or in any combination. In some embodiments, the immunogenic composition is monovalent. In some embodiments, the immunogenic composition is multivalent (*e.g.*, bivalent, trivalent or tetravalent) for dengue virus serotypes DEN1, DEN2, DEN 3 and/or DEN4 in any combination. The dengue virus chimeric E glycoproteins of this invention can be administered to a subject singly or in any combination, including any combination of priming and boosting according to such immunization protocols that are known in the art. The dengue virus chimeric E glycoprotein of this invention can be 1/2, 1/3, 1/4, 1/2/3, 1/2/4, 1/3/4, 1/2/3/4, 2/1, 2/3, 2/4, 2/1/3, 2/1/4, 2/3/4, 2/1/3/4, 3/1, 3/2, 3/4, 3/1/2, 3/1/4, 3/2/4, 3/1/2/4, 4/1, 4/2, 4/3, 4/1/3, 4/1/2, 4/3/2, or 4/3/2/1 (wherein the first number of each combination defines the serotype of the backbone and the second, third or fourth number of each combination defines the serotype of the epitope(s) or domain(s) that have been introduced into the backbone). In some embodiments, a prime/boost combination would be used that results in administration of antigens representative of all four dengue virus serotypes. Such a prime/boost regimen can include administration of any combination of antigens in any order to achieve this result. A nonlimiting example of a prime/boost protocol can include priming at day 0 and boosting at 3 months and 6 months, or boosting at 6 months and 1 year, respectively. This protocol could also be modified to include only one boost at either 3 months, 6 months or 1 year.

The invention encompasses methods of producing an immune response to a dengue virus in a subject, comprising administering to the subject an effective amount of a dengue virus protein, a chimeric dengue virus particle, a chimeric dengue virus VLP, a chimeric flavivirus VLP, a chimeric flavivirus particle, a nucleic acid molecule, a vector, a cell and/or immunogenic composition of the invention, singly or in any combination.

In some embodiments, the present invention can advantageously be practiced to induce an immune response against one, two, three or all four of the DEN1, DEN2, DEN3 and DEN4 serotypes. In some embodiments, the dengue virus chimeric E glycoprotein of this invention and/or a nucleic acid molecule encoding the dengue virus chimeric E glycoprotein of this invention can be administered to a subject singly or in any combination and/or sequence to induce an immune response (e.g., a balanced immune response, in which the parameters of dengue immunity being measured are nearly equivalent for all four DENV serotypes) to all four DENV serotypes. It is well-known in the art that effective and safe multivalent dengue vaccines have been a challenge to design because of the problem of interference among serotypes. For example, the immune response may be predominantly directed against only some of the target serotypes. Multiple vaccinations are then required to try to achieve a response against all serotypes; however, in the case of dengue virus, this approach can be dangerous because repeated administrations to a subject with pre-existing antibodies can lead to more serious complications and/or disease, such as dengue hemorrhagic fever.

A still further aspect of the invention is a method of treating a dengue virus infection, comprising administering to the subject an effective amount of a dengue virus protein, a dengue virus protein domain, a dengue virus peptide, a chimeric dengue virus particle, a chimeric dengue virus VLP, a chimeric flavivirus VLP a chimeric flavivirus particle, a nucleic acid molecule, a vector, a cell, and/or immunogenic composition of this invention, singly or in any combination or sequence of combinations.

A still further aspect of the invention is a method of preventing a dengue virus infection, comprising administering to the subject an effective amount of a dengue virus protein, a dengue virus protein domain, a dengue virus peptide, a chimeric dengue virus particle, a chimeric dengue virus VLP, a chimeric flavivirus VLP a chimeric flavivirus particle, a nucleic acid molecule, a vector, a cell, and/or immunogenic composition of this invention, singly or in any combination or sequence of combinations.

A still further aspect of the invention is a method of protecting a subject from the effects of dengue virus infection, comprising administering to the subject an effective amount

of a dengue virus protein, a dengue virus protein domain, a dengue virus peptide, a chimeric dengue virus particle, a chimeric dengue virus VLP, a chimeric flavivirus VLP a chimeric flavivirus particle, a nucleic acid molecule, a vector, a cell, and/or immunogenic composition of this invention, singly or in any combination or sequence of combinations.

5 By "protecting a subject from the effects of dengue virus infection" it is meant that the subject does not develop a disease or disorder caused by a dengue virus infection, or if the subject does develop a disease or disorder caused by a dengue virus infection, the disease or disorder is of less severity and/or symptoms are reduced and/or less severe in the subject in comparison to what the subject would experience upon infection by a dengue virus in the  
10 absence of the administration of the dengue virus protein, a dengue virus protein domain, a dengue virus peptide, a chimeric dengue virus particle, a chimeric dengue virus VLP, a chimeric flavivirus VLP a chimeric flavivirus particle, a nucleic acid molecule, a vector, a cell, and/or immunogenic composition of this invention

There are four serotypes of dengue virus (DENV-1, DENV-2, DENV-3 and DENV-  
15 4). Within each serotype there are a number of different strains or genotypes. The dengue virus epitopes and protein domains of this invention can be derived from any dengue virus, including all serotypes, strains and genotypes, now known or later identified.

In embodiments of the invention, the dengue virus is UNC1017 strain (DEN1), West Pacific 74 strain (DEN1), S16803 strain (DEN2), UNC2005 strain (DEN2), S16803 strain  
20 (DEN2), UNC3001 strain (DEN3), UNC3043 (DEN3 strain 059.AP-2 from Philippines, 1984), UNC3009 strain (DEN3, D2863, Sri Lanka 1989), UNC3066 (DEN3, strain 1342 from Puerto Rico 1977), CH53489 strain (DEN3), UNC4019 strain (DEN4), or TVP-360 (DEN4).

In embodiments of the invention, an "immunogenically active fragment" of a dengue  
25 virus polypeptide (*e.g.*, the E protein) comprises, consists essentially of or consists of at least about 6, 8, 10, 12, 15, 20, 30, 50, 75, 100, 125, 150, 200, 250, 300, 350, 400, 450 or more amino acids, optionally contiguous amino acids, and/or less than about 495, 475, 450, 425, 400, 350, 300, 250, 200, 150, 100, 75 or 50 amino acids, optionally contiguous amino acids, including any combination of the foregoing as long as the lower limit is less than the upper  
30 limit, and the "immunogenically active fragment" induces an immune response (*e.g.*, IgG and/or IgA that react with the native antigen), optionally a protective immune response, against dengue virus in a host and induces the production of antibodies (*e.g.*, neutralizing antibodies) that specifically bind to the quaternary dengue virus epitope(s) described herein.

The term “epitope” as used herein means a specific combination of amino acid residues in an amino acid sequence that, when present in the proper conformation, provides a reactive site for an antibody (*e.g.*, B cell epitope) or T cell receptor (*e.g.*, T cell epitope).

5 Portions of a given polypeptide that include a B-cell epitope can be identified using any number of epitope mapping techniques that are known in the art. (*See, e.g.*, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, Glenn E. Morris, Ed., 1996, Humana Press, Totowa, N.J.). For example, linear epitopes can be determined by, *e.g.*, concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies  
10 while the peptides are still attached to the supports. Such techniques are known in the art and described in, *e.g.*, U.S. Pat. No. 4,708,871; Geysen et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:3998-4002; Geysen et al. (1986) *Molec. Immunol.* 23:709-715.

Similarly, conformational epitopes can be readily identified by determining spatial conformation of amino acids such as by, *e.g.*, x-ray crystallography and 2-dimensional  
15 nuclear magnetic resonance. Antigenic regions of proteins can also be identified using standard antigenicity and hydropathy plots, such as those calculated using, *e.g.*, the Omega version 1.0 software program available from the Oxford Molecular Group. This computer program employs the Hopp/Woods method (Hopp et al., *Proc. Natl. Acad. Sci. USA* (1981) 78:3824-3828) for determining antigenicity profiles and the Kyte-Doolittle technique (Kyte et  
20 al., *J. Mol. Biol.* (1982) 157:105-132) for hydropathy plots.

Generally, T-cell epitopes that are involved in stimulating the cellular arm of a subject's immune system are short peptides of about 8-25 amino acids. A common way to identify T-cell epitopes is to use overlapping synthetic peptides and analyze pools of these peptides, or the individual ones, that are recognized by T cells from animals that are immune  
25 to the antigen of interest, using, for example, an enzyme-linked immunospot assay (ELISPOT). These overlapping peptides can also be used in other assays such as the stimulation of cytokine release or secretion, or evaluated by constructing major histocompatibility (MHC) tetramers containing the peptide. Such immunogenically active fragments can also be identified based on their ability to stimulate lymphocyte proliferation  
30 in response to stimulation by various fragments from the antigen of interest.

The present invention can be practiced for prophylactic, therapeutic and/or diagnostic purposes. In addition, the invention can be practiced to produce antibodies for any purpose, such as diagnostic or research purposes, or for passive immunization by transfer to another subject.

The present invention further provides a kit comprising one or more compositions of this invention. It would be well understood by one of ordinary skill in the art that the kit of this invention can comprise one or more containers and/or receptacles to hold the reagents (e.g., antibodies, antigens, nucleic acids) of the kit, along with appropriate buffers and/or diluents and/or other solutions and directions for using the kit, as would be well known in the art. Such kits can further comprise adjuvants and/or other immunostimulatory or immunomodulating agents, as are well known in the art.

The compositions and kits of the present invention can also include other medicinal agents, pharmaceutical agents, carriers, diluents, immunostimulatory cytokines, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art.

Administration to a subject can be by any route known in the art. As non-limiting examples, the route of administration can be by inhalation (e.g., oral and/or nasal inhalation), oral, buccal (e.g., sublingual), rectal, vaginal, topical (including administration to the airways), intraocular, transdermal, by parenteral (e.g., intramuscular [e.g., administration to skeletal muscle], intravenous, intra-arterial, intraperitoneal and the like), subcutaneous (including administration into the footpad), intradermal, intrapleural, intracerebral, and/or intrathecal routes.

The epitopes, polypeptides, VLPs and viral vectors of the invention can be delivered *per se* or by delivering a nucleic acid (e.g., DNA) that encodes the same.

Immunomodulatory compounds, such as immunomodulatory chemokines and cytokines (preferably, CTL inductive cytokines) can be administered concurrently to a subject.

Cytokines may be administered by any method known in the art. Exogenous cytokines may be administered to the subject, or alternatively, a nucleic acid encoding a cytokine may be delivered to the subject using a suitable vector, and the cytokine produced *in vivo*. In particular embodiments, a viral adjuvant expresses the cytokine.

In embodiments of the invention, multiple dosages (e.g., two, three or more) of a composition of the invention can be administered without detectable pathogenicity (e.g., Dengue Shock Syndrome/Dengue Hemorrhagic Fever).

In embodiments of the invention, the multivalent vaccines of the invention do not result in immune interference, e.g., a balanced immune response is induced against all antigens presented. In embodiments of the invention, the balanced response results in protective immunity against DENV-1, DENV-2, DENV-3 and DENV-4.

In embodiments of the invention, the multivalent vaccine can be administered to a subject that has anti-dengue maternal antibodies present.

It should be appreciated that the invention can be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these  
5   embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of  
10   describing particular embodiments only and is not intended to be limiting of the invention.

As used herein, "a," "an" or "the" can mean one or more than one. For example, "a" cell can mean a single cell or a multiplicity of cells.

Also as used herein, "and/or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of  
15   combinations when interpreted in the alternative ("or").

The term "about," as used herein when referring to a measurable value such as an amount of dose (*e.g.*, an amount of a fatty acid) and the like, is meant to encompass variations of  $\pm 20\%$ ,  $\pm 10\%$ ,  $\pm 5\%$ ,  $\pm 1\%$ ,  $\pm 0.5\%$ , or even  $\pm 0.1\%$  of the specified amount.

As used herein, the transitional phrase "consisting essentially of" means that the scope  
20   of a claim is to be interpreted to encompass the specified materials or steps recited in the claim, "and those that do not materially affect the basic and novel characteristic(s)" of the claimed invention. *See, In re Herz*, 537 F.2d 549, 551-52, 190 U.S.P.Q. 461, 463 (CCPA 1976) (emphasis in the original); *see also* MPEP § 2111.03. Thus, the term "consisting essentially of" when used in a claim of this invention is not intended to be interpreted to be  
25   equivalent to "comprising."

As used herein, the term "nucleic acid" encompasses both RNA and DNA, including cDNA, genomic DNA, synthetic (*e.g.*, chemically synthesized) DNA and chimeras of RNA and DNA. The nucleic acid may be double-stranded or single-stranded. The nucleic acid may be synthesized using nucleotide analogs or derivatives (*e.g.*, inosine or phosphorothioate  
30   nucleotides). Such nucleotides can be used, for example, to prepare nucleic acids that have altered base-pairing abilities or increased resistance to nucleases.

As used herein, the term "polypeptide" encompasses both peptides and proteins (including fusion proteins), unless indicated otherwise.

A "fusion protein" is a polypeptide produced when two heterologous nucleotide sequences or fragments thereof coding for two (or more) different polypeptides not found fused together in nature are fused together in the correct translational reading frame.

5 A "recombinant" nucleic acid, polynucleotide or nucleotide sequence is one produced by genetic engineering techniques.

A "recombinant" polypeptide is produced from a recombinant nucleic acid, polypeptide or nucleotide sequence.

10 As used herein, an "isolated" polynucleotide (*e.g.*, an "isolated nucleic acid" or an "isolated nucleotide sequence") means a polynucleotide at least partially separated from at least some of the other components of the naturally occurring organism or virus, for example, the cell or viral structural components or other polypeptides or nucleic acids commonly found associated with the polynucleotide. Optionally, but not necessarily, the "isolated" polynucleotide is present at a greater concentration (*i.e.*, is enriched) as compared with the starting material (*e.g.*, at least about a two-fold, three-fold, four-fold, ten-fold, twenty-fold, 15 fifty-fold, one-hundred-fold, five-hundred-fold, one thousand-fold, ten thousand-fold or greater concentration). In representative embodiments, the isolated polynucleotide is at least about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more pure.

20 An "isolated" polypeptide means a polypeptide that is at least partially separated from at least some of the other components of the naturally occurring organism or virus, for example, the cell or viral structural components or other polypeptides or nucleic acids commonly found associated with the polypeptide. Optionally, but not necessarily, the "isolated" polypeptide is present at a greater concentration (*i.e.*, is enriched) as compared with the starting material (*e.g.*, at least about a two-fold, three-fold, four-fold, ten-fold, twenty-fold, fifty-fold, one-hundred-fold, five-hundred-fold, one thousand-fold, ten thousand- 25 fold or greater concentration). In representative embodiments, the isolated polypeptide is at least about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more pure.

30 Furthermore, an "isolated" cell is a cell that has been partially or completely separated from other components with which it is normally associated in nature. For example, an isolated cell can be a cell in culture medium and/or a cell in a pharmaceutically acceptable carrier.

The terms "immunogen" and "antigen" are used interchangeably herein and mean any compound (including polypeptides) to which a cellular and/or humoral immune response can be directed. In particular embodiments, an immunogen or antigen can induce a protective immune response against the effects of dengue virus infection.

"Effective amount" as used herein refers to an amount of a vector, nucleic acid, epitope, polypeptide, cell, particle, VLP, composition or formulation of the invention that is sufficient to produce a desired effect, which can be a therapeutic and/or beneficial effect. The effective amount will vary with the age, general condition of the subject, the severity of the condition being treated, the particular agent administered, the duration of the treatment, the nature of any concurrent treatment, the pharmaceutically acceptable carrier used, and like factors within the knowledge and expertise of those skilled in the art. As appropriate, an "effective amount" in any individual case can be determined by one of ordinary skill in the art by reference to the pertinent texts and literature and/or by using routine experimentation.

The term "immunogenic amount" or "effective immunizing dose," as used herein, unless otherwise indicated, means an amount or dose sufficient to induce an immune response (which can optionally be a protective response) in the treated subject that is greater than the inherent immunity of non-immunized subjects. An immunogenic amount or effective immunizing dose in any particular context can be routinely determined using methods known in the art.

The terms "vaccine," "vaccination" and "immunization" are well-understood in the art, and are used interchangeably herein. For example, the terms vaccine, vaccination or immunization can be understood to be a process or composition that increases a subject's immune reaction to an immunogen (*e.g.*, by providing an active immune response), and therefore its ability to resist, overcome and/or recover from infection (*i.e.*, a protective immune response).

By the terms "treat," "treating" or "treatment of" (and grammatical variations thereof) it is meant that the severity of the subject's condition is reduced, at least partially improved or ameliorated and/or that some alleviation, mitigation or decrease in at least one clinical symptom is achieved and/or there is a delay in the progression of the disease or disorder. In representative embodiments, the terms "treat," "treating" or "treatment of" (and grammatical variations thereof) refer to a reduction in the severity of viremia and/or a delay in the progression of viremia, with or without other signs of clinical disease.

A "treatment effective" amount as used herein is an amount that is sufficient to treat (as defined herein) the subject. Those skilled in the art will appreciate that the therapeutic effects need not be complete or curative, as long as some benefit is provided to the subject.

The term "prevent," "preventing" or "prevention of" (and grammatical variations thereof) refer to prevention and/or delay of the onset and/or progression of a disease, disorder and/or a clinical symptom(s) in a subject and/or a reduction in the severity of the onset and/or

progression of the disease, disorder and/or clinical symptom(s) relative to what would occur in the absence of the methods of the invention. In representative embodiments, the terms "prevent," "preventing" or "prevention of" (and grammatical variations thereof) refer to prevention and/or delay of the onset and/or progression of viremia in the subject, with or  
5 without other signs of clinical disease. The prevention can be complete, *e.g.*, the total absence of the disease, disorder and/or clinical symptom(s). The prevention can also be partial, such that the occurrence of the disease, disorder and/or clinical symptom(s) in the subject and/or the severity of onset and/or the progression is less than what would occur in the absence of the present invention.

10 A "prevention effective" amount as used herein is an amount that is sufficient to prevent (as defined herein) the disease, disorder and/or clinical symptom in the subject. Those skilled in the art will appreciate that the level of prevention need not be complete, as long as some benefit is provided to the subject.

15 The efficacy of treating and/or preventing dengue virus infection by the methods of the present invention can be determined by detecting a clinical improvement as indicated by a change in the subject's symptoms and/or clinical parameters (*e.g.*, viremia), as would be well known to one of skill in the art.

20 Unless indicated otherwise, the terms "protect," "protecting," "protection" and "protective" (and grammatical variations thereof) encompass both methods of preventing and treating dengue virus infection in a subject, whether against one or multiple strains, genotypes or serotypes of dengue virus.

25 The terms "protective" immune response or "protective" immunity as used herein indicates that the immune response confers some benefit to the subject in that it prevents or reduces the incidence and/or severity and/or duration of disease or any other manifestation of infection. For example, in representative embodiments, a protective immune response or protective immunity results in reduced viremia, whether or not accompanied by clinical disease. Alternatively, a protective immune response or protective immunity may be useful in the therapeutic treatment of existing disease.

30 An "active immune response" or "active immunity" is characterized by "participation of host tissues and cells after an encounter with the immunogen. It involves differentiation and proliferation of immunocompetent cells in lymphoreticular tissues, which lead to synthesis of antibody or the development of cell-mediated reactivity, or both." Herbert B. Herscovitz, *Immunophysiology: Cell Function and Cellular Interactions in Antibody Formation*, in IMMUNOLOGY: BASIC PROCESSES 117 (Joseph A. Bellanti ed., 1985).

Alternatively stated, an active immune response is mounted by the host after exposure to immunogens by infection or by vaccination. Active immunity can be contrasted with passive immunity, which is acquired through the "transfer of preformed substances (antibody, transfer factor, thymic graft, interleukin-2) from an actively immunized host to a non-immune host." *Id.*

A "subject" of the invention includes any animal susceptible to dengue virus infection. Such a subject is generally a mammalian subject (*e.g.*, a laboratory animal such as a rat, mouse, guinea pig, rabbit, primates, *etc.*), a farm or commercial animal (*e.g.*, a cow, horse, goat, donkey, sheep, *etc.*), or a domestic animal (*e.g.*, cat, dog, ferret, *etc.*). In particular embodiments, the subject is a primate subject, a non-human primate subject (*e.g.*, a chimpanzee, baboon, monkey, gorilla, *etc.*) or a human. Subjects of the invention can be a subject known or believed to be at risk of infection by dengue virus. Alternatively, a subject according to the invention can also include a subject not previously known or suspected to be infected by dengue virus or in need of treatment for dengue virus infection.

Subjects may be treated for any purpose, such as for eliciting a protective immune response or for eliciting the production of antibodies in that subject, which antibodies can be collected and used for other purposes such as research or diagnostic purposes or for administering to other subjects to produce passive immunity therein, *etc.*

Subjects include males and/or females of any age, including neonates, juvenile, mature and geriatric subjects. With respect to human subjects, in representative embodiments, the subject can be an infant (*e.g.*, less than about 12 months, 10 months, 9 months, 8 months, 7 months, 6 months, or younger), a toddler (*e.g.*, at least about 12, 18 or 24 months and/or less than about 36, 30 or 24 months), or a child (*e.g.*, at least about 1, 2, 3, 4 or 5 years of age and/or less than about 14, 12, 10, 8, 7, 6, 5, or 4 years of age). In embodiments of the invention, the subject is a human subject that is from about 0 to 3, 4, 5, 6, 9, 12, 15, 18, 24, 30, 36, 48 or 60 months of age, from about 3 to 6, 9, 12, 15, 18, 24, 30, 36, 48 or 60 months of age, from about 6 to 9, 12, 15, 18, 24, 30, 36, 48 or 60 months of age, from about 9 to 12, 15, 18, 24, 30, 36, 48 or 60 months of age, from about 12 to 18, 24, 36, 48 or 60 months of age, from about 18 to 24, 30, 36, 48 or 60 months of age, or from about 24 to 30, 36, 48 or 60 months of age.

In embodiments of the invention, the subject has maternal antibodies to dengue virus.

A "subject in need" of the methods of the invention can be a subject known to be, or suspected of being, infected with, or at risk of being infected with, dengue virus.

Pharmaceutical formulations (*e.g.*, immunogenic formulation) comprising the dengue virus epitopes, polypeptides, chimeric flavivirus VLPs or chimeric flavivirus particles, nucleic acids, vectors, cells or compositions of the invention and a pharmaceutically acceptable carrier are also provided, and can be formulated for administration in a pharmaceutical carrier in accordance with known techniques. *See, e.g.*, Remington, *The Science And Practice of Pharmacy* (latest edition). In the manufacture of a pharmaceutical composition according to embodiments of the present invention, the composition of the invention is typically admixed with, *inter alia*, a pharmaceutically acceptable carrier. By "pharmaceutically acceptable carrier" is meant a carrier that is compatible with other ingredients in the pharmaceutical composition and that is not harmful or deleterious to the subject. The carrier may be a solid or a liquid, or both, and is preferably formulated with the composition of the invention as a unit-dose formulation, for example, a tablet, which may contain from about 0.01 or 0.5% to about 95% or 99% by weight of the composition. The pharmaceutical compositions are prepared by any of the well-known techniques of pharmacy including, but not limited to, admixing the components, optionally including one or more accessory ingredients. In certain embodiments, the pharmaceutically acceptable carrier is sterile and would be deemed suitable for administration into human subjects according to regulatory guidelines for pharmaceutical compositions comprising the carrier.

Furthermore, a "pharmaceutically acceptable" component such as a salt, carrier, excipient or diluent of a composition according to the present invention is a component that (i) is compatible with the other ingredients of the composition in that it can be combined with the compositions of the present invention without rendering the composition unsuitable for its intended purpose, and (ii) is suitable for use with subjects as provided herein without undue adverse side effects (such as toxicity, irritation, and allergic response). Side effects are "undue" when their risk outweighs the benefit provided by the composition. Non-limiting examples of pharmaceutically acceptable components include any of the standard pharmaceutical carriers such as phosphate buffered saline solutions, water, emulsions such as oil/water emulsion, microemulsions and various types of wetting agents.

In some embodiments, the compositions of the invention can further comprise one or more than one adjuvant. The adjuvants of the present invention can be in the form of an amino acid sequence, and/or in the form of a nucleic acid encoding an adjuvant. When in the form of a nucleic acid, the adjuvant can be a component of a nucleic acid encoding the polypeptide(s) or fragment(s) or epitope(s) and/or a separate component of the composition comprising the nucleic acid encoding the polypeptide(s) or fragment(s) or epitope(s) of the

invention. According to the present invention, the adjuvant can also be an amino acid sequence that is a peptide, a protein fragment or a whole protein that functions as an adjuvant, and/or the adjuvant can be a nucleic acid encoding a peptide, protein fragment or whole protein that functions as an adjuvant. As used herein, "adjuvant" describes a substance, which  
5 can be any immunomodulating substance capable of being combined with a composition of the invention to enhance, improve or otherwise modulate an immune response in a subject.

In further embodiments, the adjuvant can be, but is not limited to, an immunostimulatory cytokine (including, but not limited to, GM-CSF, interleukin-2, interleukin-12, interferon-gamma, interleukin-4, tumor necrosis factor-alpha, interleukin-1,  
10 hematopoietic factor flt3L, CD40L, B7.1 co-stimulatory molecules and B7.2 co-stimulatory molecules), SYNTEX adjuvant formulation 1 (SAF-1) composed of 5 percent (wt/vol) squalene (DASF, Parsippany, N.J.), 2.5 percent Pluronic, L121 polymer (Aldrich Chemical, Milwaukee), and 0.2 percent polysorbate (Tween 80, Sigma) in phosphate-buffered saline. Suitable adjuvants also include an aluminum salt such as aluminum hydroxide gel (alum),  
15 aluminum phosphate, or alganmmulin, but may also be a salt of calcium, iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivatized polysaccharides, or polyphosphazenes.

Other adjuvants are well known in the art and include without limitation MF 59, LT-K63, LT-R72 (Pal et al., *Vaccine* 24(6):766-75 (2005)), QS-21, Freund's adjuvant (complete  
20 and incomplete), aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn -glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE) and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A,  
25 trealose dimycolate and cell wall skeleton (MPL+TDM+CWS) in 2% squalene/Tween 80 emulsion.

Additional adjuvants can include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl. lipid A (3D-MPL) together with an aluminum salt. An enhanced adjuvant system involves the combination of a monophosphoryl  
30 lipid A and a saponin derivative, particularly the combination of QS21 and 3D-MPL as disclosed in PCT publication number WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as disclosed in PCT publication number WO 96/33739. A particularly potent adjuvant formulation involving QS21 3D-MPL & tocopherol in an oil in water emulsion is described in PCT publication number WO 95/17210. In

addition, the nucleic acid compositions of the invention can include an adjuvant by comprising a nucleotide sequence encoding the antigen and a nucleotide sequence that provides an adjuvant function, such as CpG sequences. Such CpG sequences, or motifs, are well known in the art.

5           An adjuvant for use with the present invention, such as, for example, an immunostimulatory cytokine, can be administered before, concurrent with, and/or within a few hours, several hours, and/or 1, 2, 3, 4, 5, 6, 7, 8, 9, and/or 10 days before and/or after the administration of a composition of the invention to a subject.

10           Furthermore, any combination of adjuvants, such as immunostimulatory cytokines, can be co-administered to the subject before, after and/or concurrent with the administration of an immunogenic composition of the invention. For example, combinations of immunostimulatory cytokines, can consist of two or more immunostimulatory cytokines, such as GM-CSF, interleukin-2, interleukin-12, interferon-gamma, interleukin-4, tumor necrosis factor-alpha, interleukin-1, hematopoietic factor flt3L, CD40L, B7.1 co-stimulatory  
15           molecules and B7.2 co-stimulatory molecules. The effectiveness of an adjuvant or combination of adjuvants can be determined by measuring the immune response produced in response to administration of a composition of this invention to a subject with and without the adjuvant or combination of adjuvants, using standard procedures, as described herein and as known in the art.

20           In embodiments of the invention, the adjuvant comprises an alphavirus adjuvant as described, for example in U.S. Patent No. 7,862,829.

          Boosting dosages can further be administered over a time course of days, weeks, months or years. In chronic infection, initial high doses followed by boosting doses may be advantageous.

25           The pharmaceutical formulations of the invention can optionally comprise other medicinal agents, pharmaceutical agents, stabilizing agents, buffers, carriers, diluents, salts, tonicity adjusting agents, wetting agents, and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, *etc.*

30           For injection, the carrier will typically be a liquid. For other methods of administration, the carrier may be either solid or liquid. For inhalation administration, the carrier will be respirable, and is typically in a solid or liquid particulate form.

          The compositions of the invention can be formulated for administration in a pharmaceutical carrier in accordance with known techniques. See, e.g., Remington, The

Science And Practice of Pharmacy (9<sup>th</sup> Ed. 1995). In the manufacture of a pharmaceutical composition according to the invention, the VLPs are typically admixed with, inter alia, an acceptable carrier. The carrier can be a solid or a liquid, or both, and is optionally formulated with the compound as a unit-dose formulation, for example, a tablet. A variety of

5 pharmaceutically acceptable aqueous carriers can be used, e.g., water, buffered water, 0.9% saline, 0.3% glycine, hyaluronic acid, pyrogen-free water, pyrogen-free phosphate-buffered saline solution, bacteriostatic water, or Cremophor EL[R] (BASF, Parsippany, N.J.), and the like. These compositions can be sterilized by conventional techniques. The formulations of the invention can be prepared by any of the well-known techniques of pharmacy.

10 The pharmaceutical formulations can be packaged for use as is, or lyophilized, the lyophilized preparation generally being combined with a sterile aqueous solution prior to administration. The compositions can further be packaged in unit/dose or multi-dose containers, for example, in sealed ampoules and vials.

The pharmaceutical formulations can be formulated for administration by any method

15 known in the art according to conventional techniques of pharmacy. For example, the compositions can be formulated to be administered intranasally, by inhalation (*e.g.*, oral inhalation), orally, buccally (*e.g.*, sublingually), rectally, vaginally, topically, intrathecally, intraocularly, transdermally, by parenteral administration (*e.g.*, intramuscular [*e.g.*, skeletal muscle], intravenous, subcutaneous, intradermal, intrapleural, intracerebral and intra-arterial,

20 intrathecal), or topically (*e.g.*, to both skin and mucosal surfaces, including airway surfaces).

For intranasal or inhalation administration, the pharmaceutical formulation can be formulated as an aerosol (this term including both liquid and dry powder aerosols). For example, the pharmaceutical formulation can be provided in a finely divided form along with a surfactant and propellant. Typical percentages of the composition are 0.01-20% by weight,

25 preferably 1-10%. The surfactant is generally nontoxic and soluble in the propellant.

Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute

30 0.1-20% by weight of the composition, preferably 0.25-5%. The balance of the composition is ordinarily propellant. A carrier can also be included, if desired, as with lecithin for intranasal delivery. Aerosols of liquid particles can be produced by any suitable means, such as with a pressure-driven aerosol nebulizer or an ultrasonic nebulizer, as is known to those of skill in the art. *See, e.g.*, U.S. Patent No. 4,501,729. Aerosols of solid particles can likewise

be produced with any solid particulate medicament aerosol generator, by techniques known in the pharmaceutical art. Intranasal administration can also be by droplet administration to a nasal surface.

Injectable formulations can be prepared in conventional forms, either as liquid  
5 solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Alternatively, one can administer the pharmaceutical formulations in a local rather than systemic manner, for example, in a depot or sustained-release formulation.

Extemporaneous injection solutions and suspensions can be prepared from sterile  
10 powders, granules and tablets of the kind previously described. For example, an injectable, stable, sterile formulation of the invention in a unit dosage form in a sealed container can be provided. The formulation can be provided in the form of a lyophilizate, which can be reconstituted with a suitable pharmaceutically acceptable carrier to form a liquid composition suitable for injection into a subject. The unit dosage form can be from about 1  $\mu$ g to about 10  
15 grams of the formulation. When the formulation is substantially water-insoluble, a sufficient amount of emulsifying agent, which is pharmaceutically acceptable, can be included in sufficient quantity to emulsify the formulation in an aqueous carrier. One such useful emulsifying agent is phosphatidyl choline.

Pharmaceutical formulations suitable for oral administration can be presented in  
20 discrete units, such as capsules, cachets, lozenges, or tablets, as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. Oral delivery can be performed by complexing a compound(s) of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers include plastic capsules or tablets, as known in the art.  
25 Such formulations are prepared by any suitable method of pharmacy, which includes the step of bringing into association the protein(s) and a suitable carrier (which may contain one or more accessory ingredients as noted above). In general, the pharmaceutical formulations are prepared by uniformly and intimately admixing the compound(s) with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the resulting mixture. For  
30 example, a tablet can be prepared by compressing or molding a powder or granules, optionally with one or more accessory ingredients. Compressed tablets are prepared by compressing, in a suitable machine, the formulation in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, and/or surface

active/dispersing agent(s). Molded tablets are made by molding, in a suitable machine, the powdered protein moistened with an inert liquid binder.

Pharmaceutical formulations suitable for buccal (sub-lingual) administration include lozenges comprising the compound(s) in a flavored base, usually sucrose and acacia or tragacanth; and pastilles in an inert base such as gelatin and glycerin or sucrose and acacia.

Pharmaceutical formulations suitable for parenteral administration can comprise sterile aqueous and non-aqueous injection solutions, which preparations are preferably isotonic with the blood of the intended recipient. These preparations can contain anti-oxidants, buffers, bacteriostats and solutes, which render the composition isotonic with the blood of the intended recipient. Aqueous and non-aqueous sterile suspensions, solutions and emulsions can include suspending agents and thickening agents. Examples of nonaqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.

Pharmaceutical formulations suitable for rectal administration are optionally presented as unit dose suppositories. These can be prepared by admixing the active agent with one or more conventional solid carriers, such as for example, cocoa butter and then shaping the resulting mixture.

Pharmaceutical formulations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers that can be used include, but are not limited to, petroleum jelly, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof. In some embodiments, for example, topical delivery can be performed by mixing a pharmaceutical formulation of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

Pharmaceutical formulations suitable for transdermal administration can be in the form of discrete patches adapted to remain in intimate contact with the epidermis of the subject for a prolonged period of time. Formulations suitable for transdermal administration can also be delivered by iontophoresis (*see*, for example, *Pharmaceutical Research* 3:318

(1986)) and typically take the form of a buffered aqueous solution of the compound(s). Suitable formulations can comprise citrate or bis/tris buffer (pH 6) or ethanol/water and can contain from 0.1 to 0.2M active ingredient.

In embodiments of the invention, the dosage of a virus particle of this invention can be in a range of about  $10^3$  to about  $10^8$  plaque forming units/focus forming units (PFUs/FFUs). In embodiments of this invention, the dosage of a VLP of this invention can be in a range of about 500 micrograms to about 5 milligrams. In embodiments of this invention, the dosage of a protein of this invention can be in a range of about  $10^0$  to about  $10^4$  micrograms +/- adjuvant.

Further, the composition can be formulated as a liposomal formulation. The lipid layer employed can be of any conventional composition and can either contain cholesterol or can be cholesterol-free. The liposomes that are produced can be reduced in size, for example, through the use of standard sonication and homogenization techniques.

The liposomal formulations can be lyophilized to produce a lyophilizate which can be reconstituted with a pharmaceutically acceptable carrier, such as water, to regenerate a liposomal suspension.

The immunogenic formulations of the invention can optionally be sterile, and can further be provided in a closed pathogen-impermeable container.

## EXAMPLES

### **EXAMPLE 1. Transplantation of a complex quaternary serotype-specific neutralizing antibody epitope between dengue 3 and 4 reveals determinants of polyclonal neutralization responses**

Dengue virus (DENV) is the most significant human arboviral disease worldwide with upwards of 300 million infections annually; however the determinants of human immune responses to DENV infection remain largely unknown. Thus we set out to develop tools with which to characterize antibody (Ab) responses to DENV infection in humans. Using reverse genetics we developed infectious clones (IC) for all 4 DENV serotypes which allow us to study Ab-virus interactions. Characterization of a panel of monoclonal Abs (mAb) identified a strongly type-specific neutralizing Ab of DENV3. Using a structure-guided approach a 12Å region of the envelope (E) protein domain I/II (EDI/II) hinge region encompassing mutations that led to escape of neutralization was identified and transplanted from DENV4 into DENV3 (rDENV3/4) to assess the contribution of this epitope to the polyclonal immune response in humans. Interestingly, this rDENV3/4 gained full sensitivity

to neutralization by human DENV4 immune sera while becoming resistant to DENV3 sera, indicating that this EDI/II hinge region contains major determinants of type-specific neutralization responses. When the reciprocal transplant was made into DENV4, mAb binding was not retained and there was not a significant shift in neutralization profiles, indicating that the adjacent residues in the recipient DENV serotype play a role in epitope presentation on the virion surface. The addition of 5 amino acid residues from DENV3 into DENV4 was able to restore mAb binding and neutralization, however polyclonal serum neutralization remained largely unchanged. Finally, we moved a complex quaternary epitope encompassing residues spanning multiple E dimers into DENV4 (rDENV4/3). This DENV4/3 was viable and grew to high infectious titers and exhibited sensitivity to DENV3 immune sera, while neutralization responses to DENV4 remained largely unchanged. These results provide insights into the determinants of type specific neutralization responses that could guide future development of rationally designed DENV vaccine platforms.

## **EXAMPLE 2. Development and characterization of a recombinant dengue 4 virus that captures type-specific neutralization determinants of both dengue 3 and dengue 4**

### *Development of a reverse genetics platform for recombinant DENV4 generation*

We have previously described the generation and characterization of a reverse genetics system for production of recombinant DENV3 (rDENV3) (**Fig. 1, Panel A**).

Utilizing similar techniques we have developed a cDNA infectious clone (IC) system for a clinical isolate of DENV4 isolated in Sri Lanka in 1989 and belonging to genogroup I. In order to circumvent instability and toxicity during bacterial plasmid amplification in *E coli*, the DENV4 genome was subcloned into 4 distinct fragments (**Fig. 1, Panel A**). Naturally occurring class IIs restriction endonuclease sites in the DENV4 genome at nucleotide (NT) position 3216 (PflMI; recognition sequence: CCAAACAGTGG, SEQ ID NO:7), 5482 (DraIII; CACCAGGTG), and 8855 (PflMI; CCAGATTTTGG, SEQ ID NO:8) were utilized to divide the genomic cDNA. Additionally, an EcoRV site in the bacterial vector and upstream of a T7 promoter sequence was used to generate the 5' end of the genome, while a BsmBI site in the vector was used for the 3' genomic end (**Fig. 1, Panel A**). Following bacterial amplification of plasmids containing genomic cDNA fragments, plasmids were digested with appropriate restriction endonucleases, purified by agarose gel electrophoresis, ligated with T4 DNA ligase, and transcribed with T7 RNA polymerase containing 5' cap analogue. *In vitro* transcribed RNAs were then electroporated into either Vero-81 or BHK-21 cells. Cells were cultured for 4-6 days at which time supernatants were collected, clarified by

centrifugation, and passaged onto C6/36 (*Aedes albopictus*) cells for an additional 4 days. Supernatants were again collected and clarified, and titrated for use as working viral stocks. rDENV4 demonstrated phenotypic properties (growth kinetics, peak infectious titers, and infectious focus morphology/size) identical to that of the parental natural isolate.

#### 5 *Transplantation of a type-specific neutralizing DENV3 mAb epitope into DENV4*

Previous studies have identified a strongly type-specific human monoclonal antibody (hmAb) specific for DENV3 (5J7). These studies, however, only identified single point mutations that led to escape of DENV3 neutralization from this hmAb. In order to further characterize this hmAb epitope, we sought to transplant the amino acid (AA) residues encompassing this epitope from DENV3 into DENV4 using our novel reverse genetics platform. Using both the published and unpublished escape mutations as a guide, an approximately 12 angstrom circumference encompassing the envelope domain I/II (EDI/II) hinge region was superimposed upon the DENV3 E protein crystal structure to approximate the footprint of an antibody epitope:paratope binding region. Following AA and NT alignments between DENV3 and DENV4, interserotypic variant AA were identified and selected for transplantation from DENV3 into DENV4. NT sequences in the DENV4 IC were modified to facilitate AA changes to match DENV3, and subgenomic cDNAs capturing these changes were synthesized (BioBasic; Amherst, NY). rDENV were generated as described above, and recovered virus used for phenotypic characterization. In order to maximize probability of successful epitope transplantation, 3 distinct rDENV were generated each containing sequentially additional DENV3 residues and thus transplanting larger theoretical epitope footprints. These rDENV have been designated DENV4 M12, DENV4 M14, and DENV4 M16, with increasing sizes of DENV3 sequence transplanted respectively (**Fig. 1, Panels B-C**). Of note, the DENV3 transplantation into DENV4 M16 encompasses a hypothetical complex quaternary epitope of 5J7, and to our knowledge represents the first time an epitope of this nature has been transplanted between distinct viruses.

#### *rDENV4/3 viruses are viable and demonstrate distinct fitness characteristics in vitro*

All 3 of the rDENV4/3 viruses (DENV4 M12, M14, and M16) were successfully recovered following electroporation and subsequent passage on C6/36 cells. Peak infectious titers from C6/36 cells (and measured by focus formation assay on Vero-81 cells) were found to be comparable to that of the parental WT DENV3 and DENV4 IC (**Fig. 2, Panel A**). DENV4 M12 and M14 demonstrated a peak titer similar to that of WT DENV3, all of which are approximately 1log<sub>10</sub> lower than that of WT DENV4 in this system. DENV4 M16, however, displayed a more attenuated growth phenotype with peak titers reaching about

2x10<sup>6</sup> ffu/ml, about 50-fold less than WT DENV3 and 300-fold less than WT DENV4 (**Fig. 2, Panel A**). Correspondingly, infectious foci size was also smaller in the rDENV as compared to their WT parents. DENV4 M12 and M14 foci are smaller than WT, but still significantly larger than DENV4 M16, which forms very small pinpoint foci on Vero-81 cells (**Fig. 2, Panel B**).

Similar fitness analyses were carried out on C6/36 mosquito cells. Multi-step growth curves (MOI=0.01) were performed on DENV4 M12, M14, M16, and parental WT DENV3 and DENV4 (**Fig. 3, Panel A**). In general, no significant fitness defects were seen at early time points (<96hr post-inoculation (hpi)) however DENV4 M14 lagged behind WT at 96 and 120hpi before demonstrating a burst at 144hpi. Additionally, DENV4 M16 displayed decreased growth kinetics at 120hpi and later with infectious titers about 2log<sub>10</sub> lower than other strains. In each case cell health could have played a role in this attenuation and as such further investigation is required. These data do, however, indicate that at least at early time points in infection the rDENV do not demonstrate significant growth attenuation in arthropod cells as compared to WT DENV. Interestingly, in contrast to Vero cells, infectious foci of DENV4 M12, M14, and M16 (**Fig. 3, Panel B**) do not show substantial differences in size or morphology as compared to WT DENV3 or 4, or to each other. This correlated well with growth curve data, and suggests that determinants of rDENV attenuation may be cell type specific to Vero-81 and/or mammalian cells in general. These data indicate that rDENV4 viruses containing transplanted regions of DENV3 are viable and demonstrate suitable growth characteristics for further characterization.

*rDENV4/3 display varying degrees of reactivity to hmAb 5J7*

Assays were performed to determine the level to which the epitope for hmAb 5J7 was transplanted from DENV3 into DENV4 in the 3 rDENV. ELISAs were undertaken to assess binding of the DENV3-specific hmAb 5J7 to both WT and rDENV viruses. These revealed that 5J7 bound WT DENV3, but not DENV4, consistent with previous data. Interestingly, 5J7 was completely unable to bind DENV4 M12, while both DENV4 M14 and M16 displayed enough of the DENV3 epitope to facilitate 5J7 binding at levels near or exceeding that of WT DENV3 (**Fig. 4, Panel A**). These data indicate that no more than 4 AA (the difference in transplanted AA between DENV4 M12 and M14) were responsible for conferring 5J7 binding to DENV4 M14. As a corollary to these binding studies, virus neutralization assays were performed using 5J7 to assess sensitivity to neutralization of the rDENV4 panel. In agreement with the ELISA binding data, DENV4 M12 was incapable of neutralization with 5J7, while both DENV4 M14 and M16 were neutralized by 5J7 at Ab

concentrations comparable to that of WT DENV3 (Fig. 4B and C). Significantly, these results were consistent (for DENV4 M14) in 2 distinct cell lines (Vero-81 and U937 expressing DC-

SIGN) believed to capture neutralization sensitivities for highly distinct (mature vs.

immature) virus particles, indicating particle maturation state of these rDENV may not affect

5 5J7 neutralization.

*rDENV4/3 have bivalent sensitivity to polyclonal serum neutralization*

In order to assess sensitivity to polyclonal antibody neutralization of our rDENV4/3 panel, donor sera collected from convalescent patients following primary DENV infection was used in focus reduction (Vero-81) and flow cytometry-based (U937-DC-SIGN) assays.

10 As with ELISA binding and 5J7 hmAb neutralization assays, DENV4 M12 did not demonstrate an increased sensitivity to neutralization by DENV3-specific sera in Vero cells (Fig. 5, Panel D). DENV4 M14, however, displayed a neutralization phenotype nearly

identical to that of WT DENV3 and significantly greater than that of WT DENV4 (Fig. 5, Panels A-C) in Vero cells indicating that this rDENV4/3 virus had gained sensitivity to

15 neutralization by polyclonal antibody responses generated by natural DENV3 infection in humans. Furthermore, this phenotype was confirmed in U937-DC-SIGN cells, and extended to DENV4 M16 (Fig. 5, Panels E-G) where for both rDENV polyclonal neutralization by DENV3 antisera was comparable to WT DENV3 while WT DENV4 was not neutralized at even the lowest serum dilution (1:20). Because of the small focus phenotype of DENV4 M16

20 on Vero cells, neutralization assays in this cell type were technically challenging and as such neutralization data for this rDENV is limited to U937-DC-SIGN, as the flow cytometry-based assay is easily performed on even attenuated viruses. Taken together these data indicate that DENV4 M14 and M16 have captured polyclonal determinants of DENV3 type-specific neutralization and demonstrate bivalency in neutralization sensitivity.

25 In addition to the gain of sensitivity to DENV3 polyclonal neutralization of our rDENV, we were interested in determining the retention and/or loss of DENV4 neutralization sensitivity of DENV4 M12, M14, and M16. To this end neutralization assays were performed in Vero (Fig. 6, Panel A) and U937-DC-SIGN (Fig. 6, Panels B-D) with sera collected from convalescent primary DENV4 patients. While DENV4 M12 demonstrated a slightly lower

30 neutralization titer than WT DENV4 in Vero cells (Fig. 6, Panel A), DENV4 M14 and M16 had neutralization titers equal to or exceeding WT DENV4 in both cell types (Fig. 6, Panels A-D). This significant finding suggests that the determinants of type-specific neutralization for DENV3 and DENV4 are discrete elements on the E glycoprotein, and that determinant AA sequences of the 2 can be combined without altering each other. As such DENV4 M14

and M16 have the potential to be utilized as important reagents for both vaccine diagnostics or to guide the development of new and/or improved vaccine candidates.

*rDENV4/3 polyclonal neutralization sensitivity is specific*

To eliminate the possibility that the panel of rDENV4/3 viruses had been modified in such a way as to increase their sensitivity to neutralization in a non-specific manner, neutralization assays with primary DENV1 and DENV2 sera collected from convalescent human patients were performed. Primary DENV1 sera were completely incapable of neutralizing either DENV4 M12 or M14 in Vero cells, in direct contrast to WT DENV1 which was neutralized to high levels (**Fig. 7, Panels A-B**). Additionally, DENV2 sera was also incapable of neutralizing DENV4 M14, although one sample tested did neutralize DENV4 M12, albeit at levels far lower than that of WT DENV2 (**Fig. 7, Panels C-D**). Taken together these results indicate that the gain of DENV3 neutralization sensitivity in the DENV4 background is specific for DENV3 and not the result of global structural changes that make the rDENV panel more sensitive to neutralization by heterotypic sera.

**EXAMPLE 3. Development and characterization of a recombinant dengue 2 virus that captures type-specific neutralization determinants of both dengue 1 and dengue 2**

*Development of a reverse genetics platform for recombinant DENV1 and DENV2 generation*

We have previously described the generation and characterization of a reverse genetics system for production of recombinant DENV3 (rDENV3). Utilizing similar techniques we have developed a cDNA infectious clone (IC) system for DENV1 Western Pacific 1974 (WestPac74) along with a clinical isolate of DENV2 isolated from an epidemic in Nicaragua in 2007 (V1210). In order to circumvent instability and toxicity during bacterial plasmid amplification in *E coli*, both genomes were subcloned into 4 distinct fragments (**Fig. 8, Panel A**). Naturally occurring class IIs restriction endonuclease sites in the DENV1 genome at nucleotide (NT) position 2052 (PflMI; recognition sequence: CCACCTTTTGG, SEQ ID NO:9), 4215 (PflMI; CCACTAGCTGG, SEQ ID NO:10), and 8563 (PflMI; CCAAACCATGG, SEQ ID NO:11) were utilized to divide the genomic cDNA. Additionally, an EcoRV site in the bacterial vector and upstream of a T7 promoter sequence was used to generate the 5' end of the genome, while a SapI site in the vector was used for the 3' genomic end (**Fig. 8, Panel A**). For DENV2, the first genomic division was produced at position 2340 (DraIII between fragment A and vector; recognition sequence: CACTGTGTG). In order to preserve genomic sequence, a DraIII site (CACnnnGTG) was utilized for the 3' end of the A fragment, while an AlwNI (CAGnnnCTG) site was used for

the 5' end of the B fragment. By mutating the endonuclease recognition sequence in the vector region of the recognition site (and not the DENV genomic sequence), the ligated product of these two restriction endonuclease digests preserves the native DENV2 genomic sequence without the introduction of mutations into the DENV genome to facilitate digestion.

5 Additional genomic junctions at NT 4662 (DraIII; CACGTGGTG), and 7414 (DraIII; CACACTGTG) were utilized to divide the genomic cDNA. Additionally, a SpeI site in the bacterial vector and upstream of a T7 promoter sequence was used to generate the 5' end of the genome, while an EciI site in the vector was used for the 3' genomic end (**Fig. 8, Panel A**). Following bacterial amplification of plasmids containing genomic cDNA fragments, 10 plasmids were digested with appropriate restriction endonucleases, purified by agarose gel electrophoresis, ligated with T4 DNA ligase, and transcribed with T7 RNA polymerase containing 5' cap analogue. *In vitro* transcribed RNAs were then electroporated into either Vero-81 or BHK-21 cells. Cells were cultured for 4-6 days at which time supernatants were collected, clarified by centrifugation, and passaged onto C6/36 (*Aedes albopictus*) cells for an 15 additional 4 days. Supernatants were again collected and clarified, and titrated for use as working viral stocks. rDENV1 and rDENV2 demonstrated phenotypic properties (growth kinetics, peak infectious titers, and infectious focus morphology/size) identical to that of the parental natural isolate (data not shown).

#### *Transplantation of a strongly neutralizing DENV1 mAb epitope into DENV2 IC*

20 Previous studies have identified a strongly type-specific human monoclonal antibody (hmAb) specific for DENV1 (1F4). Utilizing the crystal structure of this mAb bound to DENV1, and the contact amino acid (AA) residues identified, we sought to transplant the AA residues encompassing this epitope from DENV1 into DENV2 using our novel reverse genetics platform. Following AA and NT alignments between DENV1 and DENV2, 25 interserotypic variant AA were identified and selected for transplantation from DENV1 into DENV2. NT sequences in the DENV2 IC were modified to facilitate AA changes to match DENV1 (**Fig. 8, Panels B-C**), and subgenomic cDNAs capturing these changes were synthesized (BioBasic; Amherst, NY). rDENV were generated as described above, and recovered virus used for phenotypic characterization. This rDENV has been designated 30 DENV2-1F4E (**Fig. 8, Panels B-C**).

#### *rDENV2/1 viruses are viable and demonstrate distinct fitness characteristics in vitro*

rDENV2/1 was successfully recovered following electroporation and subsequent passage on C6/36 cells. Peak infectious titers from C6/36 cells were measured and found to be comparable to that of the parental WT DENV1 and DENV2 IC on C6/36 cells (**Fig. 9,**

**Panel B**), although highly attenuated (approximately  $3\log_{10}$ ) on Vero cells (**Fig. 9, Panel A**). Fitness analyses were carried out on C6/36 mosquito cells, with multi-step growth curves (MOI=0.01) (**Fig. 9, Panel C**). In general, no significant fitness defects were seen at early time points (<96hr post-inoculation (hpi)). DENV2-1F4E Showed a drop in titer at 96hpi  
 5 however this was an isolated lag as by 120hpi and beyond titers were equivalent to WT DENV 1 and 2 (**Fig. 9, Panel C**). Cell health could have played a role in this isolated attenuated time point and as such further investigation is required. These data do, however, indicate that DENV2-1F4E does not demonstrate significant growth attenuation in arthropod cells as compared to WT DENV1 and 2. Correspondingly to growth kinetic data, DENV2-  
 10 1F4E (**Fig. 9D**) does, **Panel** not show a substantial difference in size or morphology of infectious foci as compared to WT DENV1 or 2. These data indicate that rDENV2-1F4E containing a transplanted region of DENV1 is viable and demonstrates suitable growth characteristics for further characterization.

*hmAb 1F4 binds rDENV2/1*

15 Assays were performed to determine the level to which the epitope for hmAb 1F4 was transplanted from DENV1 into DENV2 in DENV2-1F4E. ELISAs were undertaken to assess binding of the DENV1-specific hmAb 1F4 to both WT and rDENV viruses. These revealed that 1F4 bound WT DENV1, but not DENV2, consistent with previous data. Interestingly, 1F4 bound DENV2-1F4E at levels comparable to WT DENV1 (**Fig. 10, Panel A**). These  
 20 data indicate that residues identified in the crystal structure of 1F4 bound to DENV1 are sufficient to transplant monoclonal Ab binding between DENV1 and 2. As a corollary to these binding studies, virus neutralization assays were performed using 1F4 and DENV2-1F4E. In agreement with the ELISA binding data, DENV2-1F4E was neutralized by 1F4 at Ab concentrations comparable to that of WT DENV1 (**Fig. 10, Panels B-C**). Significantly,  
 25 these results were consistent 2 distinct cell lines (C6/36 and U937 expressing DC-SIGN).

*rDENV2/1 has bivalent sensitivity to polyclonal serum neutralization*

In order to assess sensitivity to polyclonal antibody neutralization of our rDENV2/1 virus, donor sera collected from convalescent patients following primary DENV1 infection was used in flow cytometry-based (U937-DC-SIGN) assays. Because of the small focus  
 30 phenotype of DENV2-1F4E on Vero cells, neutralization assays in this cell type were technically challenging and as such neutralization data for this rDENV is limited to U937-DC-SIGN, as the flow cytometry-based assay is easily performed on even attenuated viruses. As with ELISA binding and 1F4 hmAb neutralization assays, DENV2-1F4E displayed a neutralization phenotype nearly identical to that of WT DENV1 and significantly greater than

that of WT DENV2 in U937-DC-SIGN cells (**Fig. 11, Panels A-B**), indicating that this rDENV2/1 virus had gained sensitivity to neutralization by polyclonal antibody responses generated by natural DENV1 infection in humans. These data along with the hmAb 1F4 data indicate that DENV2-1F4E captured polyclonal determinants of DENV1 type-specific neutralization and demonstrates bivalency in neutralization sensitivity.

In addition to the gain of sensitivity to DENV1 polyclonal neutralization of our rDENV, we were interested in determining the retention and/or loss of DENV2 neutralization sensitivity of DENV2-1F4E. To this end neutralization assays were performed in U937-DC-SIGN (**Fig. 11, Panels C-E**) with sera collected from convalescent primary DENV2 patients. Significantly, DENV2-1F4E had neutralization titers equal to or exceeding WT DENV2 in all cases. This finding suggests that the determinants of type-specific neutralization for DENV1 and DENV2 are discreet elements on the E glycoprotein, and that determinant AA sequences of the 2 can be combined without altering each other. As such DENV2-1F4E has the potential to be utilized as important reagents for both vaccine diagnostics or to guide the development of new and/or improved vaccine candidates.

#### *rDENV2/1 is attenuated in a murine model of DENV pathogenesis*

In order to assess the level of attenuation of our chimeric rDENV, we compared lethality of DENV2-1F4E to its parental WT DENV1 and DENV2 in an immunocompromised mouse model of DENV disease. C57BL/6 deficient in both the interferon  $\alpha/\beta$  receptor and the interferon  $\gamma$  receptor were inoculated intraperitoneally with  $3.3 \times 10^6$  ffu (C6/36 titer) of DENV1, DENV2, or DENV2-1F4E. Mice were weighed and monitored for 56dpi until termination of the study. As shown in **Fig. 12**, while mice inoculated with WT DENV1 and DENV2 displayed a >80% mortality rate, no mice receiving an equivalent dose of DENV2-1F4E succumbed to infection ( $p=0.0076$ ) demonstrating a high degree of attenuation for this rDENV. These data indicate that chimerization of DENV to generate bivalent viruses introduces a level of *in vivo* attenuation that may be suitable for vaccine development.

#### **EXAMPLE 4. Use of chimeric recombinant dengue virus to map the serotype 2 neutralizing human antibody response**

Dengue virus (DENV; DV) is the most significant human arboviral pathogen worldwide with an estimated 390 million infections and 96 million symptomatic cases annually. Nearly half the global population is at risk of disease, yet there are no licensed vaccines or therapeutics to treat or prevent dengue disease. Dengue infection can manifest as

dengue fever, a self-limiting febrile illness characterized by severe bone and joint pain, or more severe forms known as dengue hemorrhagic fever and dengue shock syndrome which are punctuated by improper clotting, vascular leakage, and in the most severe instances multiple organ failure that is typically fatal. Dengue virus exists as four distinct serotypes, and infection with one serotype does not confer protection from subsequent infection with others. In fact, immunity to a single dengue serotype is associated with an increased risk of severe disease upon infection with another serotype, a confounding factor for vaccine design. Traditional vaccination strategies have utilized a cocktail of four distinct viruses to elicit equivalent immune responses to each serotype, however none to date have consistently achieved this goal. As such there is a desperate need for diagnostic tools to aid our understanding of the complex immune response to dengue infection, and for new technologies to guide and produce new vaccine designs. This invention report describes the generation of a panel of novel recombinant chimeric dengue viruses containing critical antigenic components of heterologous serotypes that can be used to characterize human antibody responses to multiple serotypes and also to generate new multivalent vaccine candidates capable of eliciting immune responses to multiple serotypes within the context of a single virus inoculum. We believe that this strategy of antigen transplantation is compatible with multiple vaccine platforms for other human and animal pathogens, and importantly, represents a major breakthrough in dengue virus vaccine development.

#### *Generation of rDENV4/2 virus*

To identify amino acids residues that differ between DENV2 and DENV4, amino acid sequences of the envelope domain III (EDIII) region (amino acid positions 296-395) were aligned (**Fig. 13, Panel A**). Residues differing between DENV2 and DENV4 were highlighted, 40 total, and those residues from DENV4 were replaced with those from DENV2 by making the fewest nucleotide changes as possible. The 40 differing amino acids span the entire EDIII, including surface exposed residues, internal residues, and residues on the edges of the domain, likely which interact with other monomers, and dimers (**Fig. 13, Panel B**). Generation of recombinant virus utilizes four-fragment cloning strategy used to create parental wild-type viruses. DENV-4 A plasmid cassette contains envelope glycoprotein, with EDIII highlighted in grey (**Fig. 13, Panel C**). Using DENV-4 B, C, and D plasmid cassettes with recombinant DENV-4 A, DV4-EDIII-DV2 virus can be generated. Of 40 amino acid changes introduced into the recombinant virus, 14 of the amino acids introduce a change of charge (**Table 1**). Six residues increase negative charge, and eight residues introduce a more positive charge.

*Recombinant virus has similar maturation profile to parental DENV4*

Immunoblotting was performed on virus to measure ratio of E and prM proteins present on virus (**Fig. 14**). DENV2 shows high levels of prM relative to E, indicating a highly immature virus, due to either incomplete furin processing or prM dissociation. Both DENV4 and DV4-EDIII-DV2 have no detectable prM, suggesting these viruses are highly mature. However, because of significant differences in amount of E protein detected between DENV2 and the 2 DENV4 backbone viruses, we cannot preclude to presence of some prM on the surface of these virions.

*Recombinant virus is attenuated in Vero cells, but not mosquito cells*

Upon examination using a multi-step growth curve, DV4-EDIII-DV2 is has a  $2\log_{10}$  growth attenuation in Vero cells compared to both DENV2 and DENV4 parental viruses (**Fig. 15, Panel A**). DV4-EDIII-DV2 forms infectious foci in Vero cells, with a morphology between both parental viruses (**Fig. 1, Panel 5B**). Despite 1-2 additional days of infection in Vero cells, DV4-EDIII-DV2 foci do not reach the size of parental virus foci.

Despite the growth attenuation in Vero cells, DV4-EDIII-DV2 shows no attenuation in C6/36 cells (**Fig. 16, Panel A**). As observed in Vero cells, DV4-EDIII-DV2 C6/36 infectious foci display a morphology between both parental viruses. With an additional 1-2 days of infection, these foci reach a comparable size to both wild-type viruses.

*Transplantation of DENV2 EDIII, is sufficient to transfer 2D22 binding and neutralization*

2D22 is a human monoclonal antibody (MAb) that is highly type-specific for DENV2 (**Fig. 17, Panel A**). Previously, an escape mutant was generated by passaging DENV2 in the presence of 2D22 in Vero cells. This escape mutant has one point mutation, R323G, in the middle of EDIII (**Fig. 17, Panel B**), indicating this region of DENV E may be included in the 2D22 epitope. ELISA binding shows DV4-EDIII-DV2 has gained partial binding to 2D22, above DV4 levels, but not to DV2 levels (**Fig. 17, Panel C**). Binding to 2J20 (**Fig. 17, Panel D**) a cross-reactive DENV MAb, shows comparable levels of virus are present in binding assay, and that DV4-EDIII-DV2 morphology is maintained.

Neutralization by 2D22 was analyzed using two cell types and two assays. Vero-81 cells were infected in the presence of 2D22, and the amount of antibody required to neutralize 50% of foci (FRNT<sub>50</sub>) was calculated. DENV2 requires ~0.1ng/ul of 2D22 to neutralize 50% of virus, whereas DENV4 is not neutralized at the maximum concentration of antibody used, 5ng/ul (**Fig. 17, Panel E**). Transplantation of EDIII is sufficient to transfer sensitivity to neutralization by 2D22, as can be seen by the ~0.01ng/ul FRNT<sub>50</sub> value. These results are confirmed using the U937+DC-SIGN flow-cytometry based neutralization assay (**Fig. 17,**

**Panel F**), which measures neutralization by a reduction in the number of cells infected in the presence of antibody. These data further suggest that 2D22 contains EDIII as part of its epitope.

*DV4-EDIII-DV2 has gained sensitivity to neutralization by additional DENV2 MAbs*

5 A panel of 6 additional DENV2 MAbs was used to further characterize DV4-EDIII-DV2 (**Table 2**). Many of these MAbs do not bind recombinant EDIII (rEDIII), including 2D22, which we have shown contains EDIII as part of its epitope (**Fig. 17**). It is possible that 2D22 uses a complex epitope, only present in entire E monomers, E dimers, or complete virus structures, explaining the lack of binding to rEDIII alone. It is possible other MAbs in  
10 this panel have the same requirements. Additional information such as residues important for binding, determined by either generating escape mutants, or through alanine scanning mutations, is included in the table.

One point mutation was generated for DVC3.7, V382G, which maps to the lateral ridge of EDIII (**Fig. 18, Panel A**). DV4-EDIII-DV2 is sensitive to neutralization by DVC3.7,  
15 similar to DENV2, whereas parental DENV4 is not (**Fig. 18, Panel C**). One point mutation was generated for DVC10.16, E311K, which maps to the A-strand of EDIII (**Fig. 18, Panel B**). As seen with DVC3.7, DV4-EDIII-DV2 gains neutralization to DVC10.16, from the parental DENV4, below levels required for DENV2 neutralization. Scanning alanine mutagenesis revealed positions 101 and 108 of the fusion loop in EDII, to be required for  
20 DVC13.6 binding (**Fig. 18, Panel E**). DV4-EDIII-DV2 is neutralized by DVC13.6 (**Fig. 18, Panel F**). These data suggest that the DVC13.6 DENV2 epitope could span from EDIII into the fusion loop region of EDII. Two additional MAbs neutralize DV4-EDIII-DV2 similar to DENV2 and not DENV4 (**Fig. 18, Panels G-H**). Surprisingly, 3F9 which binds rEDIII (**Table 2**), does not bind or neutralize DV4-EDIII-DV2, despite the transplanted domain (**Fig.**  
25 **18, Panel I**). This suggests that 3F9's epitope requires EDIII, but perhaps additional residues outside of EDIII, present only in DENV2, and not DV4-EDIII-DV2.

*DV4-EDIII-DV2 loses neutralization to DENV4 EDIII specific MAb*

DV4-E88 is a mouse DV4 type-specific MAb with a known EDIII epitope and specific residues, 331 and 361, mapped through escape mutants (**Table 2** and **Fig. 19, Panel**  
30 **A**). As expected, DV4-E88 neutralizes DV4 and not DV2. Because EDIII of DENV4 was replaced with that from DENV2, DV4-EDIII-DV2 neutralization by DV4-E88 was lost.

*DV4-EDIII-DV2 gains neutralization to DENV2 polyclonal immune sera*

To test if antibodies present in polyclonal immune sera recognize EDIII, twelve DENV2 polyclonal immune sera were tested against DV4-EDIII-DV2 (**Fig. 20, Panels A-L**).

DV4-EDIII-DV2 gains sensitivity to neutralization by DENV2 sera, comparable to that of DENV2. DENV4 is not neutralized by any of the sera at the highest tested concentration. Despite the range in neutralization titers with the different sera (ranging from ~50 to ~3,000) the average DV4-EDIII-DV2 neutralization titer is higher than DENV2 (**Fig. 22, Panel A**).

5 *DV4-EDIII-DV2 preserves neutralization to DENV4 polyclonal immune sera*

DENV4 polyclonal immune sera neutralizes DV4-EDIII-DV2 with neutralization titers similar to that of DENV4 (**Fig. 21, Panels A-F**). These data suggest that the major DENV4 neutralizing epitope is distinct from DENV2, and is not disrupted when DENV2 EDIII is introduced into DENV4. As seen with DENV2 polyclonal immune sera, DV4-EDIII-DV2 average neutralization titer is comparable to that of DENV4 (**Fig. 22, Panel B**).

10 *DV4-EDIII-DV2 does not gain neutralization to heterotypic polyclonal immune sera*

To test if DV4-EDIII-DV2 is neutralized by heterotypic DENV1 or DENV3 polyclonal immune sera, the same FRNT assay was performed using sera from convalescent DENV1 and DENV3 donors. While in some cases DV4-EDIII-DV2 gains slight sensitivity to neutralization above levels of parental DENV4 neutralization titers, it does not exceed levels of DENV2 neutralization, and is in each case substantially lower than homotypic neutralization (**Fig. 23, Panels A-B**).

DV4-EDIII-DV2 appears to identify the major DENV2 type-specific neutralizing epitope to be a quaternary epitope containing EDIII. This recombinant virus gains neutralization to DENV2 polyclonal immune sera, without losing sensitivity to DENV4 sera, suggesting DENV4 has a different neutralizing epitope. This virus can be used as a diagnostic tool to probe for either DENV2 or DENV4 antibodies. In particular because of the isolation of the DENV2 EDIII in the heterogenous DENV4 background, relative abundance of EDIII-specific Abs from naturally infected or vaccinated individuals can be assayed. This is significant in light of our finding that EDIII of DENV2 appears to be critical for type-specific neutralizing responses after infection. This virus contains domains from both DENV2 and DENV4, and is sensitive to neutralization by both DENV2 and DENV4 antibodies, suggesting this virus might be useful as a bivalent vaccine capable of eliciting antibody responses against both serotypes. Furthermore, a tetravalent vaccine formulation may be achievable if used in concert with DENV1/3 or DENV3/1 recombinant viruses, demonstrating a significant advance in the dengue vaccine field.

30 *Virus construction*

Recombinant viruses are constructed using a four-fragment cloning strategy, the same strategy used to create wild-type DENV infectious clones. DENV-4 genome is subcloned into

four separate DNA plasmids. T7 promoter was introduced into the 5' end of the A fragment, and unique type IIS restriction sites are introduced into the 5' and 3' end of each fragment. These restriction sites ensure plasmids will only be assembled in the correct direction to generate DENV genomic sequence.

5           The EDIII residues from DENV2 were introduced into DENV4, by replacing nucleotides in DENV4 A fragment, with nucleotides encoding for DENV2 amino acids. The new A fragment with nucleotides from DENV2, was synthesized and inserted into pUC-57 plasmid (BioBasic). The new A plasmid, in addition to DENV4 B, C and D plasmids were grown in *E. coli*, purified, digested with corresponding type IIS restriction enzymes, ligated  
10       using T4 DNA ligase to create full length cDNA dengue viral genome. cDNA was transcribed using T7 polymerase. Recombinant RNA was electroporated into BHK-21 cells and cell culture supernatant containing viable virus was harvested. Virus was then passaged two times on C6/36 cells, centrifuged to removed cellular debris, and stored at -80°C.

#### *Cells*

15           Mosquito *Ae. albopictus* C6/36 cells were grown in MEM (Gibco) media at 32°C. Vero-81 cells were maintained in DMEM at 37°C. The human monocyte lymphoma cell line U937, stably expressing DC-SIGN (U937+DC-SIGN) via retroviral transduction was maintained in RPMI-1640 (Gibco) at 37°C and supplemented with 50mM β-mercaptoethanol. Media was supplemented FBS (10% for Vero-81 and U937+DC-SIGN cells, 5% for C6/36),  
20       which was lowered to 2% to make infection media. All media were additionally supplemented with 100U/ml penicillin and 100 mg/ml streptomycin. U937+DC-SIGN was additionally supplemented with 0.1mM nonessential amino acids, and 2mM glutamine. All cells were incubated in 5% CO<sub>2</sub>.

#### *Binding ELISA*

25           Equal quantities of virus (as previously titrated by ELISA) were captured using anti-E antibodies. The primary antibodies 2D22 and 2J20 were diluted fourfold starting to generate dilution series. Alkaline phosphatase-conjugated secondary antibodies were used to detect binding of primary antibodies with P-nitrophenyl phosphate substrate, and reaction color changes were quantified using spectrophotometry.

#### *DENV Immune Sera*

30           Human DENV immune sera were collected from individuals with confirmed previous natural DENV infections. Additional human immune sera were collected from individuals given DENV vaccines. Non-human primate immune sera were collected following DENV infection.

*Virus Titration and Focus Reduction Neutralization Test (FRNT)*

One day prior to infections, 24-well plates were seeded with either  $5 \times 10^4$  Vero-81 or  $1 \times 10^5$  C6/36 cells. Prior to infection, growth media was removed. Virus titrations were performed by serially diluting virus stocks 10-fold, then incubated for 1 hr at 37°C. After incubation, virus dilutions were added to cells for 1 hr at 37°C, then overlaid with 1ml 1% methylcellulose in OptiMEM (Gibco), supplemented with 2% FBS, 100U/ml penicillin and 100 mg/ml streptomycin. After 3-6 days incubation at 37°C, overlay was removed, cells were washed with PBS and fixed in 80% methanol. Plates were blocked with 5% instant milk made in PBS, then incubated with anti-E MAb 4G2 and anti-PrM MAb 2H2, both diluted 1:500 in blocking buffer. Plates were then washed, and incubated with HRP-conjugated goat anti-mouse Ab (Sigma), diluted 1:2500 in blocking buffer. Plates were then washed, and foci were developed with TrueBlue HRP substrate (KPL), and foci were counted.

For FRNT assay, either MAbs or sera were diluted four-fold and mixed with ~40 FFUs virus, then incubated for 1 hr at 37°C. After incubation, virus and MAb/sera dilutions were added to cells for 1 hr at 37°C, then overlay was added and processed as above.

*Growth Curves*

Either Vero or C6/36 cells were infected at a multiplicity of infection (MOI) of 0.01. Every 24hrs culture supernatant was harvested, and centrifuged to remove cellular debris. Samples were frozen at -80°C until use. Fresh media was replaced each day. Viruses were tittered on their propagating cell type as described above.

*U937+DC-SIGN Neutralization Assay*

As in FRNT assay, virus is diluted in U937+DC-SIGN infection media and mixed with four-fold dilution series of MAb. Virus and MAb mixture were incubated for 1 hr at 37°C. Virus and Mab mixture was then added to  $5 \times 10^4$  U937+DC-SIGN cells per well of 96-well round bottom plate and incubated for 2 hr at 37°C. After incubation, cells were centrifuged and washed twice with infection media, then resuspended in growth media. One day post infection, cells were centrifuged to collect, washed with PBS and fixed with 4% paraformaldehyde. Cells were then permeabilized and blocked in 1% normal mouse sera. Cells were stained with 1:400 dilution of anti-E 2H2 directly labeled with Alex Fluor 488. Percentage of positively staining cells was measured Guava easyCyte Flow Cytometer (Millipore).

*Immunoblotting*

Virus stocks were diluted in PBS, mixed with 4X Laemmli Sample Buffer (Bio-Rad), and heated for 10 minutes at 50°C. Samples were run on 12% PROTEAN TGX Gels (Bio-

Rad), transferred to PVDF membrane and blocked in 5% instant milk in PBS + 0.05% Tween overnight at 4°C. Membranes were probed with 0.5ug/ml anti-E 4G2, 0.5ug/ml anti-PrM 2H12 and 5L20 in blocking buffer for 2hr at 37°C. After washing HRP-conjugated anti-mouse and anti-human secondary antibodies were diluted 1:10,000 in blocking buffer, and  
 5 incubated 1hr at room temperature. Membrane was exposed to chemiluminescent substrate, and developed on film.

#### **EXAMPLE 5. Use of chimeric recombinant dengue viruses to map the serotype 2 neutralizing human antibody response**

10 Primary infection with one of the four dengue virus (DENV) serotypes (DENV1-4) results in antibodies that neutralize the infecting serotype, but not other serotypes. Our group has previously reported on the isolation of serotype specific, strongly neutralizing monoclonal antibodies (hMAbs) from people exposed to natural DENV infections. We have demonstrated that these hMAbs bind to complex quaternary structure epitopes that are only  
 15 expressed on intact virus particles. Recently we reported that it is possible to create viable recombinant DENVs in which these complex epitopes have been transplanted between serotypes. By using DENV3/4 chimeras, we observed that the hinge region between domains I/II of the envelope (E) protein contains epitopes that are the main target of type-specific antibodies that neutralize serotypes 3 and 4. In the current study we have used a similar  
 20 approach to map sites of DENV2 recognized by neutralizing hMAbs and primary DENV2 human immune sera. Our studies have led to the identification of a novel quaternary structure-dependent DENV2 epitope that is distinct from EDI/II hinge region epitopes previously defined for serotypes 3 and 4. Importantly, we use gain and loss of function studies to demonstrate that different locations in the DENV1-4 E glycoprotein encode unique  
 25 long-lived neutralizing epitopes, which are portable between serotypes. The location of a DENV2 epitope and its relative importance as a target for neutralizing antibodies in people exposed to natural infections and vaccines was examined.

##### *Design and construction of rDENV4/2 virus*

30 Residues from DENV2 (right) were moved into DENV4 backbone to generate a recombinant DENV 4/2 virus (rDENV4/2, **Fig. 24, Panel A**). A reverse genetics system for manipulating the DENV genome was used (**Fig. 24, Panel B**). Top = DENV2, bottom = DENV4. The DENV genome is divided into four plasmid cassettes which can be individually mutated, ligated together, and electroporated into cells to generate recombinant virus. The DENV4-A cassette contains the envelope gene where mutations are made. Replacing the

DENV4 residues with those from DENV 2 creates an rDENV4/2 virus, built entirely on the DENV4 genetic backbone.

*A new method for serotype identification by RT-PCR and confirmation of DENV4 backbone recombinant virus*

5 RT-PCT primers were designed for serotype-specific RT-PCR (**Fig. 25, Panel A**). The primers utilized included a common sense oligonucleotide targeting the highly conserved 3' end NS1 gene and serotype-specific antisense primers target the highly divergent NS2A gene. Viruses were grown in C6/36 cells, culture supernatant was collected and centrifuged to remove any cellular debris. Viral RNA was isolated using QIAGEN QIAmp Viral RNA  
10 Miniprep Kit. PCR was run for 35 cycles, and PCR product was analyzed on a 1.5% Ultrapure agarose gel. Control RNA (DV1/DV2/DV3/DV4) and water are run as positive and negative controls (**Fig. 25, Panel B**). Expected product sizes: DV1 = 205 bp, DV2 = 539 bp, DV3 = 455 bp, DV4 = 401 bp.

*Restriction fragment length polymorphism distinguishes rDENV4/2 from parental DENV4*

15 Restriction fragment length polymorphism (RFLP) analysis was used to distinguish rDENV4/2 (bottom) from parental DENV4 (top). Mutations (represented as asterisks) introduced into the DENV4 E genome to generate rDENV4/2 disrupt an XmnI restriction enzyme site present in DENV4 (**Fig. 26, Panel A**). PCR products were gel purified and digested with XmnI. Digest products were analyzed on a 1.5% Ultrapure agarose gel (**Fig. 26,**  
20 **Panel B**). Expected product sizes: full length undigested = 1031 bp, digested products = 931 bp and 113 bp.

*DENV4 and rDENV4/2 virions have similar maturation profiles*

Viruses were grown in C6/36 cells, and culture supernatants were collected and centrifuged to remove any cellular debris. Samples were run on a 12% SDS-PAGE gel and  
25 blots were probed with anti-E (4G2) and anti-PrM (2H12 and 5L20) antibodies (**Fig. 27**). DENV2 has substantial levels of PrM present, indicating either incomplete Furin processing or PrM dissociation. PrM bands are not detected in either DENV4 or rDENV4/2 samples.

*rDENV4/2 has a 2 log growth attenuation in Vero cells relative to parental viruses.*

Vero-81 cells were infected at an MOI = 0.01 with DENV2, DENV4 and rDENV4/2.  
30 Viral supernatants were collected every 24 hours and subsequently titered on Vero-81 cells (**Fig. 28, Panel A**). DENV forms infectious foci in Vero-81 cells. DENV2, DENV4, and rDENV4/2 were fixed 5, 4, and 6 days post-infection, respectively (**Fig. 28, Panel B**). rDENV4/2 exhibited foci that were smaller than both parental viruses.

*rDENV4/2 has no growth attenuation in C6/36 cells and forms similar infectious foci relative to parental viruses*

C6/36 cells were infected at an MOI = 0.01 with DENV2, DENV4 and rDENV4/2.. Viral supernatants were collected every 24 hours and subsequently titrated on C6/36 cells (Fig. 29, Panel A). DENV forms infectious foci on C6/36 cells. DENV2, DEVN4, and rDENV4/2 fixed 4, 3, and 5 days post-infection, respectively (Fig. 29, Panel B). With additional day(s) of growth, rDENV4/2 foci reach sizes comparable with parental viruses.

*Figure 30. Transfer of binding and neutralization of rDENV4/2 by type-specific DENV2 human MAb*

A summary of the binding of human MAb 2D22, a strongly neutralizing DV2 MAb, that binds to a quaternary epitope is shown in Fig. 30, Panel A. 2D22 shows great specificity for neutralizing DENV2. ELISA assays show a transfer of partial binding of 2D22 to rDENV4/2, above levels of parental DV4 but not to DV2 levels (Fig. 30, Panel B). ELISA binding of the cross-reactive control antibody, 2J20, showed comparable levels of virus present and maintained virus integrity (Fig. 20, Panel C). A Vero-81 based Focus Reduction Neutralization Test (FRNT) was performed using 2D22 and FRNT<sub>50</sub> (concentration of antibody required to neutralize 50% of infection) values were calculated (Fig. 30, Panel D). A U937+DC-SIGN based neutralization assay (Neut) was performed using 2D22 and Neut<sub>50</sub> values were calculated (FIG. 30, Panel E). In both assays (Fig. 30, Panels D-E), rDENV4/2 gained neutralization to 2D22 to levels higher than DV2. DV4 was not neutralized with the maximum concentration of 2D22 in either assay.

*rDENV4/2 gains neutralization to DENV2 polyclonal immune sera while preserving neutralization to DENV4 polyclonal sera*

A Vero-81 FRNT assay showed that rDENV4/2 gained neutralization to DENV2 polyclonal immune sera to levels comparable to parental DENV2 (Fig. 31, Panel A). rDENV4/2 showed no loss to neutralization by DENV4 polyclonal immune sera (Fig. 31, Panel B). rDENV4/2 showed no gain of neutralization to heterotypic DENV1 (Fig. 31, Panel C) and DENV3 (Fig. 31, Panel D) polyclonal immune sera above either parental DENV 2 or DENV4 neutralization titers. Sera from individuals with either nature infection, or experimental vaccination are coded as indicated. Samples with FRNT<sub>50</sub> < 20 graphed at sera dilution factor of 19.

In this study, a recombinant DENV virus was generated comprised of envelope residues from two DENV serotypes (DENV2 and DENV4), and in characterizing this virus have identified several key findings: a viable recombinant virus by transplanting regions from

one DENV serotype to another can be created; rDENV4/2 growth is attenuated in mammalian cells, but not insect cells; rDENV4/2 has no detectable PrM protein present, indicating it is fully processed and highly mature; binding and neutralization was transferred to the human DENV2 type-specific MAb 2D22 in two different cell types and neutralizing  
5 assays; rDENV4/2 gains neutralization to DENV2 polyclonal immune sera without losing neutralization to DENV4 polyclonal immune sera; rDENV4/2 gains no neutralization to heterotypic polyclonal immune sera; and rDENV4/2 may be developed as a bivalent vaccine to elicit protective antibody responses to both DENV2 and DENV4.

**EXAMPLE 6. Amino acid alignments of recombinant DENV with wild-type DENV  
10 sequences**

An amino acid sequence alignment of DV4-EDIII-DV2 with wild-type DENV4 and DENV2 is presented in **Fig. 32A**. An amino acid alignment of DENV2-1F4E with wild-type DENV 2 and DENV1 is presented in **Fig. 32B**. Lastly, an amino acid alignment of DENV4 M12, DENV4 M14 and DENV4 M16 with wild-type DENV4 and DENV3 is presented in  
15 **Fig. 32B**.

The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

All publications, patent applications, patents and other references cited herein are  
20 incorporated by reference in their entireties for the teachings relevant to the sentence and/or paragraph in which the reference is presented.

**Table 1, Summary of amino acid changes in recombinant DV4-EDIII-DV2 virus**

| Position | DV2 | DV4 | AA change                               |
|----------|-----|-----|-----------------------------------------|
| 307      | K   | S   | positive charge → polar uncharged       |
| 309      | V   | D   | hydrophobic uncharged → negative charge |
| 320      | I   | T   | hydrophobic uncharged → polar uncharged |
| 325      | Q   | K   | polar uncharged → positive charge       |
| 329      | D   | A   | negative charge → hydrophobic uncharged |
| 331      | S   | A   | polar uncharged → hydrophobic uncharged |
| 340      | T   | R   | polar uncharged → positive charge       |
| 343      | E   | N   | negative charge → polar uncharged       |
| 345      | R   | E   | positive charge → negative charge       |
| 353      | V   | S   | hydrophobic uncharged → polar uncharged |
| 358      | T   | E   | polar uncharged → negative charge       |
| 359      | E   | N   | negative charge → polar uncharged       |
| 360      | K   | T   | positive charge → polar uncharged       |
| 361      | D   | N   | negative charge → polar uncharged       |
| 364      | V   | T   | hydrophobic uncharged → polar uncharged |
| 382      | E   | G   | negative charge → hydrophobic uncharged |
| 383      | P   | N   | hydrophobic uncharged → polar uncharged |
| 384      | G   | S   | hydrophobic uncharged → polar uncharged |
| 385      | Q   | A   | polar uncharged → hydrophobic uncharged |
| 387      | K   | T   | positive charge → polar uncharged       |
| 389      | N   | H   | polar uncharged → positive charge       |

Of 40aa residues that were changed in recombinant virus, 14 introduced a change of charge. Six residues increase negative charge (light red = positive → uncharged, dark red = uncharged → negative), while eight residues increase positive charge (light blue = negative → uncharged, dark blue = uncharged → positive). Additional residue changes replace hydrophobic amino acids with polar amino acids, and vice versa.

**Table 2, Mabs used to probe surface topology of DV4-EDIII-DV2**

| binding specificity | MAb      | binds rEDIII | additional notes                                                                 |
|---------------------|----------|--------------|----------------------------------------------------------------------------------|
| DV2 type-specific   | 2D22     | -            | escape mutant, R323F (EDIII)                                                     |
|                     | 3F9      | +            | -----                                                                            |
|                     | 1L12     | -            | -----                                                                            |
|                     | DVC3.7   | +            | EDIII lateral ridge epitope                                                      |
| DV subcomplex       | DVC10.16 | +            | EDIII A-strand epitope                                                           |
| DV complex          | DVC13.6  | -            | scanning alanine mutations = 101 and 108 (fusion loop)                           |
|                     | DVC23.13 | -            | -----                                                                            |
| DV4 type-specific   | DV4-E88  | +            | mouse MAb, known EDIII epitope, scanning alanine mutations = 331 and 361 (EDIII) |

Additional MAbs used in subsequent experiments. A subset of DENV2 type-specific MAbs bind recombinant EDIII. Some MAbs that do not bind rEDIII are suspected to contain EDIII in their epitope.

## SEQUENCES

>Parent\_WT\_DENV3 :115-773 E [Dengue virus 3, SEQ ID NO:12]

MRCVGIGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIELQKTEATQLATLR  
 KLCIEGKITNITTD SRCPTQGEAVLP EEQDQNYVCKHTYVDRGWGNGCGLFGKGS LVT  
 5 CAKFQCLEPIEGKVVQYENLKYTVIITVHTGDQH QVGN ETQ--  
 GVTAEITPQASTTEAILPEYGT LGLECSPRTGLDFNEMILLTMKNKAWMVHRQWFFDL P  
 LPWTSGATTETPTWNRKELLVTFKNAHAKKQEVVVLGSQEGAMHTALTGATEIQNSG  
 GTSIFAGHLKCRLKMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAP  
 CKIPFSTEDGQGKAHNRLITANPVVTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYK  
 10 KGSSIGKMF EATARGARRMAILGDTAWDFG SVGGVLNSLGK MVHQIFGSAYTALFSGV  
 SWVMKIGIGVLLTWIGLNSKNTSMSFS CIAIGIITLYLGAVVQA

>DENV4\_M12 :115-775 E (SEQ ID NO:2)

MRCVG VGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTATQLATL  
 15 RKLCIEASISNITTATRCPTQGE PYLKEEQDQQYICRRDVVDRGWGNGCGLFGKGGVVT  
 CAKFSCSGPIEGKVVQIENLEYTVVVTVHNGDTHAVGNDTSNHGVTATITPRSPSVEVK  
 LPDYGELTLDCEPRSGIDFNEMILLTMKKKAWMVHRQWFFDLPLPWTSGADTSEVHW  
 NYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEIQNSGGTSIFAGHLKCKVR  
 MEKLRIKGMSYTMCSGKFSIDKEMAETQHGT TVVKVKYEGAGAPCKVPIEIRDVNKEK  
 20 VVGRVISSTPLAENTNSVTNIELEPPFGDSYIVIGVGNSALT LHWFRKGSSIGKMFESTYR  
 GAKRMAILGETAWDFG SVGGLFTSLGKA VHQVFGSVYTTMFGGVSWMIRILIGFLVLW  
 IGTNSRNTSMAMTCIAVGGITLFLGFTVQA

>DENV4\_M14 :115-775 E (SEQ ID NO:3)

MRCVG VGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTEATQLATL  
 25 RKLCIEASISNITTATRCPTQGE PYLKEEQDQQYICRRDVVDRGWGNGCGLFGKGGVVT  
 CAKFSCLEPIEGKVVQYENLEYTVVVTVHNGDTHAVGNDTSNHGVTATITPRSPSVEVK  
 LPDYGELTLDCEPRSGIDFNEMILLTMKKKAWMVHRQWFFDLPLPWTSGADTSEVHW  
 NYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEIQNSGGTSIFAGHLKCKVR  
 30 MEKLRIKGMSYTMCSGKFSIDKEMAETQHGT TVVKVKYEGAGAPCKVPIEIRDVNKEK  
 VVGRVISSTPLAENTNSVTNIELEPPFGDSYIVIGVGNSALT LHWFRKGSSIGKMFESTYR  
 GAKRMAILGETAWDFG SVGGLFTSLGKA VHQVFGSVYTTMFGGVSWMIRILIGFLVLW  
 IGTNSRNTSMAMTCIAVGGITLFLGFTVQA

>DENV4\_M16 :115-775 E (SEQ ID NO:4)

MRCVG VGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTEATQLATL  
 RKLCIEASISNITTDTRCPTQGE PYLKEEQDQQYICRRDVVDRGWGNGCGLFGKGGVVT  
 CAKFSCLEPIEGKVVQYENLEYTVVVTVHNGDQH AVGNDTSNHGVTATITPRSPSVEV  
 KLPDYGELTLDCEPRSGIDFNEMILLTMKKKAWMVHRQWFFDLPLPWTSGATTSEPHW  
 40 NYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEIQNSGGTSIFAGHLKCKVR  
 MEKLRIKGMSYTMCSGKFSIKKEMAETQHGT TVVKVKYEGAGAPCKVPIEIRDVNKEK  
 VVGRVISSTPLAENTNSPTNIELEPPFGDSYIVIGVGNSALT LHWFRKGSSIGKMFESTYR  
 GAKRMAILGETAWDFG SVGGLFTSLGKA VHQVFGSVYTTMFGGVSWMIRILIGFLVLW  
 IGTNSRNTSMAMTCIAVGGITLFLGFTVQA

>Parent\_WT\_DENV4 :115-775 E [Dengue virus 4, SEQ ID NO:1]

MRCVG VGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAKEVALL  
 RTYCIEASISNITTATRCPTQGE PYLKEEQDQQYICRRDVVDRGWGNGCGLFGKGGVVT  
 CAKFSCSGKITGNLVQIENLEYTVVVTVHNGDTHAVGNDTSNHGVTATITPRSPSVEVK  
 50 LPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHKQWFLDLPLPW TAGADTSEVHW

NYKERMVTFKVPFAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFAGHLKCKV  
 RMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTVVVKVKEYEGAGAPCKVPIEIRDVNKE  
 KVVGRVISSTPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTY  
 RGAKRMAILGETAWDFGSGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVL  
 5 WIGTNSRNTSMAMTCIAVGGITLFLGFTVQA

>Parent\_WT\_DENV2 :115-775 [Dengue virus 2, SEQ ID NO:13]

MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKY  
 CIEAKLTNTTTESRCPTQGEPSLNEEQDKRFICKHSMVDRGWGNGCGLFGKGGIVTCA  
 10 MFTCKKNMEGKVVPENLEYTIVITPHSGEEHAVGNDTGKHGKEIKITPQSSITEAELTG  
 YGTVTMECSPRTGLDFNEMVLLQMEDKAWLVHRQWFLDLPLPWLPGADTQESNWIQ  
 KETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQMSSGNLLFTGHLKCRLRMD  
 KLQLKGMSYSMCTGKFKIVKEIAETQHGTVIRVQYEGDGSPCKIPFEITDLEKRHVLGR  
 LITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGAKR  
 15 MAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFGSVSWTMKILIGVIITWIGMNS  
 RSTSLSVSLVLVGVTLYLGAVVQA

>DV4-EDIII-DV2 :115-775 [Dengue virus 4/2, SEQ ID NO:5]

MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAKEVALL  
 20 RTYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVDRGWGNGCGLFGKGGVVT  
 CAKFSCSGKITGNLVQIENLEYTVVVTVHNGDTHAVGNDTSNHGVTATITPRSPSVEVK  
 LPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHKQWFLDLPLPWTAGADTSEVHW  
 NYKERMVTFKVPFAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFAGHLKCKV  
 RMEKLRLKGMSYSMCTGKFKIVKEIAETQHGTVIRVQYEGDGSPCKIPFEITDLEKRHV  
 25 LGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFESTYRG  
 AKRMAILGETAWDFGSGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVLWI  
 GTNSRNTSMAMTCIAVGGITLFLGFTVQA

>Parent\_WT\_DENV1 :115-775 E [Dengue virus 1, SEQ ID NO:14]

MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEVTNPAVLRK  
 30 LCIEAKISNTTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRGWGNGCGLFGKGSLITCA  
 KFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGNETTEHGTTATITPQAPTSEIQLTD  
 YGALTLDSPRTGLDFNEMVLLTMEKKSWLVHKQWFLDLPLPWTSFASTSQETWNRQ  
 DLLVTFKTAHAKKQEVVVLGSQEGAMHTALTGATEIQTSGTTTIFAGHLKCRLKMDKL  
 35 TLKGMSYVMCTGSFKLEKEVAETQHGTVLVQVKYEGTDAPCKIPFSSQDEKGVTQNGR  
 LITANPIVTDKEKPVNIEAEPPFGESYIVVGAGEKALKLSWFKKGSSIGKMFEATARGAR  
 RMAILGDTAWDFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIGIGILLTWLGLNS  
 RSTSLSMTCIAVGMVTLYLGVMVQA

40 >DENV2-1F4E :115-775 (SEQ ID NO:6)

MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELFKTEVTNPAVLRKY  
 CIEAKLTNTTTESRCPTQGEPSLNEEQDKRFICKHSMVDRGWGNGCGLFGKGGIVTCA  
 MFTCKKNMEGKVVPENLKYSVIVTVHSGEEHAVGNDTTEHGTTATITPQAPTSEIQLT  
 DYGALTLECSPTGLDFNEMVLLQMEDKAWLVHRQWFLDLPLPWLPGADTQESNWIQ  
 45 KETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQTSGTTTLFTGHLKCRLRMDK  
 LQLKGMSYSMCTGKFKIVKEIAETQHGTVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLI  
 TVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGAKRM  
 AILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFGSVSWTMKILIGVIITWIGMNSRS  
 TSLSVSLVLVGVTLYLGAVVQA

50

**DENV1/4(5H2)**

MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEVTNPVAVLRK  
 LCIEAKISNTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRGWGNGCGLFGKGSLITCA  
 KFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGNEATEHGVAMITPQSPSVEVKL  
 5 PDYGELTLDSPRTGLDFNEMVLLTMKKKSWLVHKQWFLDLPLPWTSGASTSQETWN  
 RQDLLVTFKTAHAKKQEVVVLGSQEGAMHTALTGATEIQTSGTTTIFAGHLKCRLKMD  
 KLRLKGMSYVMCTGSFKLEKEVAETQHGTVLVQVKYEGTDAPCKIPFSSQDEKGVTON  
 GRLITANPIVTDKEKPVNIEAEPFPGESYIVVGAGEKALKLSWFKKGSSIGKMFETARG  
 ARMAILGDTAWDFGSGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIGIGILLTWLG  
 10 LNSRSTSLSMTCIAVGMVTLVYLGVMVQA (SEQ ID NO:15)

**DENV2/4(5H2)**

MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKY  
 CIEAKLTNTTTESRCPTQGEPSLNEEQDKRFICKHSMVDRGWGNGCGLFGKGGIVTCA  
 15 MFTCKKNMEGKVVPENLEYTIVITPHSGEEHAVGNDAGKHGVTAMITPQSSSVEVKL  
 PDYGEVTMECSPRTGLDFNEMVLLQMEDKAWLVHRQWFLDLPLPWLPADTQESNWI  
 QKETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQMSSGNLLFTGHLKCRLRM  
 DKLRLKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLG  
 RLITVNPIVTEKDSPVNIEAEPFPGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGAK  
 20 RMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFGSVSWTMKILIGVIITWIGMN  
 SRSTSLSVSLVLVGVVTLVYLGAVVQA (SEQ ID NO:16)

**DENV2-1F4E (Strain 16803)**

MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELFKTEVTNPVAVLRKY  
 25 CIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGLFGKGGIVTCA  
 MFTCKKNMEGKVVPENLKYSVIVTVHSGEEHAVGNDTTEHGTATVTPQAPTSEIQL  
 TDYGALTLECSPTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPADTQGSNWI  
 QKETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQTSGTTTLFTGHLKCRLRMD  
 KLQLKGMSYSMCTGKFKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLG  
 30 RLITVNPIVTEKDSPVNIEAEPFPGDSYIIIGVDPGQLKLNWFKKGSSIGQMFETTMRGAK  
 RMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFGSVSWTMKILIGVIITWIGMN  
 SRSTSLSVSLVLVGVVTLVYLGAVVQA (SEQ ID NO:17)

The following changes could also be made to generate 2 viruses with **smaller** regions of  
 35 DENV1 transplanted into DENV2:

1. N52Q, V55T, S138T, V139I
2. A168S, P169S, A180T, L181V, L183M (in addition to those listed in #1)

**DENV4-1F4E**

MRCVGIGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELFKTTVTNPVAVL  
 40 RTYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVDRGWGNGCGLFGKGGVVT  
 CAKFSCSGKITGNLVQIENLKYSVIVTVHNGDTHAVGNDTTEHGTATITPRAPTSEIQL  
 TDYGALTLDCEPRSGIDFNEMILMKMKKKTWLVHKQWFLDLPLPWTAGADTSEVHW  
 NYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDTGGTTTTFAGHLKCKV  
 45 RMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKE  
 KVVGRVISSTPLAENTNSVTNIELEPPFPGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTY  
 RGAKRMAILGETAWDFGSGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVL  
 WIGTNSRNTSMAMTCIAVGGITLFLGFTVQA (SEQ ID NO:18)

The following changes could also be made to generate 2 viruses with **smaller** regions of DENV1 transplanted into DENV2:

1. N52E, P53V, V55L, S138T
2. A168S, A180E (in addition to those listed in #1)

5

#### **DENV1-3M14**

MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEATQLATLRK  
LCIEAKISNTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRGWGNGCGLFGKGSLITCA  
KFKCLEPIEGKVQYENLKYSVIVTVHTGDQHQVGNETTEHGTIATITPQAPTSEIQLTD  
10 YGALTDCSPRTGLDFNEMILLTMKNKAWMVHRQWFFDLPLPWTSGASTSQETWNRQ  
DLLVTFKTAHAKKQEVVVLGSQEGAMHTALTGATEIQNSGGTSIFAGHLKCRLKMDKL  
TLKGMSYVMCTGSFKLEKEVAETQHGTVLVQVKYEGTDAPCKIPFSSQDEKGVTQNGR  
LITANPIVTDKEKPVNIEAEPFPGESYIVVGAGEKALKLSWFKKGSSIGKMFEATARGAR  
RMAILGDTAWDFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIGIGILLTWLGLNS  
15 RSTSLSMTCIAVGMVTLYLGMVQA (SEQ ID NO:19)

The following changes could also be made to generate a virus with a **larger** region of DENV3 transplanted into DENV1 (designated DENV1-3M16):

1. S225T, E229P, E307K

20

#### **DENV2/3 M12 (Strain 16803)**

MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEATQLATLRKL  
CIEAKLTNTTTSRCPTQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGLFGKGGIVTCA  
MFTCKEPIEGKVQYENLEYTIVVTPHSGEEHAVGNDTGKHGKEIKVTPQSSITEAELTG  
25 YGTVTMECSPRTGLDFNEMVLLTMKNKAWMVHRQWFFDLPLPWTSTADTQGPNIWQ  
KETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQNSGGTSIFAGHLKCRLRMDK  
LQLKGMSYSMCTGKFKVVEKIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGR  
LITVNPIVTEKDSPVNIEAEPFPGDSYIIIGVDPGQLKLNWFKKGSSIGQMFETTMRGAKR  
MAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFGSVSWTMKILIGVIITWIGMNS  
30 RSTSLSVSLVLVGIVTLYLGMVQA (SEQ ID NO:20)

The following changes could also be made to generate 2 viruses with a **larger** region of DENV3 transplanted into DENV2 (designated DENV2-M14(#1) and DENV2-M16(#2)):

1. K122L, K123E, P132Y
2. E71D, E148Q, D225T, S229P, V307K (in addition to those listed in #1)

35

#### **DENV3/4(5H2)**

MRCVGIGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIELQKTEATQLATLR  
KLCIEGKITNITDSRCPTQGEAVLPEEQDQNYVCKHTYVDRGWGNGCGLFGKGSLVT  
40 CAKFQCLEPIEGKVQYENLKYSVIVTVHTGDQHQVGNEASNQGV TAMITPQSSSVEVK  
LPDYGELGLECSPRTGLDFNEMILLTMKNKAWMVHRQWFFDLPLPWTSGATTETPTW  
NRKELLVTFKNAHAKKQEVVVLGSQEGAMHTALTGATEIQNSGGTSIFAGHLKCRLKM  
DKLRLKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIPFSTEDGQGKAH  
NGRLITANPVVTKKEEPVNIEAEPFPGESNIVIGIGDNALKINWYKKGSSIGKMFEATAR  
45 GARRMAILGDTAWDFGSGGVVLSLGMVHQIFGSAYTALFSGVSWVMKIGIGVLLT  
WIGLNSKNTSMSFSCIAIGIITLYLGAVVQA (SEQ ID NO:21)

#### **DV4-EDIII-DV2)**

MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAKEVALL  
50 RTYCIEASISNITTATRCPTQGEPLYLKEEQDQQYICRRDVDRGWGNGCGLFGKGGVVT

CAKFSCSGKITGNLVQIENLEYTVVVTVHNGDTHAVGNDTSNHGVTATITPRSPSVEVK  
 LPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHKQWFLDLPLPWTAGADTSEVHW  
 NYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFAGHLKCKV  
 RMEKLRLKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHV  
 5 LGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIIGVEPGQLKLNWFKKGSSIGKMFESTYRG  
 AKRMAILGETAWDFGSVGGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVLWI  
 GTNSRNTSMAMTCIAVGGITLFLGFTVQA (SEQ ID NO:22)

The following changes could also be made to generate 2 viruses with a **larger** region of DENV2  
 10 transplanted into DENV4:

1. Y81S, K83S, V242N, R247K
2. I68T, A71E, T72S, R93K, R94H, D95S, V96M, V113I (in addition to those listed in #1)

#### **DV1-EDIII-DV2**

15 MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEVTNPAVLRK  
 LCIEAKISNTTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRGWGNGCGLFGKGSLITCA  
 KFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGNETTEHGTATITPQAPTSEIQLTD  
 YGALTLD CSPRTGLDFNEMVLLTMEKKSWLVHKQWFLDLPLPWTSGASTSQETWNRQ  
 DLLVTFKTAHAKKQEVVVLGSQEGAMHTALTGATEIQTS GTTTIFAGHLKCRLKMDKL  
 20 TLKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLIT  
 VNPIVTEKDSPVNIEAEPPFGDSYIIIIGVEPGQLKLNWFKKGSSIGKMFETARGARRMAI  
 LGDTAWDFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIGIGILLTWLGLNSRSTS  
 LSMTCIAVGMVTL YLGVMVQA (SEQ ID NO:23)

25 The following changes could also be made to generate 2 viruses with a **larger** region of DENV2  
 transplanted into DENV1:

1. I68T, D71E, A80P, T81S, V83N, T242N, A243P, E249D
2. R93K, R94H, T95S, F96M, S112G, L113I, I114V (in addition to those listed in #1)

#### **DV3-EDIII-DV2**

30 MRCVGIGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIELQKTEATQLATLR  
 KLCIEGKITNITTTDSRCPTQGEAVLPEEQDQNYVCKHTYVDRGWGNGCGLFGKGSLVT  
 CAKFQCLEPIEGKVVQYENLK YTVIITVHTGDQHQVGNETQGVTAETPQASTTEAILPE  
 YGTLGLECSPRTGLDFNEMILLTMKNKAWMVHRQWFFDLPLPWTSGATTETPTWNRK  
 35 ELLVTFKNAHAKKQEVVVLGSQEGAMHTALTGATEIQNSGGTSIFAGHLKCRLKMDKL  
 ELKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLIT  
 VNPIVTEKDSPVNIEAEPPFGDSYIIIIGVEPGQLKLNWYKKKGSSIGKMFETARGARRMA  
 ILGDTAWDFGSVGGVLNSLGKMHQIFGSAYTALFSGVSWVMKIGIGVLLTWIGLNSK  
 NTSMSFSCIAIGIITLYLGAVVQA (SEQ ID NO:24)

40 The following changes could also be made to generate 2 viruses with a **larger** region of DENV2  
 transplanted into DENV3:

1. D71E, A80P, V81S, P83N, A243P, E249D
2. I68T, T95S, Y96M, S112G, L113I (in addition to those listed in #1)

#### **DENV2/1/3 (Strain 16803)**

45 MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELFKTEVTQLATLRKL  
 CIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGLFGKGGIIVTCA  
 MFTCKKPIEGKVVQOPENLK YTHIIVTVHSGEEHAVGNDTTEHGTATVTPQSSTSEIQLTD  
 50 YGTVTMECSPRTGLDFNEMILLTMKNKAWMVHRQWFFDLPLPWTSGADTQGSNWIQ

KETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQTSTTTIFAGHLKCRLRMDK  
 LQLKGMSYSMCTGKFKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGR  
 LITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVDPGQLKLNWFKKGSSIGQMFETTMRGAKR  
 MAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAAFSGVSWTMKILIGVIITWIGMNS  
 5 RSTSLSVSLVLVGVTLYLGAVVQA (SEQ ID NO:25)

Note: AA #50 could be a V or A, AA #52 could be a Q or N, AA #55 could be a T or V, AA  
 #272 could be a T or N, AA #275 could be a T or G, AA #276 could be a T or N, AA #277  
 could be a T or L

The following changes could also be made to generate viruses with **larger** regions of DENV1  
 and/or DENV3 transplanted into DENV2:

1. Q52N, T55V, T138S, I139V
2. S168A, S169P, T180A, V181L, M183L (in addition to those listed in #1)
- 15 3. K122L, K123E, P132Y
4. E71D, E148Q, D225T, S227P, V307K (in addition to those listed in #3)
5. Any and all combinations of 1, 2, 3, 4 and the original sequence (i.e., 1+3, 1+4, 2+3,  
 2+4)

#### 20 DENV2/1/4

MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELFKTEVTQPATLRKY  
 CIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGLFGKGGIVTCA  
 MFTCKKNMEGKVVQPENLKYTHIVTVHSGEEHAVGNDATEHGV TAMVTPQSSTVEVK  
 LPDYGEVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQGSN  
 25 WIQKETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQTSGTTTLFTGHLKCRLR  
 MDKLRLKGMSYSMCTGKFKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHV  
 LGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVDPGQLKLNWFKKGSSIGQMFETTMRG  
 AKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAAFSGVSWTMKILIGVIITWIG  
 MNSRSTSLSVSLVLVGVTLYLGAVVQA (SEQ ID NO:26)

Note: AA #160 could be a T or V, AA #163 could be a T or M, AA #168 could be a S or A, AA  
 #170 could be a T or S, AA #171 could be a S or V, AA #173 could be a V or I, AA #174 could  
 be a Q or K, AA #176 could be a P or T, AA #180 could be a E or A

The following changes could also be made to generate viruses with **larger** regions of DENV1  
 transplanted into DENV2:

1. Q52N, T55V, T138S, I139V
2. S168A, S169P, T180A, V181L, M183L (in addition to those listed in #1)

#### 40 DENV2/3/4 (Strain 16803)

MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEATQLATLRKL  
 CIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGLFGKGGIVTCA  
 MFTCKEPIEGKVVQPENLEYTIVVTPHSGEEHAVGNDAGKHGVTAMVTPQSSSVEVKL  
 PDYGEVTMECSPRTGLDFNEMVLLTMKNKAWMVHRQWFFDLPLPWTSTADTQGPNW  
 45 IQKETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQNSGGTSIFAGHLKCRLRM  
 DKLRLKGMSYSMCTGKFKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVL  
 GRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVDPGQLKLNWFKKGSSIGQMFETTMRGA  
 KRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAAFSGVSWTMKILIGVIITWIGM  
 NSRSTSLSVSLVLVGIVTLYLGVMVQA (SEQ ID NO:27)

The following changes could also be made to generate 2 viruses with a **larger** region of DENV3 transplanted into DENV2:

1. K122L, K123E, P132Y
2. E71D, E148Q, D225T, S229P, V307K (in addition to those listed in #1)

#### **DENV2/1/3/4 (Strain 16803)**

MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELFKTEVTQLATLRKL  
CIEAKLTNTTTERCPTQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGLFGKGGIVTCA  
MFTCKKPIEGKVVPENLKYTIIVTVHSGEEHAVGNDATEHGV TAMVTPQASSVEVKL  
PDYGEVTMECSPRTGLDFNEMILLTMKNKAWMVHRQWFFDLPLPWTSGADTQGSNWI  
QKETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQTSTTTIFAGHLKCRLRMD  
KLRLKGMSYSMCTGKFKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLG  
RLITVNPVTEKDSVPNIEAEPPFGDSYIIIGVDPGQLKLNWFKKGSSIGQMFETTMRGAK  
RMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFGSVSWTMKILIGVIITWIGMN  
SRSTSLSVSLVLVGVTLYLGAVVQA (SEQ ID NO:28)

Note: AA #50 could be a V or A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #160 could be a T or V, AA #163 could be a T or M, AA #168 could be a S or A, AA #170 could be a T or S, AA #171 could be a S or V, AA #173 could be a V or I, AA #174 could be a Q or K, AA #176 could be a P or T, AA #180 a E or A, AA #272 could be a T or N, AA #275 could be a T or G, AA #276 could be a T or N, AA #277 could be a T or L

The following changes could also be made to generate viruses with **larger** regions of DENV1 and/or DENV3 transplanted into DENV2:

1. Q52N, T55V, T138S, I139V
2. S168A, S169P, T180A, V181L, M183L (in addition to those listed in #1)
3. K122L, K123E, P132Y
4. E71D, E148Q, D225T, S227P, V307K (in addition to those listed in #3)
5. Any and all combinations of 1, 2, 3, 4 and the original sequence

#### **DENV1/3/4**

MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEATQLATLRK  
LCIEAKISNTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRGWGNGCGLFGKGSLLITCA  
KFKCVTKIEGKVQYENLKYSVIVTVHTGDQHQVGNEATEHGV TAMITPQSPSVEVKL  
PDYGELTLDCSPRTGLDFNEMILLTMKNKAWMVHRQWFLDLPLPWTSGASTSQETWN  
RQDLLVTFKTAHAKKQEVVVLGSQEGAMHTALTGATEIQNSGGTSIFAGHLKCRLKMD  
KLRLKGMSYVMCTGSFKLEKEVAETQHGTVLVQVKYEGTDAPCKIPFSSQDEKGVTON  
GRLITANPIVTDKEKPVNIEAEPPFGESYIVVGAGEKALKLSWFKKGSSIGKMFEATARG  
ARRMAILGDTAWDFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIGIGILLTWLG  
LNSRSTSLSMTCIAVGMVTLYLGVMVQA (SEQ ID NO:29)

Note: AA #50 could be a V or A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #272 could be a T or N, AA #275 could be a T or G, AA #276 could be a T or N, AA #277 could be a T or L

The following changes could also be made to generate viruses with a **larger** region of DENV3 transplanted into DENV1:

1. V122L, T123E, K124P, L214F
2. S225T, E229P, E307K (in addition to those listed in #1)

**DENV1/2/3**

MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEATQLATLRK  
 LCIEAKISNTTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRGWGNGCGLFGKGSLITCA  
 KFKCVTKIEGKVYQYENLKYSVIVTVHTGDQHQVGNETTEHGTATITPQAPTSEIQLT  
 5 DYGALTDCSPRTGLDFNEMILLTMKNKAWMVHRQWFLDLPLPWTSGASTSQETWNR  
 QDLLVTFKTAHAKKQEVVVLGSQEGAMHTALTGATEIQNSGGTSIFAGHLKCRLKMD  
 KLTLKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSCKIPFEITDLEKRHVLGR  
 LITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFATARGARR  
 MAILGDTAWDFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIGIGILLTWLGLNSR  
 10 STLSMTCIAVGMVTLYLGVMVQA (SEQ ID NO:30)

Note: AA #50 could be a V or A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #272 could be a T or N, AA #275 could be a T or G, AA #276 could be a T or N, AA #277 could be a T or L

15

The following changes could also be made to generate viruses with **larger** transplanted regions of DENV2 and/or DENV3 into DENV1:

1. I68T, D71E, A80P, T81S, V83N, T242N, A243P, E249D
2. R93K, R94H, T95S, F96M, S112G, L113I, I114V (in addition to those listed in #1)
- 20 3. V122L, T123E, K124P, L214F
4. S225T, E229P, E307K (in addition to those listed in #3)
5. Any and all combinations of 1, 2, 3, 4 and the original sequence

**DENV1/2/4**

25 MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEVTNPAVLRK  
 LCIEAKISNTTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRGWGNGCGLFGKGSLITCA  
 KFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGNATEHGVAMITPQSPSVEVKL  
 PDYGELTLDCSPRTGLDFNEMVLLTMEKKS WL VHKQWFLDLPLPWTSGASTSQETWN  
 RQDLLVTFKTAHAKKQEVVVLGSQEGAMHTALTGATEIQTSGTTTIFAGHLKCRLKMD  
 30 KLRLKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSCKIPFEITDLEKRHVLGR  
 LITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFATARGARR  
 MAILGDTAWDFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIGIGILLTWLGLNSR  
 STLSMTCIAVGMVTLYLGVMVQA (SEQ ID NO:31)

- 35 Note: AA #160 could be a T or V, AA #163 could be a T or M, AA #168 could be a S or A, AA #170 could be a T or S, AA #171 could be a S or V, AA #173 could be a V or I, AA #174 could be a Q or K, AA #176 could be a P or T, AA #180 could be a E or A

40 The following changes could also be made to generate 2 viruses with a **larger** region of DENV2 transplanted into DENV1:

1. I68T, D71E, A80P, T81S, V83N, T242N, A243P, E249D
2. R93K, R94H, T95S, F96M, S112G, L113I, I114V (in addition to those listed in #1)

**DENV1/2/3/4**

45 MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEATQLATLRK  
 LCIEAKISNTTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRGWGNGCGLFGKGSLITCA  
 KFKCVTKIEGKVYQYENLKYSVIVTVHTGDQHQVGNATEHGVAMITPQSPSVEVKL  
 PDYGELTLDCSPRTGLDFNEMILLTMKNKAWMVHRQWFLDLPLPWTSGASTSQETWN  
 RQDLLVTFKTAHAKKQEVVVLGSQEGAMHTALTGATEIQNSGGTSIFAGHLKCRLKMD  
 50 KLRLKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSCKIPFEITDLEKRHVLGR

LITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFEATARGARR  
MAILGDTAWDFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIGIGILLTWLGLNSR  
STSLSMTCIAVGMVTLYLGVMVQA (SEQ ID NO:32)

- 5 Note: AA #50 could be a V or A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #160 could be a T or V, AA #163 could be a T or M, AA #168 could be a S or A, AA #170 could be a T or S, AA #171 could be a S or V, AA #173 could be a V or I, AA #174 could be a Q or K, AA #176 could be a P or T, AA #180 could be a E or A, AA #272 could be a T or N, #275 could be a T or G, #276 could be a T or N, #277 could be a T or L

10 The following changes could also be made to generate 2 viruses with a **larger** region of DENV2 and/or DENV3 transplanted into DENV1:

1. I68T, D71E, A80P, T81S, V83N, T242N, A243P, E249D
2. R93K, R94H, T95S, F96M, S112G, L113I, I114V (in addition to those listed in #1)
- 15 3. V122L, T123E, K124P, L214F
4. S225T, E229P, E307K (in addition to those listed in #3)
5. Any and all combinations of 1, 2, 3, 4 and the original sequence

#### DENV3/1/4

20 MRCVGIGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIELFKTEVTQLATLR  
KLCIEGKITNITTD SRCPTQGEAVLPEEQDQNYVCKHTYVDRGWGNGCGLFGKGS LVT  
CAKFQCLEPIEGKVVQYENLKYSVIITVHTGDQH QVGNEATEHGV TAMITPQSSSVEVK  
LPDYGELGLECSPRTGLDFNEMILLTMKNKAWMVHRQWFFDLPLPWTSGATTETPTW  
NRKELLVTFKNAHAKKQEVVVLGSQEGAMHTALTGATEIQNSGTTSIFAGHLKCRLKM  
25 DKLRLKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIPFSTEDGQGKAH  
NGRLITANPVVTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKKGSSIGKMFEATAR  
GARRMAILGDTAWDFGSVGGVLNSLGKMHQIFGSAYTALFSGVSWVMKIGIGVLLT  
WIGLNSKNTSMSFS CIAIGIITLYLGAVVQA (SEQ ID NO:33)

- 30 Note: AA #50 could be a V or A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #160 could be a T or V, AA #163 could be a T or M, AA #168 could be a S or A, AA #170 could be a T or S, AA #171 could be a S or V, AA #173 could be a V or I, AA #174 could be a Q or K, AA #176 could be a P or T, AA #180 could be a E or A, AA #272 could be a T or N, AA #275 could be a T or G, AA #276 could be a T or N, AA #277 could be a T or L

35 The following changes could also be made to generate viruses with **larger** regions of DENV1 transplanted into DENV3:

1. S169P, T180A
2. Q52N, L53P, T55V (in addition to those listed in #1)

40 DENV3/1/2  
MRCVGIGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIELFKTEVTQLATLR  
KLCIEGKITNITTD SRCPTQGEAVLPEEQDQNYVCKHTYVDRGWGNGCGLFGKGS LVT  
CAKFQCLEPIEGKVVQYENLK YTVIVTVHTGDQH QVGNETTEHGT TATITPQASTSEIQL  
45 TDYGTGLGLECSPRTGLDFNEMILLTMKNKAWMVHRQWFFDLPLPWTSGATTETPTWN  
RKELLVTFKNAHAKKQEVVVLGSQEGAMHTALTGATEIQTSGTTTIFAGHLKCRLKMD  
KLELKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGR  
LITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWYKKKGSSIGKMFEATARGARR  
MAILGDTAWDFGSVGGVLNSLGKMHQIFGSAYTALFSGVSWVMKIGIGVLLTWIGLN  
50 SKNTSMSFS CIAIGIITLYLGAVVQA (SEQ ID NO:34)

Note: AA #50 could be a V or A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #272 a T or N, AA #275 could be a T or G, AA #276 could be a T or N, AA #277 could be a T or L

5

The following changes could also be made to generate 2 viruses with a **larger** region of DENV2 and/or DENV1 transplanted into DENV3:

1. D71E, A80P, V81S, P83N, A243P, E249D
2. I68T, T95S, Y96M, S112G, L113I (in addition to those listed in #1)
- 10 3. S169P, T180A
4. Q52N, L53P, T55V (in addition to those listed in #3)
5. Any and all combinations of 1, 2, 3, 4 and the original sequence

#### DENV3/2/4

15 MRCVGIGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIELQKTEATQLATLR  
KLCIEGKITNITTD SRCPTQGEAVLPEEQDQNYVCKHTYVDRGWGNGCGLFGKGS LVT  
CAKFQCLEPIEGKVVQYENLK YTVIITVHTGDQH QVGNEAQGV TAMI TPQSSSVEVKLP  
DYGELGLECSPRTGLDFNEMILLTMKNKAWMVHRQWFFDLPLPWTSGATTETPTWNR  
KELLVTFKNAHAKKQEVVVLGSQEGAMHTALTGATEIQNSGGTSIFAGHLKCRLKMD  
20 KLRLKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGR  
LITVNPIVTEKDSPVNIEAEPPFGDSYIIIIGVEPGQLKLNWYKKGSSIGKMFEATARGARR  
MAILGDTAWDFGSGVGGVLNSLGKMHQIFGSAYTALFSGVSWVMKIGIGVLLTWIGLN  
SKNTSMSFSCIAIGIITLYLGAVVQA (SEQ ID NO:35)

25 The following changes could also be made to generate 2 viruses with a **larger** region of DENV2 transplanted into DENV3:

1. D71E, A80P, V81S, P83N, A243P, E249D
2. I68T, T95S, Y96M, S112G, L113I (in addition to those listed in #1)

#### 30 DENV3/1/2/4

MRCVGIGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIELFKTEVTQLATLR  
KLCIEGKITNITTD SRCPTQGEAVLPEEQDQNYVCKHTYVDRGWGNGCGLFGKGS LVT  
CAKFQCLEPIEGKVVQYENLK YTVIVTVHTGDQH QVGNEATEHGV TAMI TPQSSSVEV  
KLPDYGELGLECSPRTGLDFNEMILLTMKNKAWMVHRQWFFDLPLPWTSGATTETPT  
35 WNRKELLVTFKNAHAKKQEVVVLGSQEGAMHTALTGATEIQTSGTTTIFAGHLKCRLK  
MDKLRLKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVL  
GRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIIGVEPGQLKLNWYKKGSSIGKMFEATARGA  
RRMAILGDTAWDFGSGVGGVLNSLGKMHQIFGSAYTALFSGVSWVMKIGIGVLLTWIG  
LNSKNTSMSFSCIAIGIITLYLGAVVQA (SEQ ID NO:36)

40

Note: AA #50 could be a V or A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #160 could be a T or V, AA #163 could be a T or M, AA #168 could be a S or A, AA #170 could be a T or S, AA #171 could be a S or V, AA #173 could be a V or I, AA #174 could be a Q or K, AA #176 could be a P or T, AA #180 could be a E or A, AA #272 could be a T or N, AA #275 could be a T or G, AA #276 could be a T or N, AA #277 could be a T or L

45

The following changes could also be made to generate 2 viruses with a **larger** region of DENV2 and/or DENV1 transplanted into DENV3:

1. D71E, A80P, V81S, P83N, A243P, E249D
- 50 2. I68T, T95S, Y96M, S112G, L113I (in addition to those listed in #1)

3. S169P, T180A
4. Q52N, L53P, T55V (in addition to those listed in #3)
5. Any and all combinations of 1, 2, 3, 4 and the original sequence

#### 5 DENV4/1/3

MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELFKTTVTQLATL  
 RKLCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWGNGCGLFGKGGVVT  
 CAKFSCSGPIEGKV VQIENLKYTVIVTVHNGDTHAVGNDTTEHGTTATITPRSPTSEIQLT  
 DYGELTLDCEPRSGIDFNEMILLTMKKKAWMVHRQWFFDLPLPWTSGADTSEVHWN  
 10 KERMVTFKVP HAKRQDVTVLGSQEGAMHSALAGATEIQNSGGTSIFAGHLKCKVRME  
 KLRIKGMSYTMCSGKFSIDKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKEKVV  
 GRVISSTPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRGA  
 KRMAILGETAWDFGSGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVLWIG  
 TNSRNTSMAMTCIAVGGITLFLGFTVQA (SEQ ID NO:37)

15

Note: AA #50 could be a V or A, AA #52 could be a Q or N, AA #55 could be a T or V, AA  
 #160 could be a T or V, #163 could be a T or M, AA #168 could be a S or A, AA #170 could be  
 a T or S, AA #171 could be a S or V, AA #173 could be a V or I, AA #174 could be a Q or K,  
 AA #176 could be a P or T, AA #180 could be a E or A, AA #272 could be a T or N, AA #275  
 20 could be a T or G, AA #276 could be a T or N, AA #277 could be a T or L

The following changes could also be made to generate viruses with a **larger** region of DENV1  
 and/or DENV3 transplanted into DENV4:

1. T49E, S122L, G123E, I132Y
- 25 2. A71D, T148Q, D225T, V229P, D307K, K321Q, V362P (in addition to those listed in  
 #1)
3. S168A, E180A
4. E52N, V53P, L55V, T138S (in addition to those listed in #3)
5. Any and all combinations of 1, 2, 3, 4 and the original sequence

30

#### DENV4/1/2

MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELFKTTVTEVALL  
 RTYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWGNGCGLFGKGGVVT  
 CAKFSCSGKITGNLVQIENLKYTVIVTVHNGDTHAVGNDTTEHGTTATITPRSPTSEIQLT  
 35 DYGELTLDCEPRSGIDFNEMILMKMKKKTWL VHKQWFLDLPLPWTAGADTSEVHWN  
 YKERMVTFKVP HAKRQDVTVLGSQEGAMHSALAGATEVDSGGTTTTFAGHLKCKVR  
 MEKLRLKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVL  
 GRLITVNPIVTEKDSPVNIEAEPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFESTYRGA  
 KRMAILGETAWDFGSGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVLWIG  
 40 TNSRNTSMAMTCIAVGGITLFLGFTVQA (SEQ ID NO:38)

Note: AA #160 could be a T or V, AA #163 could be a T or M, AA #168 could be a S or A, AA  
 #170 could be a T or S, AA #171 could be a S or V, AA #173 could be a V or I, AA #174 could  
 be a Q or K, AA #176 could be a P or T, AA #180 could be a E or A

45

The following changes could also be made to generate 2 viruses with a **larger** region of DENV1  
 and/or DENV2 transplanted into DENV4:

1. Y81S, K83S, V242N, R247K
2. I68T, A71E, T72S, R93K, R94H, D95S, V96M, V113I (in addition to those listed in #1)
- 50 3. S168A, E180A

4. E52N, V53P, L55V, T138S (in addition to those listed in #3)
5. Any and all combinations of 1, 2, 3, 4 and the original sequence

**DENV4/2/3**

5 MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTATQLATL  
 RKLCIEASISNITTATRCPTQGEPLYLKEEQDQQYICRRDVVDRGWGNGCGLFGKGGVVT  
 CAKFSCSGPIEGKVQIENLEYTVVVTVHNGDTHAVGNDTSNHGVTATITPRSPSVEVK  
 LPDYGELTLDCEPRSGIDFNEMILLTMKKKAWMVHRQWFFDLPLPWTSGADTSEVHW  
 NYKERMVTFKVPKAKRQDVTVLGSQEGAMHSALAGATEIQNSGGTSIFAGHLKCKVR  
 10 MEKRLRLKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVL  
 GRLITVNPIVTEKDSPVNIEAEPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFESTYRGA  
 KRMALGETAWDFGSGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILI  
 GFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA (SEQ ID NO:39)

15 The following changes could also be made to generate 2 viruses with a **larger** region of DENV2 and/or DENV3 transplanted into DENV4:

1. Y81S, K83S, V242N, R247K
2. I68T, A71E, T72S, R93K, R94H, D95S, V96M, V113I (in addition to those listed in #1)
3. T49E, S122L, G123E, I132Y
- 20 4. A71D, T148Q, D225T, V229P, D307K, K321Q, V362P (in addition to those listed in #3)
5. Any and all combinations of 1, 2, 3, 4 and the original sequence

**DENV4/1/2/3**

25 MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELFKTTVTQLATL  
 RKLCIEASISNITTATRCPTQGEPLYLKEEQDQQYICRRDVVDRGWGNGCGLFGKGGVVT  
 CAKFSCSGPIEGKVQIENLKYTVIVTVHNGDTHAVGNDTTEHGTTATITPRSPSVEVKL  
 TDYGELTLDCEPRSGIDFNEMILLTMKKKAWMVHRQWFFDLPLPWTSGADTSEVHWN  
 YKERMVTFKVPKAKRQDVTVLGSQEGAMHSALAGATEIQNSGGTSIFAGHLKCKVRM  
 30 EKLRLKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLG  
 RLITVNPIVTEKDSPVNIEAEPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFESTYRGAK  
 RMAILGETAWDFGSGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVLWIGT  
 NSRNTSMAMTCIAVGGITLFLGFTVQA (SEQ ID NO:40)

35 Note: AA #50 could be a V or A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #160 could be a T or V, AA #163 could be a T or M, AA #168 could be a S or A, AA #170 could be a T or S, AA #171 could be a S or V, AA #173 could be a V or I, AA #174 could be a Q or K, AA #176 could be a P or T, AA #180 could be a E or A, AA #272 could be a T or N, #275 could be a T or G, #276 could be a T or N, #277 could be a T or L

40

The following changes could also be made to generate 2 viruses with a **larger** region of DENV1, DENV2, and/or DENV3 transplanted into DENV4:

1. Y81S, K83S, V242N, R247K
2. I68T, A71E, T72S, R93K, R94H, D95S, V96M, V113I (in addition to those listed in #1)
- 45 3. T49E, S122L, G123E, I132Y
4. A71D, T148Q, D225T, V229P, D307K, K321Q, V362P (in addition to those listed in #3)
5. S168A, E180A
6. E52N, V53P, L55V, T138S
- 50 7. Any and all combinations of 1, 2, 3, 4, 5, 6 and the original sequence

**What is claimed is:**

1. A chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone that comprises amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone, wherein the dengue virus E glycoprotein backbone is from dengue virus serotype 4 and the antibody is reactive with dengue virus serotype 3.

2. The chimeric dengue virus E glycoprotein of claim 1, wherein the antibody is monoclonal antibody 5J7.

3. The chimeric dengue virus E glycoprotein of claim 1, comprising the amino acid sequence:

MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAKEVALL  
RTYCIÉASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWGNGCGLFGKGGVVT  
CAKFSCSGKITGNLVQIENLEYTVVVTVHNGDTHAVGNDTSNHGVTATITPRSPSVEVK  
LPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHKQWFLDLPLPWTAGADTSEVHW  
NYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFAGHLKCKV  
RMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKE  
KVVGRVISSTPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTY  
RGAKRMAILGETAWDFGSVGGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVL  
WIGTNSRNTSMAMTCIAVGGITLFLGFTVQA (WT\_DENV4, SEQ ID NO:1),

wherein said amino acid sequence comprises the following amino acid substitutions:

T49E, K51T, E52Q, V53L, L55T, T58K, Y59L, S122L, G123E, K124P, T126E, N128K,  
L129V, I132Y, M199L, K200T, T205A, L207M, K210R, L214F, A222S, V270I, D271Q,  
S272N, G273S, D274G, N276T, H277S and M278I, and wherein said amino acid sequence  
further comprises one or more of the following amino acid substitutions in any combination:  
A71D, T148Q, D225T, V229P, D307K, K321Q and V362P.

4. The chimeric dengue virus E glycoprotein of claim 1, comprising the amino acid sequence:

MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTEATQLATL  
RKLCEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWGNGCGLFGKGGVVT  
CAKFSCLEPIEGKVYQYENLEYTVVVTVHNGDTHAVGNDTSNHGVTATITPRSPSVEVK  
LPDYGELTLDCEPRSGIDFNEMILLTMKKKAWMVHRQWFFDLPLPWTSGADTSEVHW  
NYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEIQNSGGTSIFAGHLKCKVR  
MEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKEK

VVGRVISSTPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYR  
GAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVLW  
IGTNSRNTSMAMTCIAVGGITLFLGFTVQA (DENV\_M14, SEQ ID NO:3).

5. The chimeric dengue virus E glycoprotein of claim 1, comprising the amino acid sequence:

MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTEATQLATL  
RKLCIEASISNITTDTRCPTQGEPLYKEEQDQQYICRRDVVDRGWGNGCGLFGKGGVVT  
CAKFSCLEPIEGKVVQYENLEYTVVVTVHNGDQHAVGNDTSNHGVTATITPRSPSVEV  
KLPDYGELTLDCEPRSGIDFNEMILLTMKKKAWMVHRQWFFDLPLPWTSGATTSEPHW  
NYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEIQNSGGTSIFAGHLKCKVR  
MEKLRIKGMSYTMCSGKFSIKKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKEK  
VVGRVISSTPLAENTNSPTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYR  
GAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVLW  
IGTNSRNTSMAMTCIAVGGITLFLGFTVQA (DENV4\_M16, SEQ ID NO:4).

6 A chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone that comprises amino acid substitutions that introduce a protein domain from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone, wherein the dengue virus E glycoprotein backbone is from dengue virus serotype 4 and the protein domain is from dengue virus serotype 2.

7. The chimeric dengue virus E glycoprotein of claim 6, wherein the protein domain is E glycoprotein domain III.

8. The chimeric dengue virus E glycoprotein of claim 6, comprising the amino acid sequence:

MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAKEVALL  
RTYCIEASISNITTATRCPTQGEPLYKEEQDQQYICRRDVVDRGWGNGCGLFGKGGVVT  
CAKFSCSGKITGNLVQIENLEYTVVVTVHNGDTHAVGNDTSNHGVTATITPRSPSVEVK  
LPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHKQWFLDLPLPWTAGADTSEVHW  
NYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFAGHLKCKV  
RMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKE  
KVVGRVISSTPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTY  
RGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVL  
WIGTNSRNTSMAMTCIAVGGITLFLGFTVQA (WT\_DENV4, SEQ ID NO:1),

wherein said amino acid sequence comprises the following amino acid substitutions:

T300S, S303T, S307K, D309V, M312I, T320I, V322I, K323R, K325Q, A329D, A331S, V335I,  
I337F, R340T, V342L, N343E, E345R, K346H, V348L, V351L, S353T, S354V, T355N, L357I,

A358V, E359T, N360E, T361K, N362D, V364P, T365V, L369A, V379I, G383E, N384P, S385G, A386Q, T388K, H390N, R393K.

9. The chimeric dengue virus E glycoprotein of claim 6, comprising the amino acid sequence:

MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAKEVALL  
RTYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWGNGCGLFGKGGVVT  
CAKFSCSGKITGNLVQIENLEYTVVVTVHNGDTHAVGNDTSNHGVTATITPRSPSVEVK  
LPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHKQWFLDLPLPWTAGADTSEVHW  
NYKERMVTFKVPFAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFAGHLKCKV  
RMEKLRLKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHV  
LGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFESTYRG  
AKRMAILGETAWDFGSLGGVFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVLWI  
GTNSRNTSMAMTCIAVGGITLFLGFTVQA (DV4-EDIII-DV2, SEQ ID NO:5).

10. A chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone that comprises amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone, wherein the dengue virus E glycoprotein backbone is from dengue virus serotype 2 and the antibody is reactive with dengue virus serotype 1.

11. The chimeric dengue virus E glycoprotein of claim 10, wherein the antibody is monoclonal antibody 1F4.

12. The chimeric dengue virus E glycoprotein of claim 10, comprising the amino acid sequence:

MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELFKTEVTNPAVLRKY  
CIEAKLTNTTTESRCPTQGEPSLNEEQDKRFICKHSMVDRGWGNGCGLFGKGGIVTCA  
MFTCKKNMEGKVVPENLKYSVIVTVHSGEEHAVGNDTTEHGTTATITPQAPTSEIQLT  
DYGALTLECSPTGLDFNEMVLLQMEDKAWLVHRQWFLDLPLPWLPGADTQESNWIQ  
KETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQTSGTTTLFTGHLKCRLRMDK  
LQLKGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLI  
TVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGAKRM  
AILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFGSVSWTMKILIGVIITWIGMNSRS  
TSLSVSLVLVGCVTLVLGAVVQA (DENV2-1F4E, SEQ ID NO:6).

13. A flavivirus particle or virus like particle (VLP) comprising the E glycoprotein of any of claims 1-12.

14. An isolated nucleic acid molecule encoding the E glycoprotein of any of claims 1-12.
15. An isolated nucleic acid molecule encoding the flavivirus particle or VLP of claim 13.
16. A population of flavivirus particles comprising the flavivirus particle of claim 13.
17. A composition comprising the E glycoprotein of any of claims 1-12 in a pharmaceutically acceptable carrier.
18. A composition comprising the nucleic acid molecule of claim 14 or 15 in a pharmaceutically acceptable carrier.
19. A composition comprising the population of claim 16 in a pharmaceutically acceptable carrier.
20. A composition comprising the flavivirus particle and/or VLP of claim 13 in a pharmaceutically acceptable carrier.
21. A method of producing an immune response to a dengue virus in a subject, comprising administering to the subject an effective amount of the E glycoprotein of any of claims 1-12, the flavivirus particle of claim 13, the VLP of claim 13, the nucleic acid molecule of any of claims 14-15, the population of claim 16, and/or the composition of any of claims 17-20 and any combination thereof.
22. A method of treating a dengue virus infection in a subject, comprising administering to the subject an effective amount of the E glycoprotein of any of claims 1-12, the flavivirus particle of claim 13, the VLP of claim 13, the nucleic acid molecule of any of claims 14-15, the population of claim 16, and/or the composition of any of claims 17-20 and any combination thereof.
23. A method of preventing a disorder associated with dengue virus infection in a subject, comprising administering to the subject an effective amount of the E glycoprotein of any of claims 1-12, the flavivirus particle of claim 13, the VLP of claim 13, the nucleic acid molecule

of any of claims 14-15, the population of claim 16, and/or the composition of any of claims 17-20 and any combination thereof.

24. A method of protecting a subject from the effects of dengue virus infection, comprising administering to the subject an effective amount of the E glycoprotein of any of claims 1-12, the flavivirus particle of claim 13, the VLP of claim 13, the nucleic acid molecule of any of claims 14-15, the population of claim 16, and/or the composition of any of claims 17-20 and any combination thereof.

25. A method of identifying the presence of a neutralizing antibody to dengue virus serotype 3 and/or 4 in a biological sample from a subject, comprising:

a) administering a composition comprising the E glycoprotein of any of claims 1-5 to the subject in an amount effective to induce an antibody response to the E glycoprotein;

b) contacting a biological sample from the subject with flavivirus particles comprising the E glycoprotein of step (a) above under conditions whereby neutralization of the flavivirus particles can be detected; and

c) detecting neutralization in step (b), thereby identifying the presence of a neutralizing antibody to dengue virus serotype 3 and/or 4 in the biological sample from the subject.

26. A method of identifying the presence of a neutralizing antibody to dengue virus serotype 2 and/or 4 in a biological sample from a subject, comprising:

a) administering a composition comprising the E glycoprotein of any of claims 6-9 to the subject in an amount effective to induce an antibody response to the E glycoprotein;

b) contacting a biological sample from the subject with flavivirus particles comprising the E glycoprotein of step (a) above under conditions whereby neutralization of the flavivirus particles can be detected; and

c) detecting neutralization in step (b), thereby identifying the presence of a neutralizing antibody to dengue virus serotype 2 and/or 4 in the biological sample from the subject.

27. A method of identifying the presence of a neutralizing antibody to dengue virus serotype 1 and/or 2 in a biological sample from a subject, comprising:

a) administering a composition comprising the E glycoprotein of any of claims 10-12 to the subject in an amount effective to induce an antibody response to the E glycoprotein;

b) contacting a biological sample from the subject with flavivirus particles comprising the E glycoprotein of step (a) above under conditions whereby neutralization of the flavivirus particles can be detected; and

c) detecting neutralization in step (b), thereby identifying the presence of a neutralizing antibody to dengue virus serotype 1 and/or 2 in the biological sample from the subject.

28. A method of identifying the presence of a neutralizing antibody to dengue virus serotype 3 and/or 4 in a biological sample from a subject, comprising:

a) contacting a biological sample from a subject that has been administered a E glycoprotein of any of claims 1-5 with flavivirus particles comprising the E glycoprotein under conditions whereby neutralization of the flavivirus particles can be detected; and

b) detecting neutralization in step (a), thereby identifying the presence of a neutralizing antibody to dengue virus serotype 3 and/or 4 in the biological sample from the subject.

29. A method of identifying the presence of a neutralizing antibody to dengue virus serotype 2 and/or 4 in a biological sample from a subject, comprising:

a) contacting a biological sample from a subject that has been administered a E glycoprotein of any of claims 6-9 with flavivirus particles comprising the E glycoprotein under conditions whereby neutralization of the flavivirus particles can be detected; and

b) detecting neutralization in step (a), thereby identifying the presence of a neutralizing antibody to dengue virus serotype 2 and/or 4 in the biological sample from the subject.

30. A method of identifying the presence of a neutralizing antibody to dengue virus serotype 1 and/or 2 in a biological sample from a subject, comprising:

a) contacting a biological sample from a subject that has been administered a E glycoprotein of any of claims 10-12 with flavivirus particles comprising the E glycoprotein under conditions whereby neutralization of the flavivirus particles can be detected; and

b) detecting neutralization in step (a), thereby identifying the presence of a neutralizing antibody to dengue virus serotype 1 and/or 2 in the biological sample from the subject.

31. A method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 3 and/or 4 in a subject, the method comprising:

- a) administering an immunogenic composition comprising the E glycoprotein of any of claims 1-5 to a subject in an amount effective to induce an antibody response to the E glycoprotein;
- b) contacting a biological sample from the subject with flavivirus particles comprising the E glycoprotein of step (a) under conditions whereby neutralization of the flavivirus particles can be detected;
- c) determining if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of step (a); and
- d) identifying the immunogenic composition as inducing a neutralizing antibody to dengue virus serotype 3 and/or 4 in the subject if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of (a).

32. A method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 2 and/or 4 in a subject, the method comprising:

- a) administering an immunogenic composition comprising the E glycoprotein of any of claims 6-9 to a subject in an amount effective to induce an antibody response to the E glycoprotein;
- b) contacting a biological sample from the subject with flavivirus particles comprising the E glycoprotein of step (a) under conditions whereby neutralization of the flavivirus particles can be detected;
- c) determining if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of step (a); and
- d) identifying the immunogenic composition as inducing a neutralizing antibody to dengue virus serotype 2 and/or 4 in the subject if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of (a).

33. A method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 1 and/or 2 in a subject, the method comprising:

- a) administering an immunogenic composition comprising the E glycoprotein of any of claims 10-12 to a subject in an amount effective to induce an antibody response to the E glycoprotein;
- b) contacting a biological sample from the subject with flavivirus particles comprising the E glycoprotein of step (a) under conditions whereby neutralization of the flavivirus particles can be detected;

- c) determining if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of step (a); and
- d) identifying the immunogenic composition as inducing a neutralizing antibody to dengue virus serotype 1 and/or 2 in the subject if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of (a).

34. A method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 3 and/or 4 in a subject, the method comprising:

- a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising the E glycoprotein of any of claims 1-5 with flavivirus particles comprising the E glycoprotein under conditions whereby neutralization of the flavivirus particles can be detected;
- b) determining if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of step (a); and
- c) identifying the immunogenic composition as inducing a neutralizing antibody to dengue virus serotype 3 and/or 4 in the subject if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of (a).

35. A method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 2 and/or 4 in a subject, the method comprising:

- a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising the E glycoprotein of any of claims 6-9 with flavivirus particles comprising the E glycoprotein under conditions whereby neutralization of the flavivirus particles can be detected;
- b) determining if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of step (a); and
- c) identifying the immunogenic composition as inducing a neutralizing antibody to dengue virus serotype 2 and/or 4 in the subject if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of (a).

36. A method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 1 and/or 2 in a subject, the method comprising:

- a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising the E glycoprotein of any of claims 10-12 with flavivirus

particles comprising the E glycoprotein under conditions whereby neutralization of the flavivirus particles can be detected;

- b) determining if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of step (a); and
- c) identifying the immunogenic composition as inducing a neutralizing antibody to dengue virus serotype 1 and/or 2 in the subject if the biological sample comprises an antibody that neutralizes flavivirus particles comprising the E glycoprotein of (a).

37. A method of detecting an antibody to dengue virus serotype 3 and/or 4 in a sample, comprising:

- a) contacting the sample with the E glycoprotein of any of claims 1-5 under conditions whereby an antigen/antibody complex can form; and
- b) detecting formation of an antigen/antibody complex, thereby detecting an antibody to dengue virus serotype 3 and /or 4 in the sample.

38. A method of detecting an antibody to dengue virus serotype 2 and/or 4 in a sample, comprising:

- a) contacting the sample with the E glycoprotein of any of claims 6-9 under conditions whereby an antigen/antibody complex can form; and
- b) detecting formation of an antigen/antibody complex, thereby detecting an antibody to dengue virus serotype 3 and /or 4 in the sample.

39. A method of detecting an antibody to dengue virus serotype 1 and/or 2 in a sample, comprising:

- a) contacting the sample with the E glycoprotein of any of claims 10-12 under conditions whereby an antigen/antibody complex can form; and
- b) detecting formation of an antigen/antibody complex, thereby detecting an antibody to dengue virus serotype 1 and /or 2 in the sample.

40. A method of identifying an antibody to dengue virus serotype 3 and/or 4 in a biological sample from a subject, comprising:

- a) administering a composition comprising the E glycoprotein of any of claims 1-5 to the subject in an amount effective to induce an antibody response to the E glycoprotein;

b) contacting a biological sample from the subject with the E glycoprotein of (a) under conditions whereby an antigen/antibody complex can form; and

c) detecting formation of an antigen/antibody complex, thereby identifying an antibody to dengue virus serotype 3 and/or 4 in the biological sample from the subject.

41. A method of identifying an antibody to dengue virus serotype 2 and/or 4 in a biological sample from a subject, comprising:

a) administering a composition comprising the E glycoprotein of any of claims 6-9 to the subject in an amount effective to induce an antibody response to the E glycoprotein;

b) contacting a biological sample from the subject with the E glycoprotein of (a) under conditions whereby an antigen/antibody complex can form; and

c) detecting formation of an antigen/antibody complex, thereby identifying an antibody to dengue virus serotype 2 and/or 4 in the biological sample from the subject.

42. A method of identifying an antibody to dengue virus serotype 1 and/or 2 in a biological sample from a subject, comprising:

a) administering a composition comprising the E glycoprotein of any of claims 10-12 to the subject in an amount effective to induce an antibody response to the E glycoprotein;

b) contacting a biological sample from the subject with the E glycoprotein of (a) under conditions whereby an antigen/antibody complex can form; and

c) detecting formation of an antigen/antibody complex, thereby identifying an antibody to dengue virus serotype 1 and/or 2 in the biological sample from the subject.

43. A method of identifying an antibody to dengue virus serotype 3 and/or 4 in a biological sample from a subject, comprising:

a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising the E glycoprotein of any of claims 1-5 with the E glycoprotein under conditions whereby an antigen/antibody complex can form; and

b) detecting formation of an antigen/antibody complex, thereby identifying an antibody to dengue virus serotype 3 and/or 4 in the biological sample from the subject.

44. A method of identifying an antibody to dengue virus serotype 2 and/or 4 in a biological sample from a subject, comprising:

a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising the E glycoprotein of any of claims 6-9 with the E glycoprotein under conditions whereby an antigen/antibody complex can form; and

b) detecting formation of an antigen/antibody complex, thereby identifying an antibody to dengue virus serotype 2 and/or 4 in the biological sample from the subject.

45. A method of identifying an antibody to dengue virus serotype 1 and/or 2 in a biological sample from a subject, comprising:

a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising the E glycoprotein of any of claims 10-12 with the E glycoprotein under conditions whereby an antigen/antibody complex can form; and

b) detecting formation of an antigen/antibody complex, thereby identifying an antibody to dengue virus serotype 1 and/or 2 in the biological sample from the subject.

46. A method of identifying an immunogenic composition that induces an antibody to dengue virus serotype 3 and/or 4 in a subject, the method comprising:

a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising an E glycoprotein of any of claims 1-5 with the E glycoprotein under conditions whereby an antigen/antibody complex can form; and

b) detecting formation of an antigen/antibody complex, thereby identifying an immunogenic composition that induces an antibody to dengue virus serotype 3 and/or 4 in the subject.

47. A method of identifying an immunogenic composition that induces an antibody to dengue virus serotype 2 and/or 4 in a subject, the method comprising:

a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising an E glycoprotein of any of claims 6-9 with the E glycoprotein under conditions whereby an antigen/antibody complex can form; and

b) detecting formation of an antigen/antibody complex, thereby identifying an immunogenic composition that induces an antibody to dengue virus serotype 2 and/or 4 in the subject.

48. A method of identifying an immunogenic composition that induces an antibody to dengue virus serotype 1 and/or 2 in a subject, the method comprising:

- a) contacting a biological sample from a subject that has been administered an immunogenic composition comprising an E glycoprotein of any of claims 10-12 with the E glycoprotein under conditions whereby an antigen/antibody complex can form; and
- b) detecting formation of an antigen/antibody complex, thereby identifying an immunogenic composition that induces an antibody to dengue virus serotype 1 and/or 2 in the subject.

49. A method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 3 and/or 4 in a subject, comprising:

- a) administering an immunogenic composition comprising an E glycoprotein of any of claims 1-5 to a subject in an amount effective to induce an antibody response to the E glycoprotein;
- b) contacting a biological sample from the subject with the E glycoprotein of (a) under conditions whereby an antigen/antibody complex can form; and
- c) detecting formation an antigen/antibody complex, thereby identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 3 and/or 4 in the subject.


50. A method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 2 and/or 4 in a subject, comprising:

- a) administering an immunogenic composition comprising an E glycoprotein of any of claims 6-9 to a subject in an amount effective to induce an antibody response to the E glycoprotein;
- b) contacting a biological sample from the subject with the E glycoprotein of (a) under conditions whereby an antigen/antibody complex can form; and
- c) detecting formation an antigen/antibody complex, thereby identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 2 and/or 4 in the subject.

51. A method of identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 1 and/or 2 in a subject, comprising:

- a) administering an immunogenic composition comprising an E glycoprotein of any of claims 10-12 to a subject in an amount effective to induce an antibody response to the E glycoprotein;

- b) contacting a biological sample from the subject with the E glycoprotein of (a) under conditions whereby an antigen/antibody complex can form; and
- c) detecting formation an antigen/antibody complex, thereby identifying an immunogenic composition that induces a neutralizing antibody to dengue virus serotype 1 and/or 2 in the subject.



|           | <u>Amino Acid Residue Changed (Numbering Within Envelope Protein Amino Acid Sequence)</u> |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|-----------|-------------------------------------------------------------------------------------------|----|----|----|----|----|----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
|           | 49                                                                                        | 51 | 52 | 53 | 55 | 58 | 59 | 71 | 122 | 123 | 124 | 126 | 128 | 129 | 132 | 148 | 199 | 200 | 205 | 207 | 210 | 214 | 222 | 225 | 229 | 270 | 271 | 272 | 273 | 274 | 276 | 277 | 278 | 307 | 321 | 362 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| WT DENV4  | T                                                                                         | K  | E  | V  | L  | T  | Y  | A  | S   | G   | K   | T   | N   | L   | I   | T   | M   | K   | T   | L   | K   | L   | A   | D   | V   | V   | I   | D   | S   | G   | D   | N   | H   | M   | D   | K   | V |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| DENV4 M12 | T                                                                                         | T  | Q  | L  | T  | K  | L  | A  | S   | G   | P   | E   | K   | V   | I   | T   | L   | T   | A   | M   | R   | F   | S   | D   | V   | I   | Q   | N   | S   | G   | T   | S   | I   | D   | K   | V   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| DENV4 M14 | E                                                                                         | T  | Q  | L  | T  | K  | L  | A  | L   | E   | P   | E   | K   | V   | Y   | T   | L   | T   | A   | M   | R   | F   | S   | D   | V   | I   | Q   | N   | S   | G   | T   | S   | I   | D   | K   | V   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| DENV4 M16 | E                                                                                         | T  | Q  | L  | T  | K  | L  | D  | L   | E   | P   | E   | K   | V   | Y   | Q   | L   | T   | A   | M   | R   | F   | S   | T   | P   | I   | Q   | N   | S   | G   | T   | S   | I   | K   | Q   | P   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

**FIG. 1**




*FIG. 1 (cont'd.)*




**FIG. 2**




FIG. 3




FIG. 4




FIG. 5




FIG. 6





FIG. 7



B.

|            | Amino Acid Residue Changed (Numbering Within Envelope Protein Amino Acid Sequence) |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |  |  |  |  |  |  |
|------------|------------------------------------------------------------------------------------|----|----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|--|--|--|--|--|
|            | 50                                                                                 | 51 | 52 | 55 | 136 | 138 | 139 | 140 | 141 | 143 | 156 | 157 | 160 | 161 | 162 | 163 | 168 | 169 | 170 | 171 | 173 | 174 | 177 | 180 | 181 | 183 | 272 | 274 | 275 | 276 | 277 |  |  |  |  |  |  |  |
| WTDENV2    | A                                                                                  | K  | Q  | T  | E   | T   | I   | V   | I   | P   | G   | K   | K   | E   | I   | K   | S   | S   | I   | T   | A   | E   | G   | T   | V   | M   | M   | S   | G   | N   | L   |  |  |  |  |  |  |  |
| DENV2-1F4E | V                                                                                  | T  | N  | V  | K   | S   | V   | I   | V   | V   | T   | E   | T   | T   | A   | T   | A   | P   | T   | S   | I   | Q   | D   | A   | L   | L   | T   | G   | T   | T   | T   |  |  |  |  |  |  |  |



FIG. 8




FIG. 9






FIG. 10




**FIG. 12**

**A**

DENV2 GMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKR  
 DENV4 GMSYTMCSGKFSIDKEMAETQHGTIVVVKVYEGAGAPCKVPIEIRDVNKE  
 DENV4/2 GMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKR

DENV2 HVLGRLITVNPPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKK  
 DENV4 KVVGRVISSTPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRK  
 DENV4/2 HVLGRLITVNPPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKK

**B****C****FIG. 13**




*FIG. 14*





**FIG. 15**


**FIG. 16**

A


| MAb  | Donor                 | Specificity       |
|------|-----------------------|-------------------|
| 2D22 | Primary DV2 infection | DV2 type-specific |

| Neut <sub>50</sub> titer (ug/ml) |      |     |     |
|----------------------------------|------|-----|-----|
| DV1                              | DV2  | DV3 | DV4 |
| >10                              | 0.08 | >10 | >10 |


B




C



D



E



F








FIG. 17

**FIG. 18**

**FIG. 19**

**FIG. 20**

**FIG. 21**




FIG. 22





FIG. 23

**FIG. 24**




**FIG. 25**







*FIG. 26*

**FIG. 27**

**FIG. 28**

**FIG. 29**





FIG. 30

**FIG. 31**

33/36





FIG. 32A

34/36

**FIG. 32B**

35/36




FIG. 32C




FIG. 32C (cont'd.)

**DENV-3**  
UNC3001 (Sri Lanka 89)

0 5000 nt

C pr 3' E

DENV-3 A (3035 nt) DENV-3 B (1126 nt) DENV-3 C (3070 nt) DENV-3 E (3076 nt)

**DENV-4**  
Sri Lanka 89

0 5000 nt

C pr 3' E

DENV-4 A (3216 nt) DENV-4 B (2266 nt) DENV-4 C (3373 nt) DENV-4 E (1794 nt)

|           | Amino Acid Residue Changed (Numbering Within Envelope Protein Amino Acid Sequence) |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----------|------------------------------------------------------------------------------------|----|----|----|----|----|----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|           | 49                                                                                 | 51 | 52 | 53 | 55 | 56 | 59 | 71 | 122 | 123 | 124 | 125 | 128 | 129 | 132 | 148 | 199 | 200 | 205 | 207 | 210 | 214 | 222 | 225 | 229 | 270 | 271 | 272 | 273 | 274 | 276 | 277 | 278 | 307 | 321 | 352 |
| WT DENV4  | T                                                                                  | K  | E  | V  | L  | T  | Y  | A  | S   | G   | K   | T   | N   | L   | I   | T   | M   | K   | T   | L   | K   | L   | A   | D   | V   | V   | D   | S   | G   | D   | N   | H   | M   | D   | K   | V   |
| DENV4 M12 | T                                                                                  | T  | Q  | L  | T  | K  | L  | A  | S   | G   | P   | E   | K   | V   | I   | T   | L   | T   | A   | M   | R   | F   | S   | D   | V   | I   | Q   | N   | S   | G   | T   | S   | I   | D   | K   | V   |
| DENV4 M14 | E                                                                                  | T  | Q  | L  | T  | K  | L  | A  | L   | E   | P   | E   | K   | V   | Y   | T   | L   | T   | A   | M   | R   | F   | S   | D   | V   | I   | Q   | N   | S   | G   | T   | S   | I   | D   | K   | V   |
| DENV4 M16 | E                                                                                  | T  | Q  | L  | T  | K  | L  | D  | L   | E   | P   | E   | K   | V   | Y   | Q   | L   | T   | A   | M   | R   | F   | S   | T   | P   | I   | Q   | N   | S   | G   | T   | S   | I   | K   | Q   | P   |

**FIG. 1**